var title_f36_3_36912="Variations of aortic dissection";
var content_f36_3_36912=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F62132&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F62132&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Variations of aortic dissection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 374px; height: 359px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFnAXYDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArKutaitvEtho0kMgkvbeaeObjZmMoCnruIfP0U1q1x3xMtrmHTLPxDpsLT3+gT/AG4QoPmng2lZ4h7mNmIHdlWgDsaKq6VqFrq2m2uoadMk9ndRrNDKh4dWGQatUAFFFFABRRUN5dW9jZz3V5PHb2sCNJLNKwVI1AyWYngADnNABeXUFlaTXV5MkNtChkkkkOFRQMkk+lOt5luLeKaPdskUOu5SDgjPIPIridI87x7PDqt9BLb+GIZBLp1rKNrXxHK3MqnkR9DGh68OwztC91QAUVi+Ktfi0CxjYQtd6hdSCCyso2Ae5mPRQTwAMEsx4VQSelXtIS+TTLddWlhlv9uZmgUrHuPJCg84HQZ5OOaALlFUtW1bTtGtTc6vf2tjbj/lpcyrGv5k0ukanY6xYR32lXUN3ZyZCTQsGVsEg4I9waALlFFFABRRRQAUUVxninxdd6Dql5bvZLJDDaR38bAEtLCkm26x6vGrI4A6hqAOzqlZ6pZ3mpX9hbzBruxKC4jwQU3ruU+4I7j0I7VahljmhSWF1kikUMjochgeQQe4rkfHNrdaZdW/izR4Jri9sE8q8tIeWvLMnLKB3dOXT33L/HQB2NFVdK1C01bTbbUNNuI7myuYxLDNGcq6nkEVaoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPKfGOo6nb/HDwdpVt4ivrXTNRinmubNDDsLQgMq8oWAc8Nzk9iK9WrHvfC+gX2rxare6HpdxqkTK0d5NaRvMhU5UhyNwIPI54rYoAKQnAJOcD0GaWigCCxu4L6zhurOVZreZBJHIvRlPINT1hq+neFoooGItbC5uXKO7koksjM5XnhFJzjoATgYyBWtBdW88kkcE8Ujx43qjglcjIyB0yOaAPO5xP8MdRu7uC2nufA93I1xNDbRF30iU8u6ooyYGOWYD7hyQME462bxf4cg0SLWJtc01NLlTfHctcKEcY/hOeT7DmtqeWOCJ5Z5EjiQbmd2wFHqSa86n0D4YW2op4zkg0G2mhlcC/EixxtIMq3GQjNyecE5oA0ofiRpF9Hv0Kx1zWkLBVksdNlMbE+kjhUxz13Ypkvi/xM0ypZ/D3WHQn7899aRAD1I8w12GmX9tqmn299YSia0uEEkUgBAZT0PPNWaAONk17xiAfK8FRMccb9XjXn0OEP8AX8axNJ8PeJPFOs3EvxKtoF0yB1ls9Ls7gPZsQcgzDAeVgQDhsJkZ255r02igArB8V+KLHw5DCJxJc6hdEpZ6fbDfPdP6IvoO7HCqOSRW9XH698PNF1fXpdeEmp6fr0kK2/8AaFhfSwyCMEEJtyUK5AOCpBPWgClp1smgJdeNPiJf2dvqflFMtL/o+nQk58mInG5jgbm6uwAHAUU06n4r8Xtjw7GfDeiHpqd9b77u4HrDbtxGuP4peeR8lP0nwFND4sGreINYm8RxQxj7CuoxrvspAeWRU2xEkfxbA4wPm5Nd5QByel/D7w/Z3/8AaN3bPq+rHrf6o/2mb/gO75UHsgUe1dWqhVCqAAOgFJJIkUbySuqRoCzMxwFA6kmuLfx0dWZ4fA2mya+yuY2vRIIbGMjr++IO/HHEYb6igDtqK5fRrLxc99Fc67rGmJApJaysLNsEY4BldiffhRXUUAeR+OdU1W2+OHgrR7TxFfWmmaok8l1ax+TtzCm5QCyFgHPB55HTHWvXKxr7wt4f1DVY9Tv9C0q61OMqUu5rON5lKnKkORkYPTnitmgbegVyvxC0m9vdMt9S0NFfXdIl+2WcbHAnO0q8DH0kRmX2O09q6qgnAyelAjzf4beINOs47DR4Jtukagr3GgtICpEYP7yzbPSSFtw25+7gfwNXpFeEeJPEfgL/AITh/Do1u3vLbxBeIJrezf5tO1AcJcxSLwjMwUNg5D4bu9eq+BNWudU0eePUcNqGn3c1hcyBdqyvG2BIB23LtbHYsR2oAxbzS9U8HajPqPhWybUdHu5TNe6OjhHhY5LTW2cLknloyQGPIIJOdCx+I3hG7t951/T7WVciS1vJlt54mHVXichlI9xXWVh6v4V0jVdXstUubSIalaNlLlI18xk7xsSDlD3H5YoAyI/ij4LlXdB4gtZ19YVeQfmoNNX4o+DzcmE6sytjO9rWZUP/AAMpt/WuzjjSJAsSKi+ijAp1AFTStRtNWsIb7TbiO5tJgTHLGchsHB/UEVbpAAOAAB14paACs3xKrvoGoCK9msH8litzCVDxkDORuBX8wa0qr6hZWuo2c1nqFtBd2ky7ZIJ4xIjj0ZTwR9aAPnFPE/iOT4O+BtePjHU01PVdYS1u2H2fAjkfYQAYuNojBHoZGzkFQO80a/1MfH260N/E2oXOk2+kLfJaSGDa8rMYypKxg4A+bAIOR1xxXat4B8HPax2reE/D5to3aRIjpsOxXYKGYDbgEhEBPfaPQVbtfCfhy01ZdUtNA0iDU0ztvIrKNZhldpw4Xd90469OKANqiiuF8V+PYrFr620U2sstiR9vv7tyllYDOMO45eTPAiT5iSASvFAHcswUZYgDIHJ7npS15ToeheJNckjvbnULjbkPHqOqW6+bx0a3sxhIBwCGk3P0JFem6damysorc3FxclAczXDbnck5yTgDv2AHpQBZooooAKKKKACiiigAooooAKKKKACmyuY4ncIzlVJ2r1b2HvWP4h8TaZoE1jDqExFxezpbwQxjc7MxwDjsM8Z6c03xjZX17otzDpMFvPdzp9nKXNzJDF5TEeYSU5ztzgjnPcDNAHmPi3x7r95qdhbWWi+R4eeeCS7vJwjr9ndZEljlRhgbWGcjIwuc4rZvvGNt4YbW7fTU0yZIHG2aP91aWCbQFFxN0Lbs4jQM2MDFcZqfgie88ZNeXGnRxkW5tLLQbaYJJcIiNDvnkGRFAUyR/Ec8cnFel+EfAMOmvZ3utvDeX1oMWdvDH5dnpwPVYI/XPWRsufUcigDmLTRdd8bztdXsUkVk3KXmrQ8fW2sScID2ecs3T5a7nRfA2haXNDdG1N/qMQAF9ft58wx/dJ4T6IFA7AV09FABRRRQAUUUUAFFFFABRRRQB5Jp5u/GXjS/0H4ieTajT1R7fQ4mb7PqaZz9qYkAypnA8rkIR8wJIr1iGKOCFIoI0jiQBURBhVA6AAdBWJ4x8K6d4r05LfUBLFcQP5tpeW7+XPaSjpJG45BH5HoQRWP4Q8S3sOrf8Ir4wKp4gijL294qeXDqsSgZliHQOMjfH/CeRlTwAdtRRRQAUUV8o/tD/HxnkuPDPgK9KxrlLzVYH5Y944WHb1cde3HJAPVfit8c/DPgGSawVm1bXUBBsrZgBE2OPNfov0GW9q+SviJ8Y/GHjppItQ1A2mmsTixs8xxY9G/if/gRI9hXnbMWYsxJYnJJ5JNeyfDP4VNPNpt74ssrq5lvB5um+H4W2T3if89Zm/5YW+f4zyecdsgFf4IeCfNu7PxfrtpLNplvciPTLFDibVb0HKRxj+4pGWc/KNpzwGx9seCNGn0Tw/FBfyRzanPJJd3ssYwr3ErF32/7IJ2r/sqKx/A3gkaPcJqmsNbT6wIvIgS2j2W2nQdoLdP4V6Zb7zY5wMAdtQAUUUUAFFFFABRRRQAUUUUAFNlkSGJ5JXVI0BZnY4CgdST2FNuJora3lnuJUigiUvJJIwVUUDJJJ4AA71434l8QP4wls2aynutDuW36NogJil1t1OftFzkfu7JcqQGHz8MwOURgDS8T+MpdeT7PpL3kGhXO63hnsiBfavL3SzB+5EBndcNgd1IHz1ueDfBK2ltptxrkVuJrJR9i0y3H+h6d6bAeXl55lbJJJI2g4rV8J+GBpc82qapKl74hu0CXF2FwsaDkQQj+CJT0HUn5myTmuloAKKKKACiiigAooooAKKKKACiiigArB8c+KdP8GeFdQ13VmxbWse4ID80rnhUX3JwP16VvV8MftPfEw+NfFp0XTJh/YGkysiMCcTzdHkPqByq+2T/FQB6T8N/EeufE3xD4bvLnVr2OIX091dWjLGkLLGQwiXAzJGqmMYPRnJPIFfT1ed/BXwfD4T8J2Mdjq02o2MkCvCJFUrHuAZjERztZyzc5JBUcba9EoAYsUayPIqKJHwGYDlsdMnvT6KKACiorq4htLaW4u5o4LeJS8ksjBVRR1JJ4A968m8X/ABSiTT2u7fUIfD+gNkR6vdx77i8x/wA+lseXHbzHG3nIBHNAHp+s6zpuiWhudYv7ayg5+eeQIDj0z1PsK5cfEBL+Lf4a8O6/rKsAY5ktfs0L59JJygI9wCK+T/Evxujt70zeCtLZL4Aj+3Nbb7Zfk56oGykX+6ox6AV5r4k8ceKPE05l13XtRvCTkI8xEa/RBhR+AoA+6pvHHiVHYjw3osYVivkz+IokmP4CNlH03VasPHeq7TJqvg/UY7bp5+mXMOogH3WM7/yU1+dFXNM1O/0q5Fxpd7dWU45ElvK0bD8VINAH6ZaF4j0jXhKNJ1CG4kiOJYQdssR9HjbDL+IFa1fBfhf40Xou7WPx9anXobcbYNRhfyNSswe8VwmC3XJVjyepFfTngz4kwTaOdTOpDXvDCAb9TjQLd2BJ+7eQqBwP+eiDGBkrj56APWKKjt5orm3int5UlglUPHJGwZXUjIII4II71JQAVg+M/DkfiTSRAs7WmoW0gubC9RQXtZ1+64B6jqCvRlJHet6igDnPBHiCbXLG5h1O3W01zTpvsuoWy52rIACHTPJjdSGU+hx1Bro6wb7w/v8AFNlr2nzLbXip9mvAV3LdW/JVCM8MrHcrdssOjVynx5+I8Hw68Fy3ETqdavQ0GnxYB+fHMhH91cg/UqO9AHlH7VXxfey8/wAE+Gp9s7oBqV1E3KA/8sFI7kY3H0OO5x8nRRvNKkcSM8jkKqKMliegA7mlnmluJ5JriR5ZpGLvI7FmZickknqSa+j/AIH/AA11LTbm1nigiTxfdRC4WW4j3poNq2QJnQ8NcSDPlxn7oG5scigCT4UfCGTSLu1kv7G31Lxg6rKLK5G610VGGVmuQD88pHKxficYyPp3wh4Vs/DcNxIkkt5qt4wkvtRuSDPdP2LHso6KgwqjgCrXhjQLHw3pS2OnrIwLGSaeZt81zKfvSyv1Z2PJP4DAAFa1ABRRRQAUUUUAFFFFABRRRQAUUVzHxF1250Lw4zaYofWL6ZLDTlIyv2mU7UZv9leXPspoA4/4h6/FrV3c6YFlm0LTriOC6jhdQ2q3xIMenoSenIaQ+nynA347TwloE2nvcarrMsd14gvlUXMyDEcSDJWCIHpGmT7sSWPJwOV+HugQS6pbSW0pl0Tw6JbOzYtk3l6xIubt/wDayXQcnlpD3Fem0AFFFFABRRRQAUUUUAFFVbzULWzltoriULLcv5cSAFmc+wHOB3PQd8VaoAKKKKACiiigDzH9ovxqfBXwy1Ce1mEep3/+hWmDhgzg7nH+6u459dvrXwt4L8O3XijxRpOj2abpL64EIw4XAGC5yemFyfw79K9c/bD8UPq/xIi0SOTNro0AQrgj99IA7H3+Xyx+Bqr+yX4Xn1n4nHVB8tvo0DymXOVErgpGCM89XPB/h60Afb1jax2VpFbQ58uNdoJ6n3PuetT02IOsSCRg7gAMwGAT3OO1OoAKhvLqCytJ7q8mSC2gRpJZZGwqKBkknsAKmryP4ya3PcX8GiWcQuIYDE8tt2vbyVsWtq3/AEzyrSyf7EY9aAMrVrvVfiRr1pZpaRtppZLuGyuAfJtrfPyXV4v/AC0kcgmK24GPmfpXyB8RdQv9R8bazJqmpT6nPFdSwLczNksiOQuMcAYHAGAO1foj4J8OR+GtDS1aZrq/mY3F9eP9+6uG+/IfqeAOwAA4FfK+sfACHV/i5d6R4b1hZdIjc3GosIju04McrDu+6zkZwOoAyw9QD590zTr3Vr6Ky0u0uLy8lOI4IIzI7H2A5Ne0eFf2ZvG2sW6XGpvYaNG65EdzIXl9sqgIH4nI9K+tfAHw+8N+A9P+zeHdOjhkYYlupAHnm/3n6n6DAHYCusoA+QZP2TdbAHl+JtNY453QOOf1rj/Ev7N/j/RbUz29tZaugJ3LYTlnAHfa4Un6Lk193UUAflnf2V1p15LZ6hbT2t3C22SGeMo6H0ZTyD9a2/CWvaz4W1uPWfD929nfRDzAwIVJk3YI2nAZScDbg9D0xX318UPhn4e+Iulm31m3Ed9GpFtfxDEsJ+v8S+qnj6HBHxT4o+G3iPwb4zOlXulDVHhTzoBEjyRXMWdu4DIONzDIyME9CKAPePhB8V4ZHcQWgtfvS3+iwAsgwSZLmx5O5Qcl4Rk4BZM4YH6N0+9ttRsbe9sJ47i0uEEsU0bbldSMgg9xivi/wj4a1e/1vVdau4G0ybTYmtrm6uohHPYzgIxeKOILuZVO9MhBjI+fGD7R4S13VfAeuzWXiYRjSbgiWaWJPLijLNgXkSn7kTllEsf/ACzkO4Da5wAe4UUUUAISFBLEADkk9q/O/wCO/jh/HnxF1C/jl36bbE2liB08lScN/wACOW/EDtX17+0z4pfwv8JdUa2m8q91ErYQkHDfPneR/wAAD89q+DtC0u41vWrDS7Jd11ezpbxD/aZgB/OgD1H4E+Fbm7mPiS4so74WswtNGsbo/uru/fpkf3IlzK/+6K+1vBnhuLw1pLQec93f3Mhub69kHz3U7Y3OfQcABRwqgAdK4P4T+HLWLVx9gUnQfC8LaNprEYE9yTm7ucepf5Mj0k9a9aoAKKKKACiiigArM17X9J0C2E+s6hb2cZOF818M59FXqx9gDXNX/iTUfEd7LpngR4AlvMYb7WZk3wW5H3o4h0llH/fK9yT8tanh7wbpWjXkmoFJNQ1mX/W6lfN5tw3sGPCL/soFX2oAyf8AhYZu3A0Dwr4m1WI5IuFtBbRHHAw07JnPsDXLXvxc1zT7tf7b8D6rpFmswRpJY3uN69yGRfLX6s+Pw5r2OkZQylWAKkYIPIIoApaLqlrrOmQX1jKkkMqg/K6vtPdSVJGR0PNXqw/+EX06HUY7/TEbTLkOGlNmBGtwO4lTG1+O5G4diK3KACvKPHerSr4t1S/T5h4b05Y7GNhw+o3h2RkepCgL/wBtW6V6vXivhxX1/wAY2skkTNDea7fasXJ3boLNVtoDu7DzCCFHvQB6t4W0aLw94d07Sbdi6WkKxmQjBkb+Jz7s2Sfc1qUUUAFFFFABRRWd4i1my8PaJeatqkhjs7SMySEDJPoAO7EkADuSBQBJrOqWOiaZcajq11DaWVuu+WaVsKo/x7AdSeBXHwXvibxmgk00TeF9Cf7txcQg39wPVI2ysKkdCwLf7K0/QPDt7rup2/iXxmp+0p+8sNHJDQ6cOzMOjz46ueFJIXpk91QBxtn8ONBhmea5/tHUJpHEjve38spZgMA4LY/Dp7V2VFFABRRRQAUyaVIYXllYLGilmY9gOSafWB8QbyHT/AniK7uiRDDp9w74648tuB70AfnN4416TxP4w1nW5eDfXUkwX+6pPyr+AwPwr6d/Zl0N7LwLom6MCTXtWe9aTeY2EFqPlHq37wdOmGNfI1fdHwashFceBrZ5EcWXhMXSLtwUe4lUk/kpH4UAe2UUUUAFcXdaMdS+JllePAgstLt3uSygDzbuQeWhb1KRBsZ/56V1WqXq6fYy3TxTTLHj93CoZ2yQOASPWp41j3O8YTLH5mUckjjk98YxQBznxF8QT+HfDEs+nRrPq91Illp0J6SXMh2oD7Dlj7KaseCPDdv4V8O2+mwMZZhmW6uW+/czucySue7M2Tz2wOgFY+sRNqnxV0C2J/caRZTai6lchpJD5MfPqB5tdtQAUUUUAFFFFABWD4x0Ftb05Gs5VtdYtG8/T7sjmGXGOfVWGVYd1J9q3qKAOV8E6fDLoNpdyWl9YX0jiS5illYSCVMoUJz80YIOB90jBxzVrxt4bi8TaObdisd1EfMt5WGQGxgqw7owyrL3B+ldBRQBl+FrGbTPDunWV07PPBAqNl9+0gfd3YG4DoCRkgZPNalFFAHx1+2t4gkuvGGi6Ajj7NY2huXAPWSViOfoqLj/AHjXEfs92Jg1fX/FWNzeH9Nkmtht3Zu5QYoRt6HlmP1Aqh+0XqUmqfGfxK8sgdYLgWycYCqihcfmDXov7OGnPP4StYRGrx6v4ptoZQ3AMVrC1w2fUZ2jHqaAPqrwPoUfhnwhpGjRf8udusbtnJaTGXYn1LFj+NblFFABRRRQAVxPjPULrV9Yh8HaJM8Fxcw+fqd5HkG0tCSuFboJZCCq+gDN/CK67UbyHT9Pur26bbb20TTSN6KoJJ/IVzHwxsbhdAbWdUUf2vrb/b7k9SgYfuogfRI9q49cnvQB0ej6ZZaNpdtp2lW0drY2yCOGGMYVFH+evU1coooAKKKKACiikZgqlmICgZJPAAoA86+Lnii4s7ePw5oTyHWtRXaxgYebBEx2gr6O5yqnHGGb+GtHwL4G/wCEduIL671Ge6vIrEWEVugVLW1i3BikShQx5Ay7lmOMnHSuU+FcTeJvGeqeK7kbkyxhDj5oy/Eag/7MIXj1mY969goAKKKKACiiigArg5lXxj48a3lRJND8NSpIwPPnahjcvtiJWB/33H92u3uphb2s0zAkRoXIHfAzXKfCS1eDwDplzcYN3qKtqNw+SS0kzGQ5J5OAwH4UAdhRRRQAUUUUAFFFFABXn37QE8lv8GfFjxAFjZmM59GZVP6E16DXmv7SL7Pgn4oOJTmGMfu+vMqdfb19s0AfnrX318HEj/tlAxKz23hbRoAvT5SkpJx9eK+BiSevNfe/wevPtut2k4mUCXwppUgg2jcP9Z8xI9+MUAeuUUUUABIHXiimSxRy7fNjR9jB13AHDDoR71W0lDHYRqXmflvmmUq33j1B/wA4oA5TSy5+Mev784Gj2YT6ebPn9a7euJinaH40XEBClLnQUcMG5Vo7hgQR7iVTn2rtqACiiigAooooAKKKKACiiigAooooA/Mz4hy+d4/8TSA8Sanctx3zKxr6H/ZmBXR/BEZOEl1vUpsepWzVQf1NfOfjpdnjfxCozhdRuBz1/wBa1fVf7OumIi+A7ea1Zbiy0W+1RnI4zc3QSM59THGfwFAH0bRRRQAUUUUAcV8X0a48Ey2AfYmoXdrZSEdfLknRXH4qSPxrtFUKoVQAoGABwAK4H4z6tb6V4e01rtJdsmq2e2RYi6KyzI2GI+7kAgHpnjvXf0AFFFFABRRRQAVieOJprfwXr81snmTx2E7omM7iI2IFbdRXdvFd2s1tcLvhmRo3X1UjBH5UAcD8DYY4fB0uN32g3J84McsMIgQfTYEx7V6HXingjVZvA19qlpqttqF1bW7JZ3klnbvcNFJGmIZmjQFgksHl5YA4aMg44r17RNUs9b0i01PTJvOsrqMSwybSu5T04IBH0IzQBdooooAKKKKAKOu7v7D1HZ977PJj67TWX8OSrfD/AMNGNgynTbc5H/XNa35o1mheKQZR1KsPY1xvwYjWD4Y6BbxszJBC0CluuEdlGffigDtaKKKACiiigAooooAK4H49wmf4OeLEGeLFn4GfukN/Su+rC8eaW2teCtd02NA8lzZTRop6Fih2g+2cUAfmcxjyxijZl2DO/qpwMnj3zjPrX3L8BkRr2xkXcJE8JaRHKMcDPmlefcc47V8LndLLwuXc9FXGSewA/kK/QP4L6abCbXo1QrFZCx0hcnJJtrVA2f8AgTkfhQB6dRRRQBS1uw/tTSLyxFxNbG4iaMTwtteMkcMp9RXnnwj16K58QeJdMiup57eWUanam4UrKA5Mc6EHptmjbjtvFeoV4NqRl8K/GG+n0y3eWQzCRLbdtEy3sbArknAH2mBT7b2NAG34i1zSptf0jx7pDMsek6nL4d1eR02/uXcRlm/2Ul8tgfQmvXq+av2Y9A1bxB8PPGNr4ntgdF8QSyPHc7lLSStvjmYAHjDKpB45BxXs/wAJ9Wn1jwHpkl84bULVWsbvnJ86FjG5PJ5JXd+NAHXUUUUAFFFFABRRRQAUUUUAFFFFAH50fHPS49K+Lfiy2jUQqL1pljOSSJAJMj2+bP419Yfs7sbyCW4YMBYaPpelgdMOsHmuCMdQZRXkP7WPhJB8XNCvgJFg15IoJXA6SIwjOD0zsKcf419D/Bx45dL8RSQRCKE69exxrnPyxuIx/wCgUAd9RRRQAUUUUAYHj3RD4j8HatpUYUzzwEwbsYEqndGT9HVT+FSeCdcHiTwnperFPLkuYA0seMeXIOHX8GDD8K264P4WA2d14x0gIyQ2OuTNCC2QEmRJsD0G6RuKAO8ooooAKKKKACiiigDgtS3af8Vv3UqoNX0SVfLUfO8sEgKsOefllI6dhWh8JZfO+GnhuQ5y1lHnIwc45yPrVDxzGlt8QPAGpvAzBbq6sfNB+550BIz9TEBVr4QuT8P9OhkBWa1ea1kUjBVo5nUj9KAOyooooAKKKKAA8iuK+FCjT9AuPD0js91od1JaOztlnUnzI3/FHX8Qa7WuJ0yEWvxh13yZG2XmkWk80eeBIskqBsepUY/AUAdtRRRQAUUUUAFFFFABRRRQB8E6l4Sj0z9puDw/LEXtm16F9jAYaGSRZAOmMbGxX2B8I03eG768Zg732rX1yWHfNw6j8goH4V5p8bvDf2D41fDnxfBGoiuL+HTblz0WTd+6Y+5DNz/sCvSPgi5Pww0SOSNY54Flt50BBxKkrq+fcsCfxoA7miiigDN8Sz6na6DfT6DaRXuqRxFre3mfYsrj+Et2zXz/AOOdU8YeIlil1f4eWfh3VoUa2j1671ESi1EgwfJjQZkkOW2gbiGPA619JV8ofHf4jXtnbT6jYXBS+1Ge50/S2RubG0hby5pk/uzSyBlD9Qi4GDzQB3nhLxzJ4bbw94M8PeHHuLe1aOzkie6H24JwGuHhjVliGSXYSOp5xgV3PwoaGSHxY9smyNvEV706MwZQzD6sDXzt+zx8bLrR7S/0PxCILi1t7R57EogS4mmG0LbjA/eM5PBOWz1JHT6f+HOkXGieDNNtNQRI9QZWuLpExhZpWMjqCOuGcjPfFAHSUUUUAFFFFABRRRQAUUUUAFFFFAHkv7SWhx33g3TtaeJnPh/UoNQk2LlvIDgSgd8YIY/7lbvwdfOj69FJsFzFrt/5qrgAFpS6nA6Ao6EexrtdQs4NQsLmyvIxJbXMTQyoejIwII/EE14f4W1K7+H3i+PSdYBwsAtLnapJvLaIYt76IAfMyR4jmQZYBQ/IFAHvFFRWtzBeW0dxaTRT28g3JLE4ZWHqCOCKloAKK5i68caJbeN4PCz3tsNTkt2uHVplXyxkBVIJ5ZskhRzgZxgiuhu7q3s7WS5u54oLaNdzyyuFRR6kngCgCSSRIo3kldUjQFmZjgKB1JNcV8Kke703VvEMhfGvX8l7AG6i3AWOH80QN/wKsq/1Kf4nMdL0DzIvBxbbqGrEFRfKD81vbg8lG6NL0xkLnOR6TBFHBDHDBGkcUahERFAVVAwAAOgFAD6KKKACiiigAooooA4/4saZd6l4Ju30uIy6rp8kWo2aquWMsLiQKvI5YBl/4FVL4c6vbTapq1nA7GC+2a5YkgANBOo3AY7rIGz7sK72vD/EmlXXgHVrWaKeC10SO7kn0nUpg3k6a8x/e2d0B0tpDysv/LNsA8BcgHuFFcRbfEnRoljTxCl1oNy6hlF7HmGUHHMU6bo5AcjGGzzyBXau6JG0jsqxqNxYnAA9c0AOorzTXfF2ueJle1+GFnb30UE6i51a6lMVqwVstFC4BMjHBUuoKrnqT0Lr4ja9pmoWWn6x4A1Vb69Z1tksb23uUlKLuYglkIUDHzMo6j1FAHo11cQ2ltLcXUqQ28KGSSSRgqooGSST0AHeuK+GMb6o+s+Lpww/t2dXs1dcFbKMbYeMZG4bpP8AgdQDRNc8bsjeNLWLS9AUhhoUUwmkuWByDcyL8u0Yz5SZBP3mbpXoAAUAKAAOAB2oAWiiigAooooAKKKKACiiigDE8a+HoPFXhq90i5cxecoaKYDJhlUho5APVWAOO+MV5d4T8S3nh3XNV+2WU5mJE+vaTApeW1nIAN9aoOZbeXGWC5ZTzj7wr2ysPxP4V0jxMkB1W2JuLZt9vdQyNDPA3qkiEMv0Bwe+aALOia9pWu2kVzpF/b3cMql0Mb8kA4Jx1GDwcjrWnXPeF/DbaHNcyT6tfaq0gCQyXwjaWFOpQOqgsCeTuzzXQ0AcN8PvFV5qviPxjoGs7RqOjagfKwm3faSjfA3ucZBPsD3rjfHXwVPiG7cKdJvLBZZJrWO9SaOW0aRy8iB4nXfGXYsAwyMnBq38TJZPA/xO8PeNLS0nvItWQeHrq2hcKXkdw8D89ejgn2Ud69goA8i+FfwJ8OeBb2LU5SdU1iIkxTyJtSHPdEyefck+2Oc+u0UUAFFFcp8NL27uPDjWeqzPNqmmXM1jdO7Fi7Ix2vk9d0ZRv+BUAdXRRRQAUUUUAFFFFABRXNeFPE58T3l/PpttnQIG8m31BmwLyQEhzEO8akY3/wARzjIGT0tABWR4n8O6Z4m037Fq9v5iKwkilRiksEg6PG4wyMPUH26EitC7u7ezjR7ueKFHkWJWkYKGdiAqjPckgAVPQB5ppng7xV4SmlHhLVtKvrKdi8sGrwNHJu7MJIcAn1+Tn9ay/EEvxIa/8rXk8jw80eXfwkvm3e7IyrNMQyjrzGua9fooA8cH/CBro6adF8P9W1IhjiKbQneaSTu7SygZY93Zvxp3gf4RaQ90dW8RaBDZxKR9h0F7p7q3tAM/O4YlGlOeQMqoAAycmvYaKAGxosaKkahUUAKqjAAHYU6iigAooooAKKK82+JPiHVdF1e7jsJ5Yk/sSa9hwoKl4JkMuMj7wjbp37c0Aek0VHbTx3NvFPA4eGVA6OOjKRkH8q5H4mNJp1jpfiGOSVY9FvUublUyd1uwMcuRjkKrl/baaAOypssaTRPHKivG4KsjDIYHqCO4pVYMoZSCpGQRyCKWgDiE+GHh6zaVtBOp6CZZDI66Tfy28ZJ6/ug3lj8F47Vk6z8HtO1Ozhhn8Q+Jp3ikEoF/qDXsLkHIEkMu6N19sD616bRQBwEHhXxqimA+PIYbNQEjW10OGN41AwACWZf/AB2t7wx4R07w9cXF3C93fapcgLPqF/MZ7iRQchdx4VQf4VAX2roaKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDH8T6HHr1rZQyuEFtfW96Dt3ZMUgfHtnGM+9bFFFABXIeBHa21XxXpU8sjzW2qNcrvyf3U6rKuM9gxkX/AICa6+uK8UL/AGB4x0vxMGSOwuEGl6mzEgKrNm3lPYbZCUJPaX0FAHa1xevpH4U8Q3Pix5jHpFxbpDqybWfYUOI7gAA/dDFX/wBnB/hNdpSMoZSrAFSMEHkEUANhljmhSWF1kikUMjochgeQQe4p9cVH4c1PwqkjeC5IptPJLjRL2UrEhJyfIlwxiHX5CGT0C1SsbXx/4jgE+qajbeEY/NZTY2VvHdz7BwCbhyU568R8UAehVFdXMFpEZLqeKCMdWkcKPzNcYPhtplx/yGNX8S6sSMH7Vq8yKffZEyJ+Qqxpvwx8EadGFt/CukNg5Dz2yzvn13Pk/rQBb1Lx74T0238688SaQiH7oF2jMx9FUElj7AE1iSw6548k8u7hudB8JE/PC5Md9qK8fKwHMER7rnzGHB2AkHoIfBPhWBWWHwzokYYksEsIhknrn5a27W3htLaK2tYo4beFAkccahVRQMAADoAKAFtoIbW3it7aKOGCJBHHHGoVUUDAUAcAAcYqj4g1qw0DTXvtUnEUKkKoA3PK5+6iKOWc9Ao5NJ4lvdR07Rbi50XSm1fUEA8qzWdIPMJIH334UDrn2715fo1/fWOsTa7488J+IrnXooiYpLaCO7tbROSUtljckE92Ybj644oA6fRNKvNav4fFfjWMWgtd02m6ZKwCaehH+tmOcNMV6nogJA5yStx46utXaS38BaPLrUgO3+0J2Nvp6HpnzSMyY9I1b6iqej6S3xCjg1vxNdRXOhuyy2ehw8woR3uT1lkB6ocIpGME816LGixoqRqFRQAqqMAAdhQBheGNP1+2knufEetRX0syri1trZYoLc9whOXb6sfwrforL8QeIdH8O2gudd1Oz0+AnCtcyhNx9BnqfYUAalFYPhzxZo/iOaWPR55pxGgkLtbSxoQSQNrMoB6dq3qACiiigAooooAK4z4mwx21ppmvyRLJFo9z5t0Cu7NpIjRT5HoFfef+udXfFfjzwt4TikbX9dsLN0XcYGlDTH6RjLH8BXlWu/tN/D9RNZrZ6xqltIhRzHaoI3UjBBEjqcHJHSgD0v4ZeZYaLL4euizTaLIbaJz/AMtrY828gxwQY8Kf9pGHausuIYrm3lguI1khlUo6MMhlIwQR6Yrwb4WeLYtZ0bwXrumpcLJHqEvhi4jlOWkt/LaWIse7IqxnPP3n55r32gDi/Ak0+iXM/hHVJZZJbMGTTbiX/l5s8jaM92jyI27kBW/irtKxvE/h218QW0CzSz2t3ayCa0vbZgs1vJ0ypIIwRkFSCCDgg1gjxN4i0i5TTtX8Lajq0/zGPUNIERgmRf4nEkimJzn7mSM9GPYA7eiuQTx1FFcPFqfh3xPp4VSxkfTWuE/76tzIKu6P438M6xMkGn65YvdP0tnlEc30MbYcH2IoA6KiiigAooooAKKKKACiiigAooooAKKKKACiiigArz344eJNb8JeDP7Z8Pz2ccsVxFFJHc25lDiR1QYIdduM5756cda9CrA8Y+ENE8ZWEVl4itZbq1jfzFjS6lhBbsT5bLnGMjOcUAea+KviZrfgrV/Euj66bO7vU0qC70SSGAxfa5mIhZSm45/fMDtByFzyetevaQLxdKsxqjRPqAhT7S0Qwhk2jdtHYZzj2rE1LwL4c1S70C61HTRdXOhbTp8ss0jPERtwSS2XPyKcvu5GepNdNQAVX1CzttRsbiyvoUntbiNopYnGVdGGCD9Qag17WdP0DSbjU9Zu47SxgGZJZOgycAADkkkgADJJIArjBY6x8QEkbWlvND8LMdqacrGK7v07mdgcxIf+ea4Yj7xH3aAKHhHxPe2GtP4W02OfxXY2riOPVreVT9lUEAxXUjEKZEHQqSzADKg5J9Rqrpen2elWEFjplrBaWcC7YoIECIg9ABwKtUAFFFFABRRRQAUUUUAFFFFAAAB04qO4uIbZA9xLHEhYIGkYKCxOAOe5JAqSq2p2FpqljNZajbRXNpMu2SKVQysPcGgDjL3Xta8U3k1h4Ikis7CFzFc69PF5iBlOGS2Q8SMCCC5+QEEfMeBqeHvAuh6LKbn7O+oam2TJqOov9ouXOc/fb7o9lAHtWBbu/wALUtrOdp7jwQWEcV1I259IzgLHIcZaD0c5KdGJGCPRgQwBUgg8gjvQAteJWPxN8QTXw8KSJYjxkviI6a6iM7PsQXzTchM5x5YOOeuD7V7bWAng7QE8ZSeK106MeIJIPs7Xe9slOBjbnbnAA3YzjjOKAN+imySJFG8krqkaAszMcBQOpJr5X+OH7RpDT6H8O51KlWjuNWAOQehEH/xfPX5ezUAeu/FT4z+GPh5m2u5W1DWCMiwtWBZfQyN0QfXJ9Aa+U/H/AMffGvi3zIILwaLpzE4g08lGZewaTO4/hgH0ryiV2lZpZJC8jsSxYksT6k985rp/AfgTWvGt1KulxRQ2NuN13qN0/lW1qvq8h4H0GT7daAOXdpJ5md2aSV2ySTksT/M16t4M+EE9xbQan46u5/D+mznFpaLAZdQ1Bv7sMA+bp/EQeo4IOR7N8KPhjbWLxXHgqFZJVHz+K9WtQ6lu/wBgtyen/TV+PTcDXunhjwlp2gSS3SGa91af/j41K8YSXM3sWxwo6BVAUAcCgDnPhz4LTS10+5k09dKsNPjZNL0oMHeDfw88zj707jjgkKCQCSxNeiUUUAFFFFABVHVtH03WIfJ1bT7S9jwQFuIVkABGDjI4q9RQBj6F4fttCeRdPuL4WbKFS0luGliix3Tfll442hto7AVsUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABVDXtYsdA0i51PVZ1t7O3Xc7nnvgAAcliSAAOSSAKv1wWkx/wDCZeMLnVrrE/h7R5Vj0pMfup7kA+bcEH7xQ/Ih6AhyMkggAXw9od94j1a38T+MIGhaFvM0rR3OVsRjAllHRpyD7hM4HOSe8oooAKKKKACiq2p39ppWn3F9qVzFa2duhklmlYKqKO5JrzbxB8R7z+yX1OySz8PeHz9zWdfDo03XmC0GJHyORuKEjkAigD1KmTyxwQyTTyJHFGpd3dgFVQMkknoBXx14p+O8UfGm694r1i8jYFZw0Gm2wKnIKxJGzMpxyrnkV9N/EaDUNW+GWtppDQwahPYM8fnIsiZ27ipB4OQCMkY5zQBbsvHXhK+maGy8UaFcSryUi1CJyPwDV0KsGUMpBUjII5BFfnxa/GfxHjbq2n+G9Zi6FL7R4MFf7vyKvFei/D34t+GkmSOzkvvA2oE8CKZ7zSZWOB88DHMQPTKYwBktQB9h0VxfhHxwmp3kGla1FBZ6tNF5ttJby+daajGBkyW0vRx3KnDKD0I5rtKACiiigBk8MVxBJDcRpLDIpR43UMrKRggg9QRXEaKZvBOs2vh+cyS+Gbv93pdzI242cmeLR27pj/Vk88bCSdue6qtqNja6lZS2l/Ak9tKAHjcZBwcj8QQCD2IoAs0UV5f+0P8AEJvh/wCApZ7F1Gs6gxtbLkZjJBLS4PXaP1K560AeQ/tW/F1pJLrwN4dmKohC6pcxt949fIUjt/e9/l/vA/LZb5AuBwSc9/8APFLNLJNM8sztJLIxZ3c5LE8kk9zXs/wN+GsGoQL4x8XWrSeH4JfLsbHH7zVbnOFiRf4l3DB7EgjoGwAU/hp8KI7/AE6y8ReNnu7XRbmQJYafapuvdVfssK9l7lj2yeB8w+qfB/w5iawsx4j0+0tdNtW32Ph22bfa2vo0x/5eJu5ZsqCTgE/Md/wT4buLVm1rxGltJ4huF24iGY7CH+G3h9FA6kY3NknjAHXUAFFFVtSvrXTLCe91G4itrOBDJLNKwVUUdSSelAFmsfxH4m0Tw1bCfXtUtLBG+6JpAGf2VerH2ANcXdaz4g8X2rXenXJ8I+EFUu+rXaqt7cx8fNEjjbAhGfnkBbGCFHWsXw1/ZMV7Lc/DTw1L4k1Fzsn8S6tcsIi3QkXEgaSQDHIiUr70AdNF8STqTAeGvCXifVkZS6zmzFnCwzjh7hkz9AKWPxJ4+uUPk+ALe1Yf8/uuRDP/AH6R/wCdJH4W8ZatiTxF41ksdwBNpoFokCIe482USO31+X6U8fCvQp4DHrF/4j1g5yGvtauTg+wR1UfgKANXQdT8WTXcMWu+HLC0gcndPa6n5/ljHGVaNCcnjjNdRXN+HvBOi+HpS+krqMWeqyandSoeQfuvIR2Hb1HQmukoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDkvGEt3qupWvhfTpXthdxNcX91G2HhtgQu1PR5CSoPYBz1Az01haW+n2UFnZQpBawII4ooxhUUDAAFc34L/4mGp6/rzcrd3X2O3bH/LC3JjH4GUzsPZh9a6ugAooooAKp6vqdlo2l3Wo6pcx2tlbRmWaaQ4VFHf8A+t3q5XkPxC8S2E1zqurazl/CXhGQGWFWBGo6jgbIsY5WMsnt5jDP3DQBynxR+IS+H7a28ReLLYT30583w74ZlGFt17Xl2O8nov8ABnA+bcy/K/iTxF4j8e+IRdatc3eqanN8kUaKWwP7kaKMAewHvUXjfxJqXi3xPfa1rMxkurp94XfuWJDysa+gUEDH585r6S/Y88G6baWdz40vNUs5b2SOS1itQ6lrRNw3PJnlWbbx0+U5yd2AAeYeDf2f/HOv6hbRaho/9kadIUeW8u5ArImOQqAlixHYjqACVGa+6lsYRpgsCGa3EPkEMeSu3byfpVFPE2guyqmt6WzMxVQLuMkkdQOevIqfVtb0rRrcXGr6nZWMBGRJczrEpHsWIoA+edU/ZO0aQzHS/Et/b5JMYngSUL6AkFc/pXlviv8AZs8c6Jb3NzYpZ6xbw/MFs5D5zr3IjYDJ9gSfTNfVmofF/wCH9havPN4t0l0UZKwTec5+ipkn8q8+vf2pvBMKt9msNduHHTEEaKfxMmf0oA+a/hx8Qbnwq7aJr0VzeeG3nDzWitsns5lPE9ux5jlQ89gcYPqPs34beMpL02ekazeQ3s1zAbjStXhG2LVoB1OP4J0/5aR9uo4yF+Ifi14ts/HHji+16w0pdLiuQuYhJvLsBjzGwAAxAGQPzJ5PXfAjxekdwfBut3r2um6hOs2nXufm0y/X/VTIT0BOFYdDnngtkA+9KK5/wPrk+u6EJNQgW21a1le0v7dTkRXCHDbf9kjDqe6uproKACiiigAr4G/ad8Yv4r+KV/bxO32DR2awgU9Nyn962Pd8jPcKtfb/AI11xPDXhDWdakAYWFpJcBT/ABMqkqv4nA/GvzJnleeaSWZi8kjF2Y9SSck0AdL8MfC0njPx3o+hxhvKuZx57DjZCvzSNn2UHHvgV9yeAdPt9e1G21+3gWDw3pcZsvDtqownlgbHu8dcuAUTP8AJ/jNfNfwA8PSv4a1CaH93qHii7Tw9ZyDho7cDzbyQe3lLgEfxV9q2VrBZWcFpaRJDbQRrFFGgwqIowFA9AAKAJqKKKAGTSxwwvLM6xxRqWd3OAoHJJPYV5HqesWPiGL/hL/E3nf8ACG2cwXRdMEZaTVZ92En8rq5ZuIoz2+c4yMdD43U+K/Etn4MXcdMEYv8AWypI3QbiIoMjp5jqxYd0jYfxVX8IW48ZeJT4tuCG0TT3e18P26jCYGUluyO5cgqnYIMgfPmgCTTPCF54onh1n4iKszZMlr4fDB7OyB+75g6TzAdWbKgk7RwGPoKqFUKoAUDAA4AFLRQAUVxV/wDE3w1Dez2OnXF1reoQgl7XR7WS8ZSOxZAUU9vmYc1T/wCE28UXSpLpfw31x4GOM3t5aWrj/gBkJoA9BorhLDx9c2pf/hNfDWo+GkJ/d3EjLd25H+3LDuER/wB/A9+1dpZXdtf2kV1Y3ENzbSjdHNC4dHHqGHBFAE9FFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABWb4m1H+yPDerakTgWdpLcZ/3ELf0rSrlficPO8Hz2fB+33NrYkHus1xHG3/jrMfwoA0vB2nHSPCWjaewO+2s4onz1LBAGJ9yck+9bFFFABRRRQBj+Mdbi8N+FtU1iflbO3eVV/vvj5UHuzYA9zXyP+0rqkmheGvC/gESB7qKP+1tWlzuMl3IWJ5/3mlbB7MvpX078R1+3zeGdEDDF/qsTyoTgPFADOwP4xrxXxR47h1L4ifHLWrXRoDeXd/qMsFsDwDGmUVieyqkec9gDQB5zBDLcTJFBG8srnCoilmY+gAr02x+BXxH1Fbd4vC0lskiAgzTxxnp1ZWfcp9sD6V9jfCL4ZaP8N9BW1sUWfU5lBvL5h88z+g/uoMnCj8cnJrvaAPiPTv2XfHVzg3VzolkO4luXZv/AB1CP1rWsf2UPErsn2/xBo8KnO4wrLLj0xlVz+lfY1FAHy7p/wCyVaqh/tHxZM7548iyCAD8XNb2n/sreEYl/wBP1fWrkjgeW0UQ/wDQCT+dfQlFAHz7qX7K3g+aAiw1TW7WbszyRyr+I2D+deO/EP8AZw8WeFrdr3RXTxBZpywtYytwg9fK5yP90k+1fclFAHgfwr8aC6tPD/i6eYiHVVj0LXgTnyb6P5YLh/TeCEJ/2489K98ryTx74T07w/qOqa8kAXwzrcf2XxJaKdqoGOFvkGOHQn5sdju6qSet+HWr3NzYXOjazcefrujuLe6kIANwhGYrgD0kTBz/AHgw7UAddRRRQB4v+11qZ0/4NXVuo/5CF5Ba5zjGGMv/ALSx+NfCdfXv7b975fhrwxY5/wBddyzdf7iAdP8AtpXyl4fs21HXtNskQyNc3MUIQdWLOBj9aAPtb4PaHHaXvgzTPJiB8P8Ah43cpCltlxeuGI3dAdsb/g3pXt1cV8Oljn1PxhqKIcTau1tG5XAMcEUcQVf9kOso+ua7WgAqK7uIrS1mubl1jghRpJHY4CqBkk/gKlrhPirMdRtdL8I27kXPiG48iXaxBW0TD3DZH+wNn1kAoA4uFtRu/AwZfPg8R/EO/J3cCSzs2Xr7eXbJx6O/qa9m02xttM061sLGJYbS1iWGGNeiIoAUD6ACuO8P7Nd+JGr6lGq/YNBhGj2oGCpmbbJOy+mB5Sf8BYV21zPFbW8s9w6xwxIXd2OAqgZJP4UAZXivxHp/hfSTf6o8hDOIoIIU3zXMrfdiiQcs7HoPxOACRykXhXV/GiNcfECWS102X/V+HLOfEQX/AKeZUw0r9PlBCDHRutL8P7STxVfp491qMlrhCuh2z9LOzbpJjoJZRhmbqFKqDjOfQ6AKml6bZaTYxWWl2lvZ2cQxHBbxiNF+gHFW6KKACqOn6TYabPczWFrHbPclTKIhtViM4O3oDzyQMnjPQVeooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACuX8dfO3h235xNrFvn/gAaX/2nXUVy/i8Z8QeCM/9BiT/ANILugDqKKKKACiiigDhPE++T4qeFMsPKtNP1C629Pn/AHKAn8Hb868k/Y88MLc2useN9QUteXM8lnahhxHHkPIy/Vmxx/db1Neu+L7dv+FheFZBK0cd5b32nS9MENGsg/HMXH41mfs3Wi2XwX8OwKDlftG4nuftEmTQB6ZRRRQAUUUUAFFFFABRRRQBHcQxXNvLBcRrJDKpR0YZDKRggj0xXjeoaZq/hXXNNtrExfarP9zol5O+F1G1PLaXO5+7IMZjc5B2juGz7RWd4g0Ww8QaRcabq0AntJgNy5wVIOVZSOVYEAgjkEA0ATaTe/2jpttefZrm1MyBzBcx7JYz/dZexFW6hsrf7LZ29v5s03kxrH5szbnfAxuY9yepNTUAfKf7ckf73wdJhul2ue3/ACx/WvA/hMgf4p+DlPQ6xZ/+jkr6I/bjjJ0zwjJjhZrlc/VY/wDCvnr4QAt8VvBwH/QXtD/5FWgD7s+CszXXw+truTPm3N5ezPkY+ZruXPHau5ri/hER/wAIcyDHyalfqQOxF3LXaUAIzBVLMQFAySeABXkUPiB5IdW8fx2/nXGo7dF8NWxOGmQuQr+wlky5yOI41NdB8QZ5vEepQeB9LlkT7YnnaxcxHBtbLPKZ7PLyg/2d57CoPC8EfijxYNXgijj8M+H99ho8KoAkkyjZLcLj+FQDEnbhyOooA6rwXoKeGvDNjpYlM80Slri4brPMxLSSH3Zix/GsH4xSTT+FoNDtGdLjX72HSw6DJSNzmZvoIlkrua4LxGqaj8X/AAha+UznTbS91Fn/AIVLBIVz7/O2KAO6gijghjhhRY4o1CIijAUDgAD0p9FFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXMeLv+Rg8Ef9hiT/0gvK6euW8buLfUfCN5JxBb6yokPp5tvPAn5yTIPxoA6miiigAooooA5f4jaZdah4d+0aZH5mqaZPHqNmmM75Ijkp/wJS6f8CrH+HWp2kN/dabbZGn6jnWNKcjAeKUhpY/ZkkLZXqA49K9Ary/WvDL2mpzaZE4gtL64a+0S9A+bTdQwzOnTAjfkgd90i45FAHqFFY3hHWG1zQoLuaE292paG6gP/LKdCVkX6BgcHuMGtmgAooooAKKKKACiiigAooooAKKKKAPC/wBsXSDf/ChL1S2dOvopjhc5VgYzn05cV8feAbx9O8deHb2MAvb6jbygHoSsinH6V98/He6061+EXik6vII4JLKSJPVpWGIwB3O/bXwF4U8P33iC8uVsI7grZ20l5PJDEZDEiDOcD1OB+NAH6DfDlVtLvxZpqsp+z6zNKFXoqzKsuPrl24pfFnjVbG//ALC8N239seKZQNtpGf3VqD0luXH+rjHp95uAoOc14h4QuvD+j6Imlz/FLU7ywnYNJYaLpLw3M8rAbt0qq0rE4AJypxxkV6XoFpqdzYHRvAugS+ENBZgZ9Wvowt1Nn7xjiYlzIf8AnrL9cNigCvHp91I114O0W/e71m/Y3HijX4/laAMBmNMfdkZfljT+BBu9M+qaVp9ppOmWun6dAlvZWsawwxJ0RFGAPyqr4b0Kw8OaVHp+lxFIVJZmdi8krn70jseWcnkk1qUAFcKmnw2Xxqe/3FH1HRPL2kcO8UwyR77WXPsBXdVxviRyPiX4MVASxhv92FyAuyPkntztoA7KiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArjPi8bqHwHeXtggluNOnttQWI/8tPInjl2+2dldnWH45gW48G63G6eYv2OVtmcbsKSBn8KANtTuUEdCM0tU9FuxqGj2F4q7FuII5guc43KDj9auUAFFFFABWX4n006toF7ZxnEzx7oW/uyr8yN+DAGtSigDgPCGpufE0DxxRrZ6/YDUD5YwEuotqSj6EFOfVTXf15l4enja98L5j8xm1XVEhfzMbFHnZwO44xivTaACiiigAooooAKKKKACiiigAqvqF5badY3F7fTJBa28bSyyucKiKMkn6AVYr52/ak8XX17c6X8OPC7O+rau6G6VOnlMSFjJ7ZILN6KOeDQB5F8QPFuqfGvxdc7r1dI8EaQTK09wD5VtFnb5sgHLyv0VBySdo/iaqdn441eJZPC3wU0u/s7BiPNureEy6hfEZHmSuAdi88KuAvPPJp+jeGV+IHijS/APgqRl8Pab++1DU9vFzKOJLornpzsjUnIHpubH014K0LS/hBqR0aM+V4e1eRGtrycjMd0ECtFK/fft3J0GdyjtkA439nHw7480i+kfxBbX9rbSM01/JqNxve5kIKoEGWOFXBJOMk47V9D0UUAFFVjf2g1JdP8AtMX25oTOLfeN/lhgpfb1xkgZ9as0AFcfNuv/AIrWyx5MOlaXI0jKMjzJ5FCqfQ7YifxrY8U+IrDw3p63N+7NJK4htraIbprmU/djjXqzH9OpwATTvDthJa281zeRqmo3r+fc4bdtbGAgPcKoCjtwT3oA1qKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACmyIskbI4DIwIIPQinUUAcZ8Mbl4NMvPDt66nUNCnNq4HBaE/NBJj0MZA+qt6V2dcp4t0K/bUIPEHhh4o9dtk8p4ZjtivoM58lz/CQeVfnaSeoJqTQfGulancfYbtzpWtooMumXxEcyk91ycSL/tISKAOnopkk0UShpZERT0LMAK4LXfGZ16K90T4fMNT1Vw1vJqER/wBE09iMb3lHDMM5CJliRzgc0AegVz3jXXZ9G0+OHS7SS91q+YwWNuinBfH33PRUUfMxPbjqRXnp1b4ieELTR9DSy8KavdsiW1tDFfTpcSKow0zB1PyjG5jnjpySM9SmgeKvEMDW/jPU7G0sG277LQjKhmHdXnchth6EIFJH8WMigDM8B6f9u8QWcts/n6H4ctnsra77Xt65/wBIlX1VcFc92Z+uK9NqCxtLawtIrWxgit7aJQkcUSBEQDsAOAKnoAKKKKACiiigAooooAKKKKAI7mZLa3lnlOI4kLsfQAZNfn0fENxqMvjfx5dSlNRu5PsVlnqjXG4NjB42QI6g/wC0K+3/AIrSPF8MPFskRYSLpN0VKnBz5Td6+CL9BD8IdGIU7rjWrxi2eoSG3AH/AI8350AfWX7JPhKPQPhmmrSov27W5DcM2OREpKxr9PvN/wADr2XVdOstX06ew1S1hu7KddksEyBkcehBrA+FduLX4ZeE4R/BpVqOmOfKWupoA8/h8A6porEeEPGGqafZlgRY36LfwRqP4I9+JFH/AAM1zXiW8+KOkXyx6ldwTaCwwb/w9pRnvVOeA0MjkKMZJZQ2PSvZaKAPBZLr4apbo0N94lXxPvP+nxW92dWaT0Y+X8y9thHl+wrovC2mfEvU4p573xUdN09nH2RLzSIWvWjwOZQrBEbrxgn1APFesUUAcz4d8H22l3i6jqN5d61rQDBdQvyrPErdViVQFjU+igE9ya6aiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACszXPD+j69CsWt6XZX6KCF+0wrIVz12kjj8K06KAOCvfhB4DvYJYbnw5bOsibCd75Uf7J3ZX8MVNa+AZLSGO1tfFGu2umRKEis7UwQJGo6KpSIEAfXmu3ooAw/DfhXR/Dplk021P2ub/X3k7tNcTf78rksRnnGcDsBW5RRQAUUUUAFFFFABRRRQAUUUUAFFFFAFDX9Lg1zQtQ0q8Gba9t5LeT/AHXUqf518FXuhT/8KY1aB4XN74a8SOlySMeXHNGsZ47fvIQOfUV+gleI6l4as9K+O13p09oJtB8eaXMt3Bj5ftEIyzZHIyrZz/efIoA9F+Fmrx678OPDepRYxNYRbgBgB1UKwH0YEV1NeH/AeK78C+L/ABH8NNRuTPb2gGp6TK/V7Z2ww+oYrkeu/tXuFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVk6toUGp6zouozSSLLpcsk0SrwGLxtGc+2GzWtRQByuseD4L/wAfaF4rimeG+06OS2cD7ssLq3ykeoZgecjg8Z5rqqKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    There are several variations of aortic dissection. Class I- classic dissection with separation of intima/media and dual lumens; there is a flap between true and false aneurysm and clot in false lumen; class II- intramural hematoma with separation of intima/media but no intraluminal tear or flap imaged; class III - limited intimal tear without hematoma and eccentric bulge at tear site (limited dissection); class IV- atherosclerotic ulcer penetrating to adventitia with surrounding hematoma that is usually subadventitial; and class V- iatrogenic or traumatic dissection, as for example due to a coronary catheter causing dissection.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from Lahey Clinic, Burlington, MA, and by Svensson, LG, Lalsib, JB, Eisenhauer, AC, et al. Circulation 1999; 99:1331.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_3_36912=[""].join("\n");
var outline_f36_3_36912=null;
var title_f36_3_36913="Ruptured ovarian cyst";
var content_f36_3_36913=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F75150&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F75150&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Ruptured ovarian cyst",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 329px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Computed tomography. Arrows indicate free blood within peritoneal cavity surrounding liver and spleen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William J Mann, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_3_36913=[""].join("\n");
var outline_f36_3_36913=null;
var title_f36_3_36914="Acetaminophen toxicity CT";
var content_f36_3_36914=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F63610&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F63610&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acute liver failure",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 311px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Contrast-enhanced CT scan of the liver in a 35-year-old female who took an overdose of acetaminophen demonstrates a heterogenous poorly enhancing liver with areas of lower attenuation due to acute fatty replacement. Note also the patent recanalized paraumbilical vein coursing through the ligamentum teres (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_3_36914=[""].join("\n");
var outline_f36_3_36914=null;
var title_f36_3_36915="Trapezium fractures";
var content_f36_3_36915=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Trapezium fractures",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/3/36915/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/3/36915/contributors\">",
"     Patrice Eiff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/3/36915/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/3/36915/contributors\">",
"     Karl B Fields, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/3/36915/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/3/36915/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/3/36915/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Upper extremity injuries, including carpal fractures, are common reasons for visits to primary care offices and emergency departments. Carpal fractures are incurred through both major and minor trauma and clinicians should be familiar with the basic principles involved in diagnosis and management.",
"   </p>",
"   <p>",
"    This topic reviews fractures of the trapezium in adults. An overview of carpal fractures in adults is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/49/4886?source=see_link\">",
"     \"Overview of carpal fractures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26937608\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Upper extremity fractures are among the most common of the extremity injuries with carpal fractures accounting for 18 percent of hand fractures and 6 percent of all fractures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36915/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Of these, fractures to bones of the distal carpal row (ie, trapezium, trapezoid, capitate, hamate) are less frequent than fractures of bones in the proximal row (ie, scaphoid, lunate, triquetrum, and pisiform).",
"   </p>",
"   <p>",
"    Fractures of the trapezium account for 1 to 5 percent of all carpal fractures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36915/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. Trapezium injuries often occur in association with other injuries, such as fracture-dislocations of the first metacarpal (Rolando and Bennett injuries), first metacarpophalangeal dislocations, scaphoid fractures, and distal radius fractures. Isolated trapezium fractures are uncommon. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/26/17828?source=see_link\">",
"     \"First (thumb) metacarpal fractures\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/9/22675?source=see_link\">",
"     \"Metacarpal base fractures\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/51/1848?source=see_link\">",
"     \"Scaphoid fractures\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/13/21722?source=see_link\">",
"     \"Distal radius fractures in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26938165\">",
"    <span class=\"h1\">",
"     PERTINENT ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The trapezium is on the radial side of the distal carpal row, and is the carpus that articulates distally with the thumb metacarpal and proximally with the scaphoid and the trapezoid (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef70211 \" href=\"mobipreview.htm?37/16/38146\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef69097 \" href=\"mobipreview.htm?1/31/1527\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef78359 \" href=\"mobipreview.htm?26/34/27172\">",
"     figure 2",
"    </a>",
"    ). The trapezium forms a saddle articulation with the base of the thumb metacarpal. A longitudinal ridge is present on the volar surface, which serves as attachment for the transverse carpal ligament. A detailed discussion of wrist anatomy is provided separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/45/14039?source=see_link\">",
"     \"Anatomy and basic biomechanics of the wrist\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MECHANISM OF INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Axial loading of the 1st (thumb) metacarpal in the adducted position typically causes vertical fractures through the articular surface of the trapezium. Dorsiflexion of the wrist (ie, falling on an outstretched hand) rotates the radius and scaphoid and can make the trapezium more prone to injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36915/abstract/5\">",
"     5",
"    </a>",
"    ]. Avulsion fractures are caused by capsular and ligamentous attachments that are overloaded in forceful deviation, traction, or rotation. A direct blow to the thenar eminence or an avulsion of the transverse carpal ligament can cause a ridge fracture.",
"   </p>",
"   <p>",
"    The Walker classification system may be used to describe Trapezium fractures based upon articular surface involvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36915/abstract/5\">",
"     5",
"    </a>",
"    ]. However, a case series of six patients with open transtrapezial injuries of the thumb reported poor correlation between preoperative classification based upon plain x-rays and operative appearance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36915/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     SYMPTOMS AND EXAMINATION FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient with a trapezium fracture typically presents with minimal swelling, but may have significant discomfort (more than expected from other carpal bone fractures) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36915/abstract/4\">",
"     4",
"    </a>",
"    ]. There is pain and weakness with pinching (eg, making an \"OK\" sign, or touching the thumb to the tip of the 5th digit). Pain with resisted wrist flexion from a dorsiflexed start position or tenderness at the base of the thenar eminence may indicate a fracture of the trapezial ridge [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36915/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     RADIOGRAPHIC FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vertical or body fractures can be seen with an anterior posterior (AP) radiograph. However, overlapping shadows from other carpal bones can make detection difficult. A true AP (or Roberts view) outlines the trapezium and the first metacarpal base without superimposition of other structures (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef69169 \" href=\"mobipreview.htm?23/45/24274\">",
"     image 2",
"    </a>",
"    ). A ridge fracture is difficult to identify without using a carpal tunnel view (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef81015 \" href=\"mobipreview.htm?0/60/960\">",
"     image 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In a case series of 60 patients, up to 30 percent of wrist fractures were not seen on initial radiographs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36915/abstract/8\">",
"     8",
"    </a>",
"    ]. Trapezoid fractures were among those most difficult to identify. Therefore, if plain x-rays are unrevealing but clinical findings suggest a fracture, a CT should be obtained. CT is also helpful for assessing joint surfaces when there is any question of intraarticular fracture with displacement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR SURGICAL REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Emergent referral to a specialist should be obtained for any open fracture or fracture associated with a neurologic or vascular deficit.",
"   </p>",
"   <p>",
"    All fractures displaced more than 2 mm and any intraarticular fractures with more than 1 mm of incongruity in the joint surface should be referred to a hand surgeon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36915/abstract/4,9\">",
"     4,9",
"    </a>",
"    ]. These typically need operative fixation. All comminuted fractures should be referred, as these invariably involve intra-articular abnormalities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     INITIAL TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Non-displaced non-comminuted fractures, avulsion fractures, and ridge fractures can be treated nonoperatively with immobilization. Given that swelling is usually minimal, a short arm thumb-spica cast can be applied at initial presentation. If marked swelling is present, a thumb-spica splint can be applied for three to five days (",
"    <a class=\"graphic graphic_figure graphicRef79534 \" href=\"mobipreview.htm?26/19/26943\">",
"     figure 3",
"    </a>",
"    ), while ice and elevation are used to decrease the swelling. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/54/15208?source=see_link\">",
"     \"Splinting of musculoskeletal injuries\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     FOLLOW-UP CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immobilization with a short arm thumb-spica cast is maintained for four to six weeks. X-rays can be rechecked at two-week intervals. Displacement can occur following the initial visit so careful reassessment is important.",
"   </p>",
"   <p>",
"    If pain persists with an avulsion or ridge fracture after appropriate treatment, refer the patient to a hand surgeon for possible excision.",
"   </p>",
"   <p>",
"    Given that the trapezium has three joint faces with articular surfaces, fractures may lead to late arthrosis that may require surgical intervention. Arthritic changes may not become evident on radiographs for several years. Arthritic changes appear to develop more frequently after comminuted fractures, while collapse of the bone is more frequent after horizontal fractures or injuries with three or more parts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36915/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS FOR RETURN TO SPORT OR WORK",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the patient can perform their work or sport while wearing rigid cast protection, they may proceed with their activities as tolerated during immobilization. Semi-rigid protection in a brace should be continued for four weeks after rigid immobilization is completed. Physical or hand therapy is useful if there is weakness or motion restriction once immobilization is complete.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Isolated fractures of the trapezium are uncommon. Axial loading of the 1st (thumb) metacarpal in the adducted position typically causes vertical fractures through the articular surface of the trapezium. Dorsiflexion of the wrist (ie, falling on an outstretched hand) rotates the radius and scaphoid and can make the trapezium more prone to injury. Distal radius, scaphoid, and proximal first metacarpal fracture-dislocations can be associated with trapezium fractures. (See",
"      <a class=\"local\" href=\"#H26937608\">",
"       'Epidemiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Mechanism of injury'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The patient with a trapezium fracture typically presents with minimal swelling, but may have significant discomfort. Often, there is pain and weakness with pinching (eg, making an \"OK\" sign, or touching the thumb to the tip of the 5th digit). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Symptoms and examination findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Trapezium fractures can be difficult to visualize with standard radiographic views. A true anterior-posterior (Roberts view) and a carpal tunnel view provide better visualization in some instances, but CT may be necessary to make the diagnosis. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Radiographic findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Intra-articular fractures with more than 1 mm of incongruity at the joint surface or more than 2 mm of fracture diastasis, and all comminuted fractures, should be referred to a hand surgeon. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Indications for surgical referral'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Avulsion fractures and non-displaced fractures can be treated effectively with four to six weeks in a short arm thumb-spica cast. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Initial treatment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Follow-up care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Involvement of one of the three articular surfaces may lead to late arthrosis that requires surgical intervention.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H487677\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The author and editors would like to acknowledge Kevin E Burroughs, MD, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Dobyns JH, Beckenbaugh RD, Bryan RS, et al. Fractures of the hand and wrist. In: Hand Surgery, 3rd, Flynn JE (Ed), Williams &amp; Wilkins, Philadelphia 1982.",
"    </li>",
"    <li>",
"     Eiff MP, Hatch RL, Calmbach WL. Carpal fractures. In: Fracture Management for Primary Care, 2nd, Saunders, Philadelphia 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36915/abstract/3\">",
"      Geissler WB. Carpal fractures in athletes. Clin Sports Med 2001; 20:167.",
"     </a>",
"    </li>",
"    <li>",
"     Seitz WH, Papandrea RF. Fractures and dislocations of the wrist. In: Rockwood and Green's Fractures in Adults, 5th, Bucholz RW, Heckman JD (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36915/abstract/5\">",
"      Walker JL, Greene TL, Lunseth PA. Fractures of the body of the trapezium. J Orthop Trauma 1988; 2:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36915/abstract/6\">",
"      Giannikas D, Karabasi A, Fotinopoulos E, Tyllianakis M. Open transtrapezial injuries of the thumb: operative treatment. J Trauma 2008; 65:1468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36915/abstract/7\">",
"      Botte MJ, von Schroeder HP, Gellman H, Cohen MS. Fracture of the trapezial ridge. Clin Orthop Relat Res 1992; :202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36915/abstract/8\">",
"      Welling RD, Jacobson JA, Jamadar DA, et al. MDCT and radiography of wrist fractures: radiographic sensitivity and fracture patterns. AJR Am J Roentgenol 2008; 190:10.",
"     </a>",
"    </li>",
"    <li>",
"     Geissler W, Slade JF. Fractures of the carpal bones. In: Operative Hand Surgery, 6th, Green DP (Ed), Churchill Livingstone, Edinburgh 2011. p.639.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 194 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-61.234.146.186-AFBC45AB80-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_3_36915=[""].join("\n");
var outline_f36_3_36915=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26937608\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26938165\">",
"      PERTINENT ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MECHANISM OF INJURY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      SYMPTOMS AND EXAMINATION FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      RADIOGRAPHIC FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      INDICATIONS FOR SURGICAL REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      INITIAL TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      FOLLOW-UP CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      RECOMMENDATIONS FOR RETURN TO SPORT OR WORK",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H487677\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/194\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/194|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?37/16/38146\" title=\"diagnostic image 1\">",
"      Normal adult wrist AP xray",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?23/45/24274\" title=\"diagnostic image 2\">",
"      True AP x-ray of the thumb (Roberts view)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?0/60/960\" title=\"diagnostic image 3\">",
"      Carpal tunnel view of the wrist",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/194|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?1/31/1527\" title=\"figure 1\">",
"      Anatomy of the volar aspect of the wrist",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?26/34/27172\" title=\"figure 2\">",
"      Anatomy wrist dorsal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?26/19/26943\" title=\"figure 3\">",
"      Thumb spica splint 2",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/45/14039?source=related_link\">",
"      Anatomy and basic biomechanics of the wrist",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/13/21722?source=related_link\">",
"      Distal radius fractures in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/26/17828?source=related_link\">",
"      First (thumb) metacarpal fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/9/22675?source=related_link\">",
"      Metacarpal base fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/49/4886?source=related_link\">",
"      Overview of carpal fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/51/1848?source=related_link\">",
"      Scaphoid fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/54/15208?source=related_link\">",
"      Splinting of musculoskeletal injuries",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_3_36916="Genital herpes";
var content_f36_3_36916=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Genital herpes (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?36/3/36916/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/3/36916/contributors\" id=\"au4221\">",
"       Mary A Albrecht, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?36/3/36916/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/3/36916/contributors\" id=\"se636\">",
"       Martin S Hirsch, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?36/3/36916/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/3/36916/contributors\" id=\"de1919\">",
"       Anna R Thorner, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?36/3/36916?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      WHAT IS GENITAL HERPES?",
"     </span>",
"    </p>",
"    <p>",
"     Genital herpes is a common sexually transmitted disease that is caused by the herpes simplex virus. It is estimated that at least one in five adults in the United States is infected with the virus, but many people have no symptoms and do not realize that they are infected.",
"    </p>",
"    <p>",
"     After getting infected, most people have recurrent episodes of genital ulcers for several years. Although the infection can stay in the body for years, symptom outbreaks become less and less common over time. The infection can be managed with medication and self-care measures.",
"    </p>",
"    <p>",
"     People who have genital herpes are encouraged to talk to their sexual partner, use condoms, and take other preventive measures to prevent transmission (passing the virus to others). Genital herpes can be spread even when there are no visible ulcers or blisters.",
"    </p>",
"    <p>",
"     Being diagnosed with genital herpes can be an emotional and distressing experience, and it is important to speak with your healthcare provider about how to manage symptoms and avoid passing the virus to sexual partners. Counseling and support groups can also be beneficial to individuals living with genital herpes infection.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      GENITAL HERPES CAUSE",
"     </span>",
"    </p>",
"    <p>",
"     Genital herpes is caused by infection with the herpes simplex virus (HSV, usually type 2). It can also be caused by herpes simplex virus type 1, which is the cause of oral herpes (cold sores on the mouth and lips). The spread of HSV is discussed below. (See",
"     <a class=\"local\" href=\"#H15\">",
"      'Genital herpes transmission and risk factors'",
"     </a>",
"     below.)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      GENITAL HERPES SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     The symptoms of genital herpes can vary widely, depending upon whether you are having an initial or recurrent episode. However, many people infected with genital herpes never experience symptoms.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Initial episode",
"     </span>",
"     &nbsp;&mdash;&nbsp;For most people, the first herpes outbreak is the most severe, and symptoms tend to be more severe in women than men. The first outbreak usually occurs within a few weeks after infection with the virus. Symptoms tend to resolve within two to three weeks.",
"    </p>",
"    <p>",
"     The signs of an initial (or primary) episode of genital herpes include multiple blisters in the genital area. For women, the sites most frequently involved include the vagina, vulva, buttocks, anus, and thighs; for men, the penis, scrotum, anus, buttocks and thighs may be affected. Signs and symptoms typically include blisters that become painful ulcers. Blisters on the penis or outer labia may crust over and heal. New lesions may develop for up to five to seven days after the first group appears.",
"    </p>",
"    <p>",
"     There may also be tender, swollen lymph nodes in the groin, flu-like symptoms, such as joint pain, fever, and headache, and it may be painful to urinate.",
"    </p>",
"    <p>",
"     A small percentage of people can develop headache, nausea and vomiting, or difficulty urinating. These symptoms occur when the herpes infection affects the nervous system.",
"    </p>",
"    <p>",
"     People who have pain when they try to defecate may have proctitis (inflammation of the rectum or anus). Men who have sex with men are more prone to this complication than other patients.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Latent stage",
"     </span>",
"     &nbsp;&mdash;&nbsp;After the initial outbreak, the virus travels to a bundle of nerves at the base of the spine, where it remains inactive for a period of time. This is called the latent stage. There are no symptoms during this stage.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Recurrent episodes",
"     </span>",
"     &nbsp;&mdash;&nbsp;Many people experience recurrent episodes of genital herpes, which occur when the virus travels through nerves to the skin's surface, causing an outbreak of ulcers. These recurrent episodes tend to be milder than the initial outbreak.",
"    </p>",
"    <p>",
"     Ulcers may develop in the same area as those of the first outbreak, or may appear in other areas. It is possible to develop lesions in areas where there was no direct contact; for example, it is possible to have lesions around the anus without having had anal sex.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h3\">",
"      Likelihood of recurrence",
"     </span>",
"     &nbsp;&mdash;&nbsp;Genital herpes recurs frequently in many patients, especially in those with HSV type 2. Over time, recurrences generally become less frequent and less severe. However, it is also possible to have a recurrence a few years after the initial HSV infection was acquired. This type of delayed herpes outbreak can be especially distressing if you never had symptoms during the initial infection, leading you to worry about the sexual activities of your past or present sexual partner(s). (See",
"     <a class=\"local\" href=\"#H10\">",
"      'When did I become infected?'",
"     </a>",
"     below.)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h3\">",
"      Prodrome",
"     </span>",
"     &nbsp;&mdash;&nbsp;As many as 50 percent of people with a recurrent outbreak experience mild symptoms before ulcers develop. These are called prodromal symptoms, and may include itching, tingling, or pain in the buttocks, legs, or hips. Recurrences tend to become less frequent and less severe after the first year.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h3\">",
"      Triggers for recurrence",
"     </span>",
"     &nbsp;&mdash;&nbsp;Illness, stress, sunlight, and fatigue can trigger recurrent herpes outbreaks. In women, menstrual periods may trigger an outbreak.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      When did I become infected?",
"     </span>",
"     &nbsp;&mdash;&nbsp;The first time a person has noticeable signs or symptoms of herpes may not be the initial episode. For example, it is possible to be infected for the first time, have few or no symptoms, and then have a recurrent outbreak with noticeable symptoms several years later. For this reason, it is often difficult to determine when the initial infection occurred, especially if a person has had more than one sexual partner. Thus, a current sexual partner may not be the source of the infection.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H11\">",
"     <span class=\"h1\">",
"      GENITAL HERPES DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     The diagnosis of genital herpes is based on an individual's medical history, their signs and symptoms, and the results of tests. It is important to distinguish genital herpes from other sexually transmitted diseases, particularly those that also produce genital ulcers, such as syphilis and chancroid.",
"    </p>",
"    <p>",
"     Several diagnostic tests may also be used to diagnose genital herpes. These tests can usually confirm infection and identify which virus (HSV-1 or HSV-2) is responsible. The choice of testing will depend on your symptoms and whether you have any blisters or ulcers at the time you see your doctor.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Culture test",
"     </span>",
"     &nbsp;&mdash;&nbsp;A culture test determines if herpes simplex virus is present in blisters or ulcers. However, a herpes culture detects the virus in only about 50 percent of individuals with genital ulcers. The culture is more likely to detect the virus when ulcers are new and open, as compared to when they are older and healing. Therefore, it is important to see a healthcare provider within 48 hours of the first symptoms. The test is also more sensitive in individuals experiencing an initial episode of genital herpes than in individuals experiencing a recurrent episode.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Blood test",
"     </span>",
"     &nbsp;&mdash;&nbsp;Blood tests are often used when a person believes he or she may have been exposed to the herpes virus in the past, but has no visible ulcers. A blood test can detect antibodies (proteins that are produced by the body in response to a foreign substance) to HSV type 1 and type 2. Having a positive test for these antibodies indicates that the person was infected with the virus at some time in the past, although it is usually not possible to know when or from whom the virus was transmitted.",
"    </p>",
"    <p>",
"     The results of antibody testing may be negative early on during the initial episode of infection since antibody formation takes a few weeks. The antibody test remains positive for life.",
"    </p>",
"    <p>",
"     Blood tests may be helpful for couples if one person has a history of genital herpes and the other does not. If the partner has not been infected, then it is important to discuss ways to prevent transmission.",
"    </p>",
"    <p>",
"     Determining the type of herpes (1 or 2) can also help to predict the likelihood of future recurrences, given that type 2 recurs more frequently than type 1 (see",
"     <a class=\"local\" href=\"#H7\">",
"      'Likelihood of recurrence'",
"     </a>",
"     above).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Polymerase chain reaction (PCR) test",
"     </span>",
"     &nbsp;&mdash;&nbsp;The polymerase chain reaction (PCR) test is a very sensitive test for identifying the herpes virus in cells and secretions from the urinary and genital tracts. The PCR test is more sensitive than the culture test, but is not routinely used due to its higher cost.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H15\">",
"     <span class=\"h1\">",
"      GENITAL HERPES TRANSMISSION AND RISK FACTORS",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Transmission between sexual partners",
"     </span>",
"     &nbsp;&mdash;&nbsp;The herpes virus is most often transmitted between partners during oral, anal, or vaginal sex.",
"    </p>",
"    <p>",
"     It is also possible for a person to develop genital herpes after exposure to a cold sore on an infected person's lip during oral sex; in this case, genital herpes may be due to infection with HSV type 1. Transmission from person to person can occur even if there are no visible ulcers",
"    </p>",
"    <p>",
"     There is no risk of becoming infected after exposure to environmental surfaces (door knobs, toilet seats, utensils, bed sheets).",
"    </p>",
"    <p>",
"     The risk of transmission from an infected male to an uninfected female partner is slightly higher than the risk of transmission from an infected female to an uninfected male partner. As with any sexually transmitted infection, the risk of contracting genital herpes increases according to the number of sex partners you have, how often you have sex, and how infrequently you use condoms.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      When am I most likely to spread the virus?",
"     </span>",
"     &nbsp;&mdash;&nbsp;The risk of spreading the infection is much greater when a person has signs or symptoms of active infection. But it is still possible to spread the infection even when no ulcers are present.",
"    </p>",
"    <p>",
"     One study examined rates of genital herpes transmission in heterosexual couples when only one partner was initially infected [",
"     <a class=\"abstract\" href=\"mobipreview.htm?36/3/36916/abstract/1\">",
"      1",
"     </a>",
"     ]. Over one year, the virus was transmitted to the other partner in 10 percent of couples. In 70 percent of cases, infection occurred at a time when there were no symptoms.",
"    </p>",
"    <p>",
"     Use of condoms and suppressive antiviral medication can decrease the risk of spreading the infection to partners who are not infected, especially during the first year after a person becomes infected (see",
"     <a class=\"local\" href=\"#H25\">",
"      'Suppressive therapy'",
"     </a>",
"     below).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h2\">",
"      Pregnancy and herpes",
"     </span>",
"     &nbsp;&mdash;&nbsp;Women who have their first outbreak of genital herpes near the time of delivery are at risk of transmitting herpes to their newborn. Careful planning during the pregnancy and precautions during pregnancy and at the time of delivery can reduce the likelihood of transmission.",
"    </p>",
"    <p>",
"     Since herpes in infants is a very serious condition, women should inform their healthcare provider if they have a history of the infection. While women who acquire genital herpes before becoming pregnant are not likely to pass the virus to the baby, it is still possible for this to happen. For example, transmission from mother to child can occasionally occur if the mother has a recurrence at the time of delivery.",
"    </p>",
"    <p>",
"     For this reason, preventive antiviral therapy with acyclovir is often recommended for women with one or more recurrences during pregnancy. A caesarean delivery is usually recommended in women who experience an outbreak of symptoms at the time of labor.",
"    </p>",
"    <p>",
"     Women with no history of genital herpes whose partner has a history of cold sores (generally HSV type 1) or genital herpes (generally HSV type 2) should avoid oral, vaginal, and anal sex during the last trimester of pregnancy. Condoms are recommended during the entire pregnancy.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H19\">",
"     <span class=\"h1\">",
"      GENITAL HERPES AND HIV",
"     </span>",
"    </p>",
"    <p>",
"     Individuals with genital herpes are at an increased risk of acquiring HIV. During an outbreak, blisters and ulcers make it easier for a partner's genital fluids to enter the body. Therefore, if a person with herpes is exposed to HIV through sexual contact while herpetic lesions are present, HIV can more easily travel through the skin. Condoms help decrease the spread of HSV and HIV. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?7/0/7170?source=see_link\">",
"      \"Patient information: Symptoms of HIV infection (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H20\">",
"     <span class=\"h1\">",
"      GENITAL HERPES TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     Although there is no cure for genital herpes, the infection can be managed with antiviral drug therapy and self-care measures.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21\">",
"     <span class=\"h2\">",
"      Antiviral medications",
"     </span>",
"     &nbsp;&mdash;&nbsp;Three antiviral medications are used to treat genital herpes: acyclovir (Zovirax&reg;), famciclovir (Famvir&reg;), and valacyclovir (Valtrex&reg;). They are usually taken by mouth (in pill form). Acyclovir (Zovirax&reg;) is the oldest and least expensive antiviral medication. It usually requires more frequent dosing than famciclovir and valacyclovir.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H22\">",
"     <span class=\"h2\">",
"      Treatment regimen",
"     </span>",
"     &nbsp;&mdash;&nbsp;The dose and length of treatment depends upon whether the outbreak is the first episode or is a recurrence.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H23\">",
"     <span class=\"h3\">",
"      Initial episode",
"     </span>",
"     &nbsp;&mdash;&nbsp;The first episode of genital herpes is generally treated with 7 to 10 days of one antiviral medication, taken by mouth.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H24\">",
"     <span class=\"h3\">",
"      Episodic therapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Episodic therapy is a treatment strategy of taking antiviral medicines only when outbreaks occur. Episodic therapy may be recommended if you have fewer than six outbreaks each year. Unfortunately, episodic treatment does not reduce the frequency of outbreaks.",
"    </p>",
"    <p>",
"     The advantage of episodic therapy is that it can decrease the duration and severity of the illness by hours to a few days.",
"    </p>",
"    <p>",
"     Treatment is most likely to be effective if it is started within 72 hours of the first symptoms. People with a history of recurrent genital herpes are often advised to keep a supply of antiviral medication in their home, which they can initiate at the first signs of a recurrence (eg, pain or tingling symptoms or at the sign of their first blister).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H25\">",
"     <span class=\"h3\">",
"      Suppressive therapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Suppressive therapy is low dose antiviral treatment that is taken every day to prevent outbreaks.",
"    </p>",
"    <p>",
"     The advantage of suppressive therapy is that it decreases the frequency and duration of recurrences, and can reduce the risk of transmitting HSV to an uninfected sex partner.",
"    </p>",
"    <p>",
"     Suppressive therapy may be recommended if you have six or more recurrences each year or have a weakened immune system due to the human immunodeficiency virus (HIV), use of immune-suppressing drugs, or other factors.",
"    </p>",
"    <p>",
"     Suppressive therapy may also be an option if you are in a sexual relationship with a partner who does not have a history of genital herpes or antibodies to HSV-1 or 2 (as determined by blood testing). One study of valacyclovir showed that taking suppressive therapy can reduce the chances of transmitting the virus by approximately one-half.",
"    </p>",
"    <p>",
"     It is not clear how long suppressive therapy should continue. Some experts recommend taking a break from treatment periodically (every few years) to determine if suppressive therapy is still needed. If recurrent outbreaks develop, suppressive therapy may be restarted.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H26\">",
"     <span class=\"h3\">",
"      No treatment",
"     </span>",
"     &nbsp;&mdash;&nbsp;It is not necessary to treat a recurrent episode of genital herpes. No treatment may be appropriate for some patients, particularly those with infrequent outbreaks or minimal symptoms. It also may be appropriate if the patient is not currently sexually active, so transmission of HSV is not a consideration.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H27\">",
"     <span class=\"h3\">",
"      Which treatment regimen is right for me?",
"     </span>",
"     &nbsp;&mdash;&nbsp;Many people with recurrent herpes are unsure which treatment regimen (episodic or daily suppression) is right for them. The factors you should consider include how often you have outbreaks, how severe your symptoms are, and the risk of passing the infection to a sexual partner.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       If you have frequent outbreaks, severe symptoms, or want to avoid infecting a sexual partner, suppressive treatment might be recommended.",
"      </li>",
"      <li>",
"       If you do not have frequent outbreaks, are not bothered by symptoms (pain) during an outbreak, and are not concerned about infecting a sexual partner (because you are not sexually active), episodic therapy or no therapy are reasonable options.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H28\">",
"     <span class=\"h2\">",
"      Self-care measures",
"     </span>",
"     &nbsp;&mdash;&nbsp;In addition to antiviral medications, local treatments may be used to relieve the pain of a herpes outbreak. Sitting in a few inches of cool water (called a sitz bath) can temporarily decrease ulcer pain. This can be done in a bathtub or a specially designed sitz bath, available at most pharmacies without a prescription.",
"    </p>",
"    <p>",
"     Women who are having trouble urinating may find it helpful to urinate in the sitz bath or at the end of a warm bath. Soaps and bubble baths should be avoided. It is important to keep the genital area clean and dry, and to avoid tight or irritating underwear and clothing.",
"    </p>",
"    <p>",
"     Acetaminophen (Tylenol&reg;) or ibuprofen (Advil&reg;) may also help relieve the pain of genital ulcers. Over-the-counter creams and ointments are generally not recommended.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H29\">",
"     <span class=\"h1\">",
"      COUNSELING AND SUPPORT",
"     </span>",
"    </p>",
"    <p>",
"     The diagnosis of genital herpes can cause feelings of shame, fear, and distress. While these reactions are normal, it is important to remember that genital herpes is a manageable condition. Education is important for infected individuals and their partner to know what to expect and how to protect themselves.",
"    </p>",
"    <p>",
"     Many patients find that counseling, either with their family healthcare provider or a mental health professional, is helpful in dealing with the issues that come with a diagnosis of genital herpes. Counseling may be especially important for people who have tested positive for the virus, but have not developed symptoms.",
"    </p>",
"    <p>",
"     There are many genital herpes support groups in the United States and worldwide; these provide a safe environment for people to share their experiences and feelings, and also to learn accurate information about the disease. Infected individuals are encouraged to speak with their healthcare provider or visit the websites listed below (see",
"     <a class=\"local\" href=\"#H32\">",
"      'Where to get more information'",
"     </a>",
"     below).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H30\">",
"     <span class=\"h1\">",
"      GENITAL HERPES PREVENTION",
"     </span>",
"    </p>",
"    <p>",
"     Because all sexually active people are at some risk of acquiring genital herpes, it is important to communicate with a sexual partner before the first sexual encounter. Discussing herpes can be uncomfortable and embarrassing, but it ensures that both partners understand the possibility of transmitting the infection through sexual activity. Regular testing for sexually transmitted diseases is also recommended, especially if one or both partners have other sexual partners.",
"    </p>",
"    <p>",
"     After being diagnosed with genital herpes, it is still possible to have a safe and healthy sex life; however, it is important to take precautions.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Using a latex condom with every sexual encounter can reduce the risk of herpes transmission when only one member of a couple has the virus. The more often you use latex condoms, the lower the risk of transmission.",
"      </li>",
"      <li>",
"       Even when a person has no ulcers or blisters, use of a condom is recommended.",
"      </li>",
"      <li>",
"       Sex should be avoided any time genital ulcers are present. Oral sex should be avoided if there are ulcers or blisters around the mouth because a person with the oral form of herpes can give a partner genital herpes by performing oral sex.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H31\">",
"     <span class=\"h1\">",
"      SUMMARY",
"     </span>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Genital herpes is a viral infection that is spread during sex.",
"      </li>",
"      <li>",
"       Symptoms of genital herpes include blisters in the genital area (eg, penis, buttocks, anus, vulva). The blisters become painful ulcers. Some people have no symptoms at all.",
"      </li>",
"      <li>",
"       Symptoms are usually most severe when they first appear. Outbreaks usually become less intense and less frequent over time. Most people have an outbreak of genital herpes more than once in their life. The frequency of these outbreaks varies from individual to individual.",
"      </li>",
"      <li>",
"       Several tests are available to diagnose genital herpes. Some tests use blood while others require a swab of the blister.",
"      </li>",
"      <li>",
"       It is possible to spread herpes even if there are no visible ulcers. It is not possible to catch herpes by touching a surface (door knobs, toilet seat, bed sheets).",
"      </li>",
"      <li>",
"       Several medications are available to treat genital herpes (acyclovir, valacyclovir, and famciclovir). These drugs help to speed healing of ulcers in people who have just been infected or in those who are having repeat outbreaks.",
"      </li>",
"      <li>",
"       Some people who have herpes outbreaks take medicine every day to prevent future outbreaks or prevent spread to their sex partner.",
"      </li>",
"      <li>",
"       There are ways to lower the risk of being infected with genital herpes. People should use a latex condom every time they have sex. Sex (oral, vaginal, and anal) is not recommended if a person has blisters or ulcers.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H32\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3498518120\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H256863\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/25/21906?source=see_link\">",
"      Patient information: Genital herpes (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?16/13/16594?source=see_link\">",
"      Patient information: Genital warts (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?9/61/10195?source=see_link\">",
"      Patient information: Syphilis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/57/1940?source=see_link\">",
"      Patient information: Screening for sexually transmitted diseases (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?4/44/4803?source=see_link\">",
"      Patient information: Urethritis (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H256856\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?7/0/7170?source=see_link\">",
"      Patient information: Symptoms of HIV infection (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H33\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/60/10183?source=see_link\">",
"      Acyclovir: An overview",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/15/12538?source=see_link\">",
"      Approach to the patient with genital ulcers",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/10/9386?source=see_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/10/6308?source=see_link\">",
"      Famciclovir: An overview",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/14/33001?source=see_link\">",
"      Genital herpes simplex virus infection and pregnancy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/15/21751?source=see_link\">",
"      Prevention of genital herpes virus infections",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/32/7690?source=see_link\">",
"      Treatment of genital herpes simplex virus infection",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/19/30003?source=see_link\">",
"      Valacyclovir: An overview",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Centers for Disease Control and Prevention (CDC)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;Phone: (404) 639-3534",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;Toll-free: (800) 311-3435",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cdc.gov/\">",
"      www.cdc.gov",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Allergy and Infectious Diseases",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.niaid.nih.gov/\">",
"      www.niaid.nih.gov/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Herpes Resource Center",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;American Social Health Association",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;Phone: (800) 230-6039",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.ashastd.org/\">",
"      www.ashastd.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     UpToDate wishes to acknowledge Kelly Crowley for her contributions to this topic.",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"mobipreview.htm?36/3/36916/abstract/1-11\">",
"      1-11",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 1, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?36/3/36916?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36916/abstract/1\">",
"      Mertz GJ, Benedetti J, Ashley R, et al. Risk factors for the sexual transmission of genital herpes. Ann Intern Med 1992; 116:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36916/abstract/2\">",
"      Benedetti J, Corey L, Ashley R. Recurrence rates in genital herpes after symptomatic first-episode infection. Ann Intern Med 1994; 121:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36916/abstract/3\">",
"      Arvin AM, Prober CG. Herpes simplex virus type 2--a persistent problem. N Engl J Med 1997; 337:1158.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention, Division of Sexually Transmitted Diseases. Sexually Transmitted Diseases Surveillance, Other Sexually Transmitted Diseases, 2003. www.cdc.gov/std/stats/03pdf/otherSTDs.pdf (Accessed on January 01, 2004).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36916/abstract/5\">",
"      Corey L, Adams HG, Brown ZA, Holmes KK. Genital herpes simplex virus infections: clinical manifestations, course, and complications. Ann Intern Med 1983; 98:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36916/abstract/6\">",
"      Kimberlin DW, Rouse DJ. Clinical practice. Genital herpes. N Engl J Med 2004; 350:1970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36916/abstract/7\">",
"      Douglas JM, Critchlow C, Benedetti J, et al. A double-blind study of oral acyclovir for suppression of recurrences of genital herpes simplex virus infection. N Engl J Med 1984; 310:1551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36916/abstract/8\">",
"      Sacks SL. Famciclovir suppression of asymptomatic and symptomatic recurrent anogenital herpes simplex virus shedding in women: a randomized, double-blind, double-dummy, placebo-controlled, parallel-group, single-center trial. J Infect Dis 2004; 189:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36916/abstract/9\">",
"      Fife KH, Barbarash RA, Rudolph T, et al. Valaciclovir versus acyclovir in the treatment of first-episode genital herpes infection. Results of an international, multicenter, double-blind, randomized clinical trial. The Valaciclovir International Herpes Simplex Virus Study Group. Sex Transm Dis 1997; 24:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36916/abstract/10\">",
"      Bodsworth NJ, Crooks RJ, Borelli S, et al. Valaciclovir versus aciclovir in patient initiated treatment of recurrent genital herpes: a randomised, double blind clinical trial. International Valaciclovir HSV Study Group. Genitourin Med 1997; 73:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36916/abstract/11\">",
"      Corey L, Wald A, Patel R, et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med 2004; 350:11.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f36_3_36916=[""].join("\n");
var outline_f36_3_36916=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           WHAT IS GENITAL HERPES?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           GENITAL HERPES CAUSE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           GENITAL HERPES SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H11\">",
"           GENITAL HERPES DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H15\">",
"           GENITAL HERPES TRANSMISSION AND RISK FACTORS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H19\">",
"           GENITAL HERPES AND HIV",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H20\">",
"           GENITAL HERPES TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H29\">",
"           COUNSELING AND SUPPORT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H30\">",
"           GENITAL HERPES PREVENTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H31\">",
"           SUMMARY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H32\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f36_3_36917="Stasis dermatitis advanced 2";
var content_f36_3_36917=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F78163&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F78163&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Advanced stasis dermatitis, with hyperpigmentation, lichenification, sclerosis, and ulceration",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_3_36917=[""].join("\n");
var outline_f36_3_36917=null;
var title_f36_3_36918="Quadrivalent (A, C, Y, W-135) meningococcal conjugate vaccine: Pediatric drug information";
var content_f36_3_36918=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Quadrivalent (A, C, Y, W-135) meningococcal conjugate vaccine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?10/35/10807?source=see_link\">",
"    see \"Quadrivalent (A, C, Y, W-135) meningococcal conjugate vaccine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?16/2/16417?source=see_link\">",
"    see \"Quadrivalent (A, C, Y, W-135) meningococcal conjugate vaccine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F192572\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Menactra&reg;;",
"     </li>",
"     <li>",
"      Menveo&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F12592734\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Menactra&reg;;",
"     </li>",
"     <li>",
"      Menveo&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1060172\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Vaccine, Inactivated Bacteria",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1060165\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?10/35/10807?source=see_link\">",
"      see \"Quadrivalent (A, C, Y, W-135) meningococcal conjugate vaccine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Primary Immunization:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Infants and Children 9-23 months: Menactra&reg;: I.M.: 0.5 mL per dose given as a 2-dose series, 3 months apart",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children &ge;2 years and Adults &le;55 years: Menactra&reg;, Menveo&reg;: I.M.: 0.5 mL per dose given as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     ACIP Recommendations:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Infants and Children 9-23 months of age at high risk for invasive meningococcal disease (except those with functional or anatomic asplenia): Routine vaccination: 2 doses, 3 months apart.  A booster dose should be given as recommended if still at risk for meningococcal disease (see 'Booster dose' section) (CDC, 2011a).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children &ge;2 years with persistent complement component deficiency, or functional or anatomic asplenia or HIV infection: 2 doses, 2 months apart. A booster dose should be given as recommended if still at risk for meningococcal disease (see 'Booster dose' section) (CDC, 2011; CDC, 2011a). Children at high risk for invasive meningococcal disease with functional or anatomic asplenia should receive their first dose at 2 years of age and &ge;4 weeks after completion of the PCV13 vaccine series (CDC, 2011a).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children &ge;2 years with prolonged increased risk of exposure: 1 dose. If still at risk for meningococcal disease, a booster dose should be given as recommended based on the age at first dose (see 'Booster dose' section) (CDC, 2011; ACIP Resolution No. 6/11-1).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children and Adolesecents11-18 years of age: Routine Vaccination: 1 dose at 11 or 12 years of age with a booster dose at age 16. If primary dose was given at age 13-15 years, one booster dose should be given at 16-18 years of age. If primary dose was given &ge;16 years of age, no booster dose is needed. Children in this age group receiving routine vaccination and who are also HIV positive should initially receive 2 doses, 2 months apart, and a booster dose as recommended, based on age at primary dose (see 'Booster dose' section) (CDC, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     College Students: Persons &le;21 years of age should have documentation of vaccination &le;5 years prior to enrollment. If the primary dose was given at &lt;16 years of age, a booster dose should be given any time after the 16th birthday and prior to college enrollment. The minimum interval between doses is 8 weeks (CDC, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Adults &le;55 years with persistent complement component deficiency; functional or anatomic asplenia or HIV infection:2 doses, 2 months apart (CDC, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Adults &le;55 years with prolonged increased risk of exposure: 1 dose; follow with booster dose as indicated (CDC, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Booster Dose:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Booster dose following routine vaccination: 1 booster dose should be given based on age at primary vaccination: If initial dose was at 11 or 12 years of age, a one-time booster dose should be given at age 16. If primary dose was given at age 13-15 years, a one-time booster dose should be given at 16-18 years of age. If primary dose was given &ge;16 years of age, no booster dose is needed (CDC, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Booster dose for all other indications in patients with continued risk:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Age at",
"     <b>",
"      first",
"     </b>",
"     dose:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     9-23 months of age: Repeat dose 3 years after primary vaccination, and every 5 years thereafter if the person remains at 	increased risk (CDC, 2011a).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     2-6 years of age: Repeat dose 3 years after primary vaccination, and every 5 years thereafter if the person remains at increased risk (CDC, 2009; CDC, 2011; CDC, 2011a).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     7 years of age: Repeat dose 5 years after primary vaccination, and every 5 years thereafter if the person remains at increased risk (CDC, 2009; CDC, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     College students: Persons &le;21 years of age should have documentation of vaccination &le;5 years prior to enrollment. If the primary dose was given at &lt;16 years of age, a booster dose should be given any time after the 16th birthday and prior to college enrollment. The minimum interval between doses is 8 weeks (CDC, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults &le;55 years with prolonged increase risk of exposure or with persistent complement component deficiency; functional or anatomic asplenia or HIV infection: A booster dose should be given every 5 years if still at risk for meningococcal disease. (CDC, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F192561\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, solution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Menactra&reg;: 4 mcg each of polysaccharide antigen groups A, C, Y, and W-135 [bound to diphtheria toxoid 48 mcg] per 0.5 mL [MCV4 or MenACWY-D]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Menveo&reg;: MenA oligosaccharide 10 mcg, MenC oligosaccharide 5 mcg, MenY oligosaccharide 5 mcg, and MenW-135 oligosaccharide 5 mcg [bound to CRM",
"     <sub>",
"      197",
"     </sub>",
"     protein 32.7-64.1 mcg] per 0.5 mL (0.5 mL) [MenACWY-CRM; supplied in two vials, one containing MenA powder and one containing MenCYW-135 liquid]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F192551\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1060176\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer by I.M. injection;",
"     <b>",
"      not for intradermal, subcutaneous, or I.V. administration.",
"     </b>",
"     Adolescents and adults should be vaccinated while seated or lying down. U.S. law requires that the date of administration, the vaccine manufacturer, lot number of vaccine, and the administering person's name, title, and address be entered into the patient's permanent medical record.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Menveo&reg;: Prior to use, remove liquid contents from vial of MenCYW-135 and inject into vial containing MenA powder. Gently invert or swirl until dissolved. The resulting solution should be clear and colorless. A small amount of liquid will remain in the vial after withdrawing the 0.5 mL dose. Use immediately after reconstitution but may be stored at &le;25&deg;C (77&deg;F) for up to 8 hours. Do not mix with other vaccines in the same syringe.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1060168\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Menactra&reg;: Store at 2&deg;C to 8&deg;C (35&deg;F to 46&deg;F); do not freeze; protect from light",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Menveo&reg;: Prior to reconstitution, store between 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); protect from light and do not freeze. Discard product exposed to freezing.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1060175\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Provide active immunization of children and adults against invasive meningococcal disease caused by",
"     <i>",
"      N. meningitidis",
"     </i>",
"     serogroups A, C, Y, and W-135 (Menactra&reg;: FDA approved 9 months to 55 years; Menveo&reg;: FDA approved in ages 2-55 years).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     The Advisory Committee on Immunization Practices (ACIP) recommends routine vaccination of all persons at age 11 or 12 years of age, followed by a booster at age 16 years of age [CDC, 60(3), 2011].",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     The ACIP also recommends vaccination for:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Infants and children 9-23 months of age at increased risk for meningococcal disease [CDC 60(40), 2011]. Infants and children at increased risk include:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     - Traveling to or who reside in countries where",
"     <i>",
"      N. meningitidis",
"     </i>",
"     hyperendemic or epidemic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     - With persistent complement component deficiencies (eg, C5-C9, properidin, factor H, or factor D)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     - Who are in a defined risk group during a community or institutional meningococcal outbreak",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Persons 2-55 years of age who are at an increased risk for meningococcal disease [CDC, 60(3), 2011]. Meningococcal conjugate vaccine (MCV4) is preferred for persons aged 2-55 years; meningococcal polysaccharide vaccine (MPSV4) is preferred in adults &ge;56 years of age (CDC, 2005). Persons at increased risk include:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     - Previously unvaccinated college freshmen living in dormitories",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     - Microbiologists routinely exposed to isolates of",
"     <i>",
"      N. meningitidis",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     - Military recruits",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     - Persons traveling to or who reside in countries where",
"     <i>",
"      N. meningitidis",
"     </i>",
"     is hyperendemic or epidemic, particularly if contact with local population will be prolonged",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     - Persons with persistent complement component deficiencies (eg, C5-C9, properidin, factor H, or factor D)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     - Persons with anatomic or functional asplenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Use is also recommended during meningococcal outbreaks caused by vaccine-preventable serogroups [CDC, 2005; CDC 60(40), 2011].",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F3343086\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issue:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Menactra&reg; (MCV4) should be administered by intramuscular (I.M.) injection only. Inadvertent subcutaneous (SubQ) administration has been reported; possibly due to confusion of this product with Menomune&reg; (MPSV4), also a meningococcal polysaccharide vaccine, which is administered by the SubQ route.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F192590\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      All serious adverse reactions must be reported to the U.S. Department of Health and Human Services (DHHS) Vaccine Adverse Event Reporting System (VAERS) 1-800-822-7967 or online at",
"      <a href=\"https://vaers.hhs.gov/esub/index\" target=\"_blank\">",
"       https://vaers.hhs.gov/esub/index",
"      </a>",
"      .",
"     </b>",
"     In Canada, adverse reactions may be reported to local provincial/territorial health agencies or to the Vaccine Safety Section at Public Health Agency of Canada (1-866-844-0018).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      May vary by product and age group:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Chills, crying (abnormal), drowsiness, fatigue, fever, headache, irritability, malaise, sleepiness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, diarrhea, eating changes, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site: Erythema, induration, pain, redness, swelling, tenderness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, myalgia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Acute disseminated encephalomyelitis, ALT increased, anaphylactic reactions, anaphylactoid reactions, balance disorder, bone pain, breathing difficulties, dizziness,  ear pain, eyelid ptosis, facial palsy, facial paresis,  Guillain-Barr&eacute; syndrome, hearing impaired, hypersensitivity, hypotension, injection site reactions (cellulitis, inflammation, pruritus), oropharyngeal pain, paresthesia, pruritus, seizure, skin exfoliation, syncope, tonic convulsion, transverse myelitis, upper airway swelling, urticaria, vasovagal syncope, vertigo, vestibular disorder, wheezing",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1060178\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to any component of the formulation, including diphtheria toxoid or CRM",
"     <sub>",
"      197",
"     </sub>",
"     (a diphtheria toxin carrier protein) or other meningococcal containing vaccines; Menactra&reg;: History of Guillain-Barr&eacute; Syndrome (GBS)",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1060164\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The decision to administer or delay vaccination because of current or recent febrile illness depends on the severity of symptoms and the etiology of the disease. Immunization should be delayed during the course of an acute severe febrile illness; may administer to patients with mild acute illness (with or without fever). Use with caution in severely immunocompromised patients (eg, patients receiving chemo/radiation therapy or other immunosuppressive therapy, including high-dose corticosteroids); may have a reduced response to vaccination and vaccination may not result in effective immunity in all patients. Response depends upon multiple factors (eg, type of vaccine, age of patient) and may be improved by administering the vaccine at the recommended dose, route, and interval (CDC, 2011). In general, household and close contacts of persons with altered immunocompetence may receive all age-appropriate vaccines.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Use with caution in patients with coagulation disorders including thrombocytopenia, due to an increased risk for bleeding following I.M. administration; if the patient receives antihemophilia or other similar therapy, I.M. injection can be scheduled shortly after such therapy is administered; defer vaccination for persons with moderate or severe acute febrile illness until recovery; may administer to patient with mild acute illness (with or without fever). Children may have higher incidence of local adverse effects (erythema, swelling, tenderness). Antipyretics have not been shown to prevent febrile seizures; antipyretics may be used to treat fever or discomfort following vaccination (CDC, 2011). One study reported that routine prophylactic administration of acetaminophen to prevent fever prior to vaccination decreased the immune response of some vaccines; the clinical significance of this reduction in immune response has not been established (Prymula, 2009).",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1060163\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Immediate treatment for anaphylactoid or acute hypersensitivity reactions should be available during vaccine use; Guillain-Barr&eacute; syndrome has been reported in a temporal relationship following Menactra&reg; administration; the risk of developing Guillain-Barr&eacute; syndrome may be increased following vaccination in persons previously diagnosed with Guillain-Barr&eacute; syndrome. The risk of developing Guillain-Barr&eacute; syndrome was evaluated in a study of healthcare claims of persons 11-18 years of age (n=~9,600,000; 15% were vaccinated with Menactra&reg;); 72 cases of Guillain-Barr&eacute; syndrome were confirmed and none received the vaccine within 42 days prior to symptoms; 129 reported cases of Guillain-Barr&eacute; syndrome could not be confirmed or excluded. Data not currently available to assess possible risk of Guillain-Barr&eacute; syndrome following use of Menveo&reg;. Individuals with a previous history of GBS should not receive  Menactra&reg;; data not currently available to assess possible risk of GBS following use of Menveo&reg;. Syncope has been reported with use of injectable vaccines and may be accompanied by transient visual disturbances, weakness, or tonic-clonic movements. Procedures should be in place to avoid injuries from falling and to restore cerebral perfusion if syncope occurs. In general, household and close contacts of persons with altered immune competence may receive all age-appropriate vaccines.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Latex is used in stopper of the vial; patients with known hypersensitivity should avoid doses from vial formulation and use prefilled syringe for dose.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299661\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F192557\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Belimumab: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immunosuppressants: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Cytarabine (Liposomal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F192559\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B/C (manufacturer dependent) (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F192568\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted with Menactra&reg; (therefore classified as pregnancy category C). An isolated teratogenic effect was observed in an animal developmental toxicity study; not necessarily vaccine related. Carcinogenic or mutagenic studies have not been performed. Patients should contact the Sanofi Pasteur Inc vaccine registry at 1-800-822-2463 if they are pregnant or become aware they were pregnant at the time of Menactra&reg; vaccination.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Adverse events were not observed in animal reproduction studies conducted with Menveo&reg; (therefore classified as pregnancy category B). Patients should contact the Novartis Vaccines and Diagnostics Inc. pregnancy registry at 1-877-311-8972 if they are pregnant or become aware they were pregnant at the time of Menveo&reg; vaccination.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Limited information is available following inadvertent use of meningococcal diphtheria conjugate vaccine during pregnancy; safety and effectiveness have not been established. Inactivated bacterial vaccines have not been shown to cause increased risks to the fetus (CDC, 60[2], 2011).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F13929203\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Observe for syncope for 15 minutes following administration. If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenburg position to reestablish adequate cerebral perfusion.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1060162\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Induces the formation of bactericidal antibodies to meningococcal antigens; the presence of these antibodies is strongly correlated with immunity to meningococcal disease caused by",
"     <i>",
"      Neisseria meningitides",
"     </i>",
"     groups A, C, Y and W-135.",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1060170\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?16/2/16417?source=see_link\">",
"      see \"Quadrivalent (A, C, Y, W-135) meningococcal conjugate vaccine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inform patients about common side effects; patients should report serious and unusual effects to physician",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F10284076\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;margin-top:0em;display:inline\">",
"     Two meningococcal (Groups A/C/Y and W-135) diphtheria conjugate vaccines are available. Menveo&reg; uses oligosaccharides of the",
"     <i>",
"      N. meningitidis",
"     </i>",
"     serogroups linked to CRM",
"     <sub>",
"      197",
"     </sub>",
"     (a nontoxic diphtheria toxin carrier protein) and Menactra&reg; uses polysaccharides from the serogroups linked to diphtheria toxoid.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     In order to maximize vaccination rates, the ACIP recommends simultaneous administration (ie, &gt;1 vaccine on the same day at different anatomic sites) of all age-appropriate vaccines (live or inactivated) for which a person is eligible at a single visit, unless contraindications exist. If available, the use of combination vaccines is generally preferred over separate injections, taking into consideration provider assessment, patient preference, and potential adverse events. If separate vaccines being used, evaluate product information regarding same syringe compatibility of vaccines. Separate needles and syringes should be used for each injection. The ACIP prefers each dose of specific vaccine in a series come from the same manufacturer if possible (CDC, 2011).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     For additional information, please refer to the following website:",
"     <a href=\"file://www.cdc.gov/vaccines/vpd-vac/\" target=\"_blank\">",
"      file://www.cdc.gov/vaccines/vpd-vac/",
"     </a>",
"     .",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      AAP Steering Committee on Quality Improvement and Management, Subcommittee on Febrile Seizures American Academy of Pediatrics, \"Febrile Seizures: Clinical Practice Guideline for the Long-Term Management of the Child With Simple Febrile Seizures,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008, 121(6):1281-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/3/36918/abstract-text/18519501/pubmed\" id=\"18519501\" target=\"_blank\">",
"        18519501",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC), \"Report From the Advisory Committee on Immunization Practices (ACIP): Decision Not to Recommend Routine Vaccination of All Children Aged 2-10 Years With Quadrivalent Meningococcal Conjugate Vaccine (MCV4),\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2008, 57(17):462-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/3/36918/abstract-text/18451758/pubmed\" id=\"18451758\" target=\"_blank\">",
"        18451758",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Advisory Committee on Immunization Practices (ACIP) Vaccines for Children Program - Vaccines to Prevent Meningococcal Disease, Resolution No. 6/11-1. Available at:",
"      <a href=\"file://www.cdc.gov/vaccines/programs/vfc/downloads/resolutions/06-11mening-mcv.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/vaccines/programs/vfc/downloads/resolutions/06-11mening-mcv.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Prevention and Control of Meningococcal Disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP).",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2005, 54(RR-7):1-21. Available at",
"      <a href=\"file://www.cdc.gov/mmwr/pdf/rr/rr5407.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/mmwr/pdf/rr/rr5407.pdf",
"      </a>",
"      .",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Recommendation of the Advisory Committee on Immunization Practices (ACIP) for Use of Quadrivalent Meningococcal Conjugate Vaccine (MenACWY-D) Among Children Aged 9 Through 23 Months at Increased Risk for Invasive Meningococcal Disease,\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2011, 60(40):1391-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/3/36918/abstract-text/21993344/pubmed\" id=\"21993344\" target=\"_blank\">",
"        21993344",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Recommendations of the Advisory Committee on Immunization Practices (ACIP): General Recommendations on Immunization,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2011, 60(2):1-61. Available at",
"      <a href=\"file://www.cdc.gov/mmwr/pdf/rr/rr6002.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/mmwr/pdf/rr/rr6002.pdf",
"      </a>",
"      .",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Syncope After Vaccination-United States, January 2005-July 2007,\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2008, 2;57(17):457-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/3/36918/abstract-text/18451756/pubmed\" id=\"18451756\" target=\"_blank\">",
"        18451756",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Updated Recommendation From the Advisory Committee on Immunization Practices (ACIP) for Revaccination of Persons at Prolonged Increased Risk for Meningococcal Disease,\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2009, 58(37):1042-3. Available at:",
"      <a href=\"file://www.cdc.gov/mmwr/preview/mmwrhtml/mm5837a4.htm?s_cid=mm5837a4_e\" target=\"_blank\">",
"       file://www.cdc.gov/mmwr/preview/mmwrhtml/mm5837a4.htm?s_cid=mm5837a4_e",
"      </a>",
"      .",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/3/36918/abstract-text/19779400/pubmed\" id=\"19779400\" target=\"_blank\">",
"        19779400",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Updated Recommendations for Use of Meningococcal Conjugate Vaccines --- Advisory Committee on Immunization Practices (ACIP), 2010,\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2011, 60(3):72-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/3/36918/abstract-text/21270745/pubmed\" id=\"21270745\" target=\"_blank\">",
"        21270745",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Center for Immunization and Respiratory Diseases, \"General Recommendations on Immunization - Recommendations of the Advisory Committee on Immunization Practices (ACIP),\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2011, 60(2):1-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/3/36918/abstract-text/21293327/pubmed\" id=\"21293327\" target=\"_blank\">",
"        21293327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Prymula R, Siegrist CA, Chlibek R, et al, \"Effect of Prophylactic Paracetamol Administration at Time of Vaccination on Febrile Reactions and Antibody Responses in Children: Two Open-Label, Randomised Controlled Trials,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 2009, 374(9698):1339-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/3/36918/abstract-text/19837254/pubmed\" id=\"19837254\" target=\"_blank\">",
"        19837254",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12931 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-199.231.185.123-23AA9155C3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_3_36918=[""].join("\n");
var outline_f36_3_36918=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192572\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12592734\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060172\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060165\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192561\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192551\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060176\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060168\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060175\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3343086\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192590\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060178\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060164\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060163\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299661\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192557\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192559\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192568\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13929203\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060162\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060170\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10284076\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12931\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12931|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?10/35/10807?source=related_link\">",
"      Quadrivalent (A, C, Y, W-135) meningococcal conjugate vaccine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?16/2/16417?source=related_link\">",
"      Quadrivalent (A, C, Y, W-135) meningococcal conjugate vaccine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_3_36919="Amenorrhea and infertility associated with exercise";
var content_f36_3_36919=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Amenorrhea and infertility associated with exercise",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/3/36919/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/3/36919/contributors\">",
"     Michelle P Warren, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/3/36919/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/3/36919/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/3/36919/contributors\">",
"     William F Crowley, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/3/36919/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/3/36919/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/3/36919/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many women of reproductive age engage in some kind of exercise. Most obtain benefits such as improved exercise capacity, control of body weight, strengthening of weight-bearing bones, and reduction in cardiovascular risk factors. However, some can also become amenorrheic or infertile [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36919/abstract/1\">",
"     1",
"    </a>",
"    ]. In addition, excessive exercise at a critical time in development may delay puberty and menarche [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36919/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will review the major issues related to amenorrhea and infertility associated with exercise. An overall approach to the woman with amenorrhea is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/2/2089?source=see_link\">",
"     \"Etiology, diagnosis, and treatment of primary amenorrhea\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/56/34697?source=see_link\">",
"     \"Etiology, diagnosis, and treatment of secondary amenorrhea\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Type of exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise alone does not induce amenorrhea. The likelihood of amenorrhea varies with the type and amount of exercise and the rapidity of increase in exercise. Activities that tend to be associated with low body weight (eg, running, ballet dancing) and sports in which scoring is subjective (eg, figure skating or gymnastics) are associated with a higher incidence of amenorrhea than are other activities such as swimming.",
"   </p>",
"   <p>",
"    Gradually increasing exercise is less likely to be associated with amenorrhea than are more acute increases, such as when a woman quickly increases training for a competition.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Relative caloric deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low body weight alone is not sufficient to explain the onset of amenorrhea, because women with similar body mass indexes vary in their menstrual response to exercise. It appears that amenorrhea occurs only when there is",
"    <strong>",
"     relative caloric deficiency",
"    </strong>",
"    due to inadequate nutritional intake for the amount of energy expended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36919/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Young women with restrictive eating disorders and amenorrhea have been referred to as having the \"female athlete triad,\" which consists of an eating disorder, amenorrhea, and osteoporosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/2/23593?source=see_link\">",
"     \"Eating disorders: Epidemiology, pathogenesis, clinical features, and course of illness\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H133384\">",
"    <span class=\"h2\">",
"     Genetic predisposition",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is marked interpatient variability in the degree of weight loss or exercise required to induce amenorrhea. This may in part be due to an underlying genetic predisposition in susceptible women. A number of gene mutations have been identified in patients with congenital GnRH deficiency; heterozygous mutations in some of the same genes (KAL1, FGFR1, PROKR2, GNRHR) have now been identified in women with hypothalamic amenorrhea as well [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36919/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/56/34697?source=see_link&amp;anchor=H132415#H132415\">",
"     \"Etiology, diagnosis, and treatment of secondary amenorrhea\", section on 'Genetic basis'",
"    </a>",
"    .)",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Leptin and other peptides",
"    </span>",
"    &nbsp;&mdash;&nbsp;The discovery of the hormone leptin, which is secreted by fat cells in proportion to body fat stores, has renewed interest in the hypothesis that a minimal amount of body fat is required for normal reproductive function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36919/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/50/13094?source=see_link\">",
"     \"Physiology of leptin\"",
"    </a>",
"    .) Mice and rats deficient in leptin fail to undergo pubertal development, while the administration of leptin to such animals results in pubertal onset [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36919/abstract/7\">",
"     7",
"    </a>",
"    ]. However, in humans, eumenorrheic and amenorrheic athletes have similar amounts of body fat, and similar fasting serum leptin concentrations, so that leptin cannot be the only etiologic factor causing amenorrhea.",
"   </p>",
"   <p>",
"    Exercising women with regular menstrual cycles and women with amenorrhea who do not exercise excessively have a clear diurnal rhythm of leptin, while exercising women with amenorrhea do not [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36919/abstract/8\">",
"     8",
"    </a>",
"    ]. The observation that exogenous leptin therapy reversed hypothalamic amenorrhea in three of eight subjects, some of whom were exercising, supports this concept [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36919/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/50/13094?source=see_link\">",
"     \"Physiology of leptin\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Of note, leptin may be influenced by other neuropeptides, such as ghrelin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36919/abstract/10\">",
"     10",
"    </a>",
"    ], as both peptides are instrumental in signaling the body's nutritional status and ghrelin appears to be a better discriminator in clinical studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36919/abstract/10-12\">",
"     10-12",
"    </a>",
"    ].",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Effect on H-P-O axis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effects of exercise on hypothalamic-pituitary-ovarian function has been compared in lean women with normal cycles who were sedentary, women athletes with normal cycles, and exercise-matched women with amenorrhea with the following results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36919/abstract/3,13\">",
"     3,13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The women athletes with amenorrhea had decreases in both the frequency and amplitude of pulses of gonadotropin-releasing (GnRH)-induced luteinizing hormone (LH) secretion; the women athletes with normal cycles had similar but less marked abnormalities in LH secretion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/3/36919/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Exercise was associated with a 20 to 30 percent decrease in LH pulse frequency in the mid-follicular phase of the menstrual cycle [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/3/36919/abstract/3,13\">",
"       3,13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Exercise, especially if associated with a relative deficit of caloric intake, may be associated with an increase in pituitary responsiveness to exogenous GnRH, suggesting that almost all of the decrease in LH secretion is due to reduced GnRH secretion.",
"     </li>",
"     <li>",
"      Exercising women who continue to have regular menses have diminished progesterone secretion during the luteal phase of their cycles [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/3/36919/abstract/13\">",
"       13",
"      </a>",
"      ], consistent with a luteal phase defect. The importance of this abnormality is not clear, because the study women were not trying to conceive.",
"     </li>",
"     <li>",
"      The decrease in pulsatile LH secretion could be induced by inadequate caloric balance, whether caused by increased energy expenditure (increased activity) or by decreased energy intake (inadequate to keep up with the exercise) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/3/36919/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast, a study of 24 amenorrheic swimmers, who tended to have higher body weight, demonstrated a relative",
"    <strong>",
"     increase",
"    </strong>",
"    in the secretion of LH and also in the adrenal androgen dehydroepiandrosterone sulfate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36919/abstract/14\">",
"     14",
"    </a>",
"    ]. Thus, the amenorrhea in swimmers did not appear to be secondary to GnRH deficiency. However, these women were not studied before they began swimming; it is therefore possible that women with a hyperandrogenic tendency might be self-selected to become swimmers because of a more muscular body habitus. This argument has been similarly used to explain the high rates of hypothalamic amenorrhea in ballet dancers: girls with smaller body size and an inherent tendency to delayed puberty self-select themselves to be dancers because of an increased likelihood of success [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36919/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CONSEQUENCES OF EXERCISE-INDUCED AMENORRHEA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because women with exercise-induced hypothalamic amenorrhea are estrogen-deficient, they are at increased risk for the consequences of estrogen deficiency, including infertility, vaginal and breast atrophy, and osteopenia. Hot flushes rarely occur in women with hypothalamic amenorrhea unless they have recently discontinued estrogen therapy; the presence of hot flushes should suggest another diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Low bone density/fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with exercise-induced amenorrhea, especially those engaged in activities associated with restrictive eating habits and low weight, may have decreased bone density, in spite of the bone-building effect of weight-bearing exercise [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36919/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. However, the changes in bone density may be unevenly distributed. A study of ballet dancers found that bone density was normal or increased at weight-bearing sites and decreased at non-weight bearing sites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36919/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another sign of poor eating habits and low weight in athletes is repeated stress fractures, which occur in up to 30 percent of ballet dancers. They are much more common in athletes with distorted eating patterns than in those with normal eating patterns [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36919/abstract/18\">",
"     18",
"    </a>",
"    ]. The etiology is partly due to low bone mass, but is also thought to be related to a low-energy state, which leads to low bone turnover",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    favors a resorptive state. The uncoupling of bone turnover with suppression of bone formation and increases in resorption are unique and not typical of estrogen loss, but rather nutritional deprivation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36919/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Whether women athletes with normal cycles but luteal phase defects also have decreased bone density is controversial. One study found that exercising women with luteal phase defects had low bone density [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36919/abstract/20\">",
"     20",
"    </a>",
"    ], but this was not confirmed in other studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36919/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fractures, particularly stress fractures, are known to occur with a much higher frequency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36919/abstract/18,23\">",
"     18,23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Cardiovascular",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is possible that prolonged exercise-induced amenorrhea has adverse cardiovascular consequences [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36919/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. In a study of 68 women athletes, 24 with amenorrhea and 44 with regular cycles, the women with amenorrhea had significantly higher serum concentrations of [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36919/abstract/25\">",
"     25",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Total cholesterol &mdash; 210 versus 186",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (5.47 versus 4.84",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      Triglycerides &mdash; 68 versus 55",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (0.75 versus 0.61",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      Low-density lipoprotein (LDL) cholesterol &mdash; 121 versus 108",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (3.2 versus 2.8",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      High-density lipoprotein (HDL) cholesterol &mdash; 75 versus 66",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (1.95 versus 1.73",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Whether the cardiovascular consequences of these differences are clinically important, or whether the increased serum HDL cholesterol concentration is protective, is not known.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Excess mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is also possible that low body weight per se is associated with excess mortality, as illustrated by an analysis of the National Health and Nutrition Examination Survey (NHANES). In this report, being underweight (BMI &lt;18.5",
"    <span class=\"nowrap\">",
"     kg/m2;",
"    </span>",
"    excluding subjects with illness-related weight loss) was associated with excess mortality (33,746 excess annual deaths in the United States); excess risk was present for both smokers and nonsmokers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36919/abstract/26\">",
"     26",
"    </a>",
"    ]. However, this study did not separate women from men. The mechanism for this finding is not known, and further studies are required to confirm this observation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most women with exercise-induced amenorrhea have hypothalamic amenorrhea, which is suppression of pulsatile GnRH secretion from the hypothalamus, resulting in decreased secretion of follicle-stimulating hormone (FSH) and LH and, therefore, loss of ovarian cyclicity and estrogen deficiency. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/2/27685?source=see_link\">",
"     \"Physiology of the normal menstrual cycle\"",
"    </a>",
"    .) Thus, women with exercise-induced amenorrhea are at risk for all the complications of estrogen deficiency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise-induced amenorrhea is a diagnosis of exclusion. As in every woman with new-onset amenorrhea, other causes should be ruled out before exercise is accepted as the cause. The characteristic history is that of a woman with previously normal cycles in whom the cycles became irregular and then ceased after she began to exercise, especially if she lost weight at the same time. If a woman had exercise-induced amenorrhea in the past, which remitted when she stopped exercising, it is likely to recur if she resumes exercising.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Lab tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women suspected to have exercise-induced amenorrhea should have the following studies to rule out other causes of amenorrhea. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/56/34697?source=see_link\">",
"     \"Etiology, diagnosis, and treatment of secondary amenorrhea\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Measurement of serum human chorionic gonadotropin (hCG), to rule out pregnancy.",
"     </li>",
"     <li>",
"      Measurement of serum prolactin to rule out a prolactinoma and other causes of hyperprolactinemic amenorrhea (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/51/19254?source=see_link\">",
"       \"Clinical manifestations and diagnosis of hyperprolactinemia\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Measurement of serum FSH and LH to rule out primary ovarian insufficiency (premature ovarian failure). FSH is the best test for ovarian failure, but we measure both LH and FSH when we suspect hypothalamic amenorrhea. Very low levels of both LH and FSH are seen with hypothalamic amenorrhea.",
"     </li>",
"     <li>",
"      Measurement of serum TSH to rule out thyroid dysfunction.",
"     </li>",
"     <li>",
"      Measurement of bone mineral density if amenorrhea is present for greater than six months. If low, 25-hydroxy vitamin D levels should be measured to determine if patient has vitamin D deficiency.",
"     </li>",
"     <li>",
"      Women with primary amenorrhea should be evaluated for anatomic abnormalities of the uterus and uterine outflow tract (cervix, vagina, and hymen). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/2/2089?source=see_link\">",
"       \"Etiology, diagnosis, and treatment of primary amenorrhea\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Infertility",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercising women who present with infertility in association with apparently normal menstrual cycles should have a standard infertility evaluation. This includes measurements of serum FSH, thyrotropin, prolactin, and progesterone (the latter late in the cycle to document ovulation), imaging to document patent fallopian tubes, and semen analysis in the partner (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/56/17287?source=see_link\">",
"     \"Overview of infertility\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    As noted above, the most subtle menstrual cycle abnormality associated with exercise is an abnormal luteal phase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36919/abstract/13,20\">",
"     13,20",
"    </a>",
"    ], which may prevent implantation or nourishment of the developing embryo. In one report, women who exercised more than four hours per week were significantly less likely to have a live birth with in vitro fertilization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36919/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once a diagnosis of exercise-induced amenorrhea has been confirmed, treatment should begin with an explanation of the need for adequate caloric intake to compensate for energy expenditure. Patients should be instructed to increase caloric intake or reduce exercise and to work to increase body weight if they are less than 90 percent of ideal body weight.",
"   </p>",
"   <p>",
"    The use of hormonal therapies may give a false sense of security in the form of hormonally-induced menses, despite a continued state of amenorrhea due to nutritional deficiency. Ongoing behavioral therapy is indicated if there is a history of irregular eating behavior or distorted body image and resistance to decreasing exercise",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    weight gain. In women resistant to increasing caloric energy or decreasing exercise, a therapy of estrogen replacement and progestin may be indicated as a last resort.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Amenorrhea",
"    </span>",
"    &nbsp;&mdash;&nbsp;For some women, simply explaining the need for adequate caloric intake to match energy expenditure results in increased caloric intake",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    reduced exercise, and their menses resume [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36919/abstract/18\">",
"     18",
"    </a>",
"    ]. It is estimated that pulsatile LH secretion is disrupted at energy intakes below 30",
"    <span class=\"nowrap\">",
"     kcal/kg",
"    </span>",
"    lean body",
"    <span class=\"nowrap\">",
"     mass/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36919/abstract/28\">",
"     28",
"    </a>",
"    ]. Recovery has been found to be related to increases in BMI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36919/abstract/29\">",
"     29",
"    </a>",
"    ], in particular in cases where BMI is low.",
"   </p>",
"   <p>",
"    In those women in whom no other etiology of amenorrhea can be found, but who are unable or unwilling to either increase caloric intake or decrease the amount of exercise, estrogen therapy may be indicated. Appropriate therapy consists of any estrogen replacement regimen that includes endometrial protection (an oral contraceptive pill or cyclic or continuous estrogen and progestin replacement). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/42/40615?source=see_link\">",
"     \"Treatment of menopausal symptoms with hormone therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Bone density",
"    </span>",
"    &nbsp;&mdash;&nbsp;The results of treatment with hormone therapy have been conflicting and bone density should be monitored as further loss may occur in the face of poor nutritional intake. Results of clinical trials are variable, with some, but not all, showing recovery. However, these trials include a heterogeneous group of patients with hypothalamic amenorrhea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36919/abstract/30\">",
"     30",
"    </a>",
"    ]. Weight gain shows a greater effect on bone mineral density (BMD) than oral contraceptives [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36919/abstract/24,31\">",
"     24,31",
"    </a>",
"    ]. The patient should also be warned that menses are artificial and underlying amenorrhea may persist.",
"   </p>",
"   <p>",
"    In women worried about bone density or who are reluctant to increase dietary intake or decrease their exercise, a baseline measurement of bone density should be done, even if estrogen is to be given, to ensure compliance and to rule out osteoporosis.",
"   </p>",
"   <p>",
"    The etiology of the bone loss is multifactorial. An important effect of nutrition is to increase bone formation. Estrogen or oral contraceptive therapy is not sufficient. We first recommend an increase in caloric intake and follow them for three to six months to determine if menstrual cyclicity resumes before recommending estrogen replacement. In these women, measurement of bone density can be helpful to convince them that intervention in terms of increasing nutritional intake, decreasing exercise, or as a last resort, estrogen replacement. The increases in bone density are much greater with return of menses (6 to 17 percent) versus estrogen replacement or oral contraceptives (0 to 2 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36919/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Despite these increases in bone density, normalization of bone mass does not occur.",
"   </p>",
"   <p>",
"    Since bone loss is the most important short-term consequence of exercise-induced amenorrhea, all women athletes with amenorrhea should be encouraged to take 1200 to 1500 mg of calcium daily (diet plus 800 to 1000 mg of supplemental calcium) and supplemental vitamin D (400 int. units daily). If 25-hydroxy vitamin D level is low, larger doses are necessary. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/56/12170?source=see_link\">",
"     \"Calcium and vitamin D supplementation in osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In women who choose not to take estrogen, we suggest against starting a bisphosphonate. Increasing evidence indicates they have low bone formation and low bone turnover, and do not respond to antiresorptive therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36919/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additionally, bisphosphonates reside in the bone for 10 years, an issue of concern should these women later become pregnant, as the chemical is leeched from the bone and the effects on the fetus are unknown.",
"   </p>",
"   <p>",
"    Clinical trial data suggest that IGF-1, in combination with oral contraceptives, has a small positive effect on bone accretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36919/abstract/30,34\">",
"     30,34",
"    </a>",
"    ], but the increase is more modest than the 5 to 15 percent increase that is seen with return of menses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36919/abstract/23\">",
"     23",
"    </a>",
"    ]. It has been suggested that leptin may improve bone accretion because of its effects on bone markers but this is not proven [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36919/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Increasing evidence indicates that recovery of normal bone metabolism may require both nutritional recovery, causing bone formation, and activation of the hypothalamic-pituitary-ovarian axis, decreasing bone resorption. It is important to decrease exercise and increase caloric intake. If patients are less than 90 percent ideal body weight, they should gain weight. It is important to examine nutritional intake in depth, as patients may think their intake is normal, but it may not be enough for their activity level. A nutritionist is often helpful in this situation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/5/14425?source=see_link&amp;anchor=H5#H5\">",
"     \"Overview of treatment of female infertility\", section on 'Low body weight'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Infertility",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infertility associated with exercise-induced amenorrhea can be overcome with exogenous gonadotropin administration or pulsatile administration of GnRH. However,",
"    <strong>",
"     neither",
"    </strong>",
"    can be recommended as a first-line treatment for these women, since increased caloric intake (a much simpler therapy) is highly effective. Furthermore, if a woman does not eat enough to have regular cycles and normal fertility, her nutrient intake during a hormonally-induced pregnancy is likely to be inadequate for normal fetal growth and development and in those with low weight, the spontaneous abortion rate is elevated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36919/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Exercising women with an inadequate luteal phase are also best treated by an increase in caloric intake or a decrease in exercise. Some may need to gain weight to within 95 percent of their ideal weight. In those women whose nutritional status seems adequate, treatment during the luteal phase with progesterone for 10 days (50 to 100 mg via vaginal suppositories, or 25 to 50 mg by intramuscular injection) is an option, although it is of uncertain efficacy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/4/36930?source=see_link\">",
"       \"Patient information: Absent or irregular periods (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?29/12/29891?source=see_link\">",
"       \"Patient information: Absent or irregular periods (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3114400\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some women of reproductive age engage in excessive exercise that may result in menstrual cycle disorders and infertility. Amenorrhea occurs only when there is",
"    <strong>",
"     relative caloric deficiency",
"    </strong>",
"    due to inadequate nutritional intake for the amount of energy expended. Women with this disorder are considered to have &ldquo;exercise-induced amenorrhea&rdquo; or &ldquo;hypothalamic amenorrhea.&rdquo; Young exercising women with restrictive eating disorders and amenorrhea have been referred to as having the \"female athlete triad,\" which consists of an eating disorder, amenorrhea, and osteoporosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/56/34697?source=see_link&amp;anchor=H4#H4\">",
"     \"Etiology, diagnosis, and treatment of secondary amenorrhea\", section on 'Functional hypothalamic amenorrhea'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For restoration of menses and improvement in bone density, patients should be instructed to increase caloric intake or reduce exercise, and to work to increase body weight if they are less than 90 percent of ideal body weight. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Amenorrhea'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ongoing behavioral therapy is indicated if there is a history of irregular eating behavior or distorted body image and resistance to decreasing exercise",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      weight gain. The use of hormonal therapies may give a false sense of security in the form of hormonally-induced menses. However, in women resistant to increasing caloric energy or decreasing exercise, estrogen and progestin replacement may be indicated as a last resort.",
"     </li>",
"     <li>",
"      After a baseline measurement of bone density is obtained, women should be followed for three to six months to determine if menses resume before recommending estrogen replacement. However, bone loss may continue despite estrogen therapy, and fractures have been reported in women on oral contraceptives if nutritional intake is inadequate. We suggest not using bisphosphonates in these women, even in bone density is low (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Bone density'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that ovulation induction therapies not be initiated unless the patient has achieved a healthy weight and understands the need for continued focus on adequate caloric intake (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Infertility'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36919/abstract/1\">",
"      Shangold MM. Athletic amenorrhea. Clin Obstet Gynecol 1985; 28:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36919/abstract/2\">",
"      Frisch RE, Wyshak G, Vincent L. Delayed menarche and amenorrhea in ballet dancers. N Engl J Med 1980; 303:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36919/abstract/3\">",
"      Laughlin GA, Dominguez CE, Yen SS. Nutritional and endocrine-metabolic aberrations in women with functional hypothalamic amenorrhea. J Clin Endocrinol Metab 1998; 83:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36919/abstract/4\">",
"      Loucks AB, Verdun M, Heath EM. Low energy availability, not stress of exercise, alters LH pulsatility in exercising women. J Appl Physiol 1998; 84:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36919/abstract/5\">",
"      Caronia LM, Martin C, Welt CK, et al. A genetic basis for functional hypothalamic amenorrhea. N Engl J Med 2011; 364:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36919/abstract/6\">",
"      Bray GA, York DA. Clinical review 90: Leptin and clinical medicine: a new piece in the puzzle of obesity. J Clin Endocrinol Metab 1997; 82:2771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36919/abstract/7\">",
"      Ahima RS, Prabakaran D, Mantzoros C, et al. Role of leptin in the neuroendocrine response to fasting. Nature 1996; 382:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36919/abstract/8\">",
"      Laughlin GA, Yen SS. Hypoleptinemia in women athletes: absence of a diurnal rhythm with amenorrhea. J Clin Endocrinol Metab 1997; 82:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36919/abstract/9\">",
"      Welt CK, Chan JL, Bullen J, et al. Recombinant human leptin in women with hypothalamic amenorrhea. N Engl J Med 2004; 351:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36919/abstract/10\">",
"      Schneider LF, Warren MP. Functional hypothalamic amenorrhea is associated with elevated ghrelin and disordered eating. Fertil Steril 2006; 86:1744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36919/abstract/11\">",
"      Christo K, Cord J, Mendes N, et al. Acylated ghrelin and leptin in adolescent athletes with amenorrhea, eumenorrheic athletes and controls: a cross-sectional study. Clin Endocrinol (Oxf) 2008; 69:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36919/abstract/12\">",
"      Schneider LF, Monaco SE, Warren MP. Elevated ghrelin level in women of normal weight with amenorrhea is related to disordered eating. Fertil Steril 2008; 90:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36919/abstract/13\">",
"      Loucks AB, Mortola JF, Girton L, Yen SS. Alterations in the hypothalamic-pituitary-ovarian and the hypothalamic-pituitary-adrenal axes in athletic women. J Clin Endocrinol Metab 1989; 68:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36919/abstract/14\">",
"      Constantini NW, Warren MP. Menstrual dysfunction in swimmers: a distinct entity. J Clin Endocrinol Metab 1995; 80:2740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36919/abstract/15\">",
"      Loucks AB, Vaitukaitis J, Cameron JL, et al. The reproductive system and exercise in women. Med Sci Sports Exerc 1992; 24:S288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36919/abstract/16\">",
"      Robinson TL, Snow-Harter C, Taaffe DR, et al. Gymnasts exhibit higher bone mass than runners despite similar prevalence of amenorrhea and oligomenorrhea. J Bone Miner Res 1995; 10:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36919/abstract/17\">",
"      Young N, Formica C, Szmukler G, Seeman E. Bone density at weight-bearing and nonweight-bearing sites in ballet dancers: the effects of exercise, hypogonadism, and body weight. J Clin Endocrinol Metab 1994; 78:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36919/abstract/18\">",
"      Warren MP, Perlroth NE. The effects of intense exercise on the female reproductive system. J Endocrinol 2001; 170:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36919/abstract/19\">",
"      Dominguez J, Goodman L, Sen Gupta S, et al. Treatment of anorexia nervosa is associated with increases in bone mineral density, and recovery is a biphasic process involving both nutrition and return of menses. Am J Clin Nutr 2007; 86:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36919/abstract/20\">",
"      Prior JC, Vigna YM, Schechter MT, Burgess AE. Spinal bone loss and ovulatory disturbances. N Engl J Med 1990; 323:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36919/abstract/21\">",
"      De Souza MJ, Miller BE, Sequenzia LC, et al. Bone health is not affected by luteal phase abnormalities and decreased ovarian progesterone production in female runners. J Clin Endocrinol Metab 1997; 82:2867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36919/abstract/22\">",
"      Hetland ML, Haarbo J, Christiansen C, Larsen T. Running induces menstrual disturbances but bone mass is unaffected, except in amenorrheic women. Am J Med 1993; 95:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36919/abstract/23\">",
"      Warren MP, Brooks-Gunn J, Fox RP, et al. Osteopenia in exercise-associated amenorrhea using ballet dancers as a model: a longitudinal study. J Clin Endocrinol Metab 2002; 87:3162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36919/abstract/24\">",
"      Rickenlund A, Carlstr&ouml;m K, Ekblom B, et al. Effects of oral contraceptives on body composition and physical performance in female athletes. J Clin Endocrinol Metab 2004; 89:4364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36919/abstract/25\">",
"      Friday KE, Drinkwater BL, Bruemmer B, Chesnut C, III, Chait A. Elevated plasma low-density lipoprotein and high-density lipoprotein cholesterol levels in amenorrheic athletes: effects of endogenous hormone status and nutrient intake. J Clin Endocrinol Metab 1993; 77:1605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36919/abstract/26\">",
"      Flegal KM, Graubard BI, Williamson DF, Gail MH. Excess deaths associated with underweight, overweight, and obesity. JAMA 2005; 293:1861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36919/abstract/27\">",
"      Morris SN, Missmer SA, Cramer DW, et al. Effects of lifetime exercise on the outcome of in vitro fertilization. Obstet Gynecol 2006; 108:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36919/abstract/28\">",
"      Loucks AB, Thuma JR. Luteinizing hormone pulsatility is disrupted at a threshold of energy availability in regularly menstruating women. J Clin Endocrinol Metab 2003; 88:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36919/abstract/29\">",
"      Falsetti L, Gambera A, Barbetti L, Specchia C. Long-term follow-up of functional hypothalamic amenorrhea and prognostic factors. J Clin Endocrinol Metab 2002; 87:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36919/abstract/30\">",
"      Liu SL, Lebrun CM. Effect of oral contraceptives and hormone replacement therapy on bone mineral density in premenopausal and perimenopausal women: a systematic review. Br J Sports Med 2006; 40:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36919/abstract/31\">",
"      Hotta M, Shibasaki T, Sato K, Demura H. The importance of body weight history in the occurrence and recovery of osteoporosis in patients with anorexia nervosa: evaluation by dual X-ray absorptiometry and bone metabolic markers. Eur J Endocrinol 1998; 139:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36919/abstract/32\">",
"      Warren MP, Brooks-Gunn J, Fox RP, et al. Persistent osteopenia in ballet dancers with amenorrhea and delayed menarche despite hormone therapy: a longitudinal study. Fertil Steril 2003; 80:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36919/abstract/33\">",
"      Warren MP, Miller KK, Olson WH, et al. Effects of an oral contraceptive (norgestimate/ethinyl estradiol) on bone mineral density in women with hypothalamic amenorrhea and osteopenia: an open-label extension of a double-blind, placebo-controlled study. Contraception 2005; 72:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36919/abstract/34\">",
"      Grinspoon S, Thomas L, Miller K, et al. Effects of recombinant human IGF-I and oral contraceptive administration on bone density in anorexia nervosa. J Clin Endocrinol Metab 2002; 87:2883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36919/abstract/35\">",
"      Chan JL, Mantzoros CS. Role of leptin in energy-deprivation states: normal human physiology and clinical implications for hypothalamic amenorrhoea and anorexia nervosa. Lancet 2005; 366:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36919/abstract/36\">",
"      Blais MA, Becker AE, Burwell RA, et al. Pregnancy: outcome and impact on symptomatology in a cohort of eating-disordered women. Int J Eat Disord 2000; 27:140.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7393 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-79.123.134.1-8BED796ECD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_3_36919=[""].join("\n");
var outline_f36_3_36919=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H3114400\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Type of exercise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Relative caloric deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H133384\">",
"      Genetic predisposition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Leptin and other peptides",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Effect on H-P-O axis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CONSEQUENCES OF EXERCISE-INDUCED AMENORRHEA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Low bone density/fractures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Cardiovascular",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Excess mortality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Lab tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Amenorrhea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Bone density",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3114400\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/56/12170?source=related_link\">",
"      Calcium and vitamin D supplementation in osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/51/19254?source=related_link\">",
"      Clinical manifestations and diagnosis of hyperprolactinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/2/23593?source=related_link\">",
"      Eating disorders: Epidemiology, pathogenesis, clinical features, and course of illness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/2/2089?source=related_link\">",
"      Etiology, diagnosis, and treatment of primary amenorrhea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/56/34697?source=related_link\">",
"      Etiology, diagnosis, and treatment of secondary amenorrhea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/56/17287?source=related_link\">",
"      Overview of infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/5/14425?source=related_link\">",
"      Overview of treatment of female infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?29/12/29891?source=related_link\">",
"      Patient information: Absent or irregular periods (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/4/36930?source=related_link\">",
"      Patient information: Absent or irregular periods (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/50/13094?source=related_link\">",
"      Physiology of leptin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/2/27685?source=related_link\">",
"      Physiology of the normal menstrual cycle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/42/40615?source=related_link\">",
"      Treatment of menopausal symptoms with hormone therapy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_3_36920="Chest radiograph of left ventricular aneurysm II";
var content_f36_3_36920=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F82699%7ECARD%2F67669&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F82699%7ECARD%2F67669&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chest radiograph of left ventricular aneurysm II",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 348px; height: 269px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This plain frontal chest radiograph from an 80-year-old female demonstrates prominence to the left heart border, a characteristic location for a left ventricular aneurysm (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Photo courtesy of Jonathan Kruskal, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior view of a normal chest radiograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chest radiograph of left ventricular aneurysm III",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 341px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This plain frontal chest radiograph from a 60-year-old male with history of angina and myocardial infarction demonstrates a prominent bulge along the lateral aspect of the left ventricular margin consistent with an aneurysm (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Photo courtesy of Jonathan Kruskal, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior view of a normal chest radiograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_3_36920=[""].join("\n");
var outline_f36_3_36920=null;
var title_f36_3_36921="Susceptibility to malignant hyperthermia";
var content_f36_3_36921=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Susceptibility to malignant hyperthermia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/3/36921/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/3/36921/contributors\">",
"     Ronald S Litman, DO, FAAP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/3/36921/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/3/36921/contributors\">",
"     Stephanie B Jones, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/3/36921/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/3/36921/contributors\">",
"     Kari G Doucette, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/3/36921/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malignant hyperthermia (MH) is a complex genetic disorder of skeletal muscle typically manifesting clinically as a hypermetabolic crisis when a susceptible individual receives an inhalational anesthetic agent or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33510?source=see_link\">",
"     succinylcholine",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36921/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Susceptibility to MH is inherited in an autosomal dominant fashion and is suspected in individuals with a clinical event strongly suspicious for MH, a family history of proven susceptibility or hypermetabolism with anesthesia, or conditions associated with MH. The mainstay of prevention is the identification of these genetically susceptible individuals. Avoidance of anesthetic triggers in MH-susceptible patients, and prompt administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/22/22887?source=see_link\">",
"     dantrolene",
"    </a>",
"    when an acute event occurs has reduced the mortality associated with malignant hyperthermia from historic rates of 70 percent to about 5 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36921/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will review the pathophysiology, genetic basis of, and testing for MH-susceptibility. The clinical manifestations, diagnosis, and management of an acute MH crisis are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/13/32984?source=see_link\">",
"     \"Malignant hyperthermia: Clinical diagnosis and management of acute crisis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;MH-susceptible patients have genetic skeletal muscle receptor abnormalities allowing excessive calcium accumulation in the presence of certain anesthetic triggering agents. Very little is known about the specific mechanisms by which anesthetics interact with these abnormal receptors to trigger an MH crisis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36921/abstract/6-8\">",
"     6-8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Normal muscle physiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depolarization spreads throughout the muscle cell via the transverse tubule system which activates dihydropyridine (DHP) receptors located within the t-tubule membrane (",
"    <a class=\"graphic graphic_figure graphicRef58185 \" href=\"mobipreview.htm?23/34/24106\">",
"     figure 1",
"    </a>",
"    ). These receptors are coupled to ryanodine receptors (RYR1) which are homo-tetrameric calcium channels embedded in the wall of the sarcoplasmic reticulum (SR). Calcium release through the DHP receptor's voltage-dependent calcium channels triggers the RYR1 receptors to release calcium from the sarcoplasmic reticulum into the intracellular space [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36921/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Calcium combines with troponin allowing actin and myosin to cross-link, resulting in muscle cell contraction. Reuptake of calcium by the sarco(endo)plasmic reticulum calcium ATPase (SERCA) leads to muscle cell relaxation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Malignant hyperthermia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of MH-susceptible patients have mutations encoding for abnormal RYR1 or DHP receptors that trigger unregulated passage of calcium from the sarcoplasmic reticulum into the intracellular space, which may lead to an acute MH crisis (",
"    <a class=\"graphic graphic_figure graphicRef58185 \" href=\"mobipreview.htm?23/34/24106\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36921/abstract/9-18\">",
"     9-18",
"    </a>",
"    ]. The accumulation of myoplasmic calcium causes sustained muscle contraction which, over time, generates heat. Accelerated levels of aerobic metabolism sustain the muscle for a time, but produce carbon dioxide and cellular acidosis, and deplete oxygen and adenosine triphosphate (ATP) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36921/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. A change to anaerobic metabolism worsens acidosis with the production of lactate. Once energy stores are depleted, the muscle fibers die, with rhabdomyolysis leading to hyperkalemia and myoglobinuria. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Genetic basis'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/55/32632?source=see_link\">",
"     \"Clinical manifestations and diagnosis of rhabdomyolysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/13/32984?source=see_link&amp;anchor=H8#H8\">",
"     \"Malignant hyperthermia: Clinical diagnosis and management of acute crisis\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Administration of certain anesthetic agents in MH-susceptible patients can trigger these events. Prolonged RYR1 channel opening has been demonstrated in an experimental model [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36921/abstract/22\">",
"     22",
"    </a>",
"    ]. Volatile anesthetics potentiate sarcoplasmic calcium release in patients with MH sensitivity. Halothane, for example, increases the fluidity of the lipid membrane activating sarco(endoplasmic) calcium dependent ATPase, limiting reuptake of calcium from the cytosol [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36921/abstract/23\">",
"     23",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33510?source=see_link\">",
"     Succinylcholine",
"    </a>",
"    is an analog of acetylcholine and stimulates the motor endplate to initiate muscle depolarization, which in MH-susceptible patients can become sustained. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31288?source=see_link&amp;anchor=H4#H4\">",
"     \"Neuromuscular blocking agents (NMBA) for rapid sequence intubation in adults\", section on 'Succinylcholine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/22/22887?source=see_link\">",
"     Dantrolene",
"    </a>",
"    binds to the RYR1 receptor inhibiting the release of calcium from the sarcoplasmic reticulum reversing the negative cascade of effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36921/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/13/32984?source=see_link&amp;anchor=H17#H17\">",
"     \"Malignant hyperthermia: Clinical diagnosis and management of acute crisis\", section on 'Acute management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     GENETIC BASIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Susceptibility to MH can be conferred by any inherited (or spontaneous) mutation of genes associated with proteins that control levels of cytosolic calcium and therefore skeletal muscle contraction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36921/abstract/27\">",
"     27",
"    </a>",
"    ]. Genes responsible for coding proteins of the RYR1 and DHP receptors are most commonly affected. The likelihood of developing MH in susceptible patients depends upon the specific type of receptor mutation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36921/abstract/28\">",
"     28",
"    </a>",
"    ]. Approximately one half of cases are inherited in an autosomal dominant fashion. Because of incomplete genetic penetrance and variable expressivity, considerable inter- and intra-individual variability exists in the clinical expression of the syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36921/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/13/32984?source=see_link&amp;anchor=H8#H8\">",
"     \"Malignant hyperthermia: Clinical diagnosis and management of acute crisis\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Approximately 50 percent of known cases of MH are caused by mutations on chromosome 19 in regions that encode the hydrophilic, amino-terminal portion of the RYR1 receptor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36921/abstract/8,18\">",
"     8,18",
"    </a>",
"    ]. Over 40 distinct mutations in this region have been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36921/abstract/15,31-39\">",
"     15,31-39",
"    </a>",
"    ]. A small number (approximately 1 percent) are caused by a mutation of the CACNA1S gene, which encodes the alpha-subunit of the voltage-gated DHP receptor located on chromosome 1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36921/abstract/15,35-39\">",
"     15,35-39",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Pathophysiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Six types of MH-susceptibility (MHS1-6) have been described, based upon the chromosomal locus affected:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      MHS1 &ndash; Associated with the RYR1 gene on chromosome 19q13.1",
"     </li>",
"     <li>",
"      MHS2 &ndash; Associated with the DHP receptor isolated to the 17q11.2-q24 locus",
"     </li>",
"     <li>",
"      MHS3 &ndash; Associated with the",
"      <span class=\"nowrap\">",
"       alpha-2/gamma",
"      </span>",
"      subunit of the DHP receptor, linked to 7q21-q22 locus",
"     </li>",
"     <li>",
"      MHS4 &ndash; Linked to the 3q13.2 locus",
"     </li>",
"     <li>",
"      MHS5 &ndash; Encoding of the alpha-1 subunit of the DHP receptor and locus 1q32",
"     </li>",
"     <li>",
"      MHS6 &ndash; Linked to chromosomal locus 5p",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PREVALENCE OF SUSCEPTIBILITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of susceptibility for malignant hyperthermia in the general population is unknown.",
"   </p>",
"   <p>",
"    Published prevalence rates vary widely depending upon the characteristics of the population studied and the manner in which MH-susceptibility was determined. Prevalence is most often studied in family cohorts known to have susceptibility for MH; rates range from 1:200 to 1:5000 in these cohorts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36921/abstract/40,41\">",
"     40,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The variable penetrance of genetic inheritance leads to far fewer cases of clinically significant MH than prevalence rates would suggest. Many patients with susceptibility for MH have received general anesthetic triggering agents without developing an acute crisis. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Genetic basis'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/13/32984?source=see_link&amp;anchor=H2#H2\">",
"     \"Malignant hyperthermia: Clinical diagnosis and management of acute crisis\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CONDITIONS ASSOCIATED WITH MH",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of conditions have been associated with malignant hyperthermia (",
"    <a class=\"graphic graphic_table graphicRef65645 \" href=\"mobipreview.htm?37/49/38687\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Myopathies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some individuals with preexisting muscle diseases due to genetic abnormalities in RYR1 or DHP receptors are at higher than normal risk for developing MH; therefore triggering agents are contraindicated in these individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36921/abstract/15,35,42-52\">",
"     15,35,42-52",
"    </a>",
"    ]. These conditions include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Central core myopathy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/3/36921/abstract/16,35,42,52,53\">",
"       16,35,42,52,53",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Multicore myopathy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/3/36921/abstract/54\">",
"       54",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      King-Denborough syndrome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/3/36921/abstract/1,55\">",
"       1,55",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Native American myopathy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/3/36921/abstract/15,56\">",
"       15,56",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These patients can be safely anesthetized using non-triggering agents. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Anesthesia in MH-susceptible patients'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Conditions associated with rhabdomyolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some conditions characterized by muscle atrophy are associated with an increased risk for life-threatening rhabdomyolysis or hyperkalemia following administration of inhalational anesthetics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36921/abstract/43-50,57-74\">",
"     43-50,57-74",
"    </a>",
"    ]. This clinical syndrome can closely resemble acute MH. These patients are also at risk for developing rhabdomyolysis and life-threatening hyperkalemia following exposure to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33510?source=see_link\">",
"     succinylcholine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36921/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. Evidence of causation is limited and while these patients do not appear to have a higher risk of developing fulminant MH compared to the general population, we suggest withholding MH triggering agents from patients with the following conditions.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Heat induced rhabdomyolysis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/3/36921/abstract/58-60,75,76\">",
"       58-60,75,76",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Exercise-related rhabdomyolysis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/3/36921/abstract/57,61,76\">",
"       57,61,76",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Dystrophinopathies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/3/36921/abstract/43-47,62-68,70,71,77,78\">",
"       43-47,62-68,70,71,77,78",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Myoadenylate deaminase deficiency [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/3/36921/abstract/48\">",
"       48",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      McArdle's disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/3/36921/abstract/50,72\">",
"       50,72",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/16/21766?source=see_link\">",
"       Carnitine",
"      </a>",
"      palmitoyl transferase type 2 deficiency [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/3/36921/abstract/73,79\">",
"       73,79",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Other conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of other genetic syndromes have been associated with MH-susceptibility but without sufficient evidence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36921/abstract/80-90\">",
"     80-90",
"    </a>",
"    ]. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Osteogenesis imperfecta [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/3/36921/abstract/80-83\">",
"       80-83",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Arthrogryposis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/3/36921/abstract/84-86\">",
"       84-86",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Myotonia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/3/36921/abstract/91\">",
"       91",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Noonan syndrome",
"     </li>",
"     <li>",
"      Neuroleptic malignant syndrome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/3/36921/abstract/87-90\">",
"       87-90",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Triggering agents can be administered to patients with these conditions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     MH CLINICAL GRADING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The MH clinical grading scale is used to judge the likelihood that a prior event represents true MH which helps provide guidance in patient counseling. The MH clinical grading scale assigns points to previous clinical events (",
"    <a class=\"graphic graphic_table graphicRef54539 \" href=\"mobipreview.htm?32/15/33020\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36921/abstract/92\">",
"     92",
"    </a>",
"    ]. The total number of points determines an MH rank between one and six (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?14/19/14642?source=see_link\">",
"     calculator 1",
"    </a>",
"    ). The more clinical criteria fulfilled, the more likely an MH episode has occurred; an MH rank of 6 (50+ points) indicates an almost certain likelihood that the event represented MH. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/13/32984?source=see_link&amp;anchor=H8#H8\">",
"     \"Malignant hyperthermia: Clinical diagnosis and management of acute crisis\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Important clinical indicators associated with an event and valued at more than 10 points each include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Respiratory acidosis &mdash; The presence of end-tidal CO2 &gt;55 mmHg or PaCO2 &gt;60 mm Hg with controlled ventilation, PETCO2 &gt;60 mmHg or PaCO2 &gt;65 mmHg with spontaneous ventilation.",
"     </li>",
"     <li>",
"      Metabolic acidosis &mdash; Base deficit &gt;8 mEq, pH &lt;7.25",
"     </li>",
"     <li>",
"      Muscle rigidity &mdash; Either severe masseter muscle rigidity or generalized rigidity. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/13/32984?source=see_link&amp;anchor=H12#H12\">",
"       \"Malignant hyperthermia: Clinical diagnosis and management of acute crisis\", section on 'Masseter muscle rigidity'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Muscle breakdown &mdash; Serum CK &gt;20,000",
"      <span class=\"nowrap\">",
"       IU/L",
"      </span>",
"      or &gt;10,000",
"      <span class=\"nowrap\">",
"       IU/L",
"      </span>",
"      without the use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33510?source=see_link\">",
"       succinylcholine",
"      </a>",
"      , cola colored urine in the postoperative period.",
"     </li>",
"     <li>",
"      Temperature &mdash; Rapidly increasing temperature, or core temperature &gt;38.8&ordm; C (101.8&ordm;F).",
"     </li>",
"     <li>",
"      Elevated resting serum CK",
"     </li>",
"     <li>",
"      Family history of MH (autosomal dominant inheritance)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SCREENING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     General population",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nearly all new cases of MH occur in phenotypically normal patients who were not previously known to be at risk. Unfortunately, there are no practical MH-susceptibility screening tests for the general population.",
"   </p>",
"   <p>",
"    While resting plasma creatinine kinase (CK) levels may be elevated in up to 70 percent of MH-susceptible individuals, preoperative testing of CK levels is not useful because CK may be elevated for multiple other reasons (eg, muscle trauma) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36921/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is customary to screen preoperative patients for any adverse reactions to prior anesthesia; however, a negative history does not provide assurance that an event will not occur. Up to 50 percent of patients who develop acute MH after anesthetic exposure have prior uneventful exposures to triggering agents. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/13/32984?source=see_link&amp;anchor=H4#H4\">",
"     \"Malignant hyperthermia: Clinical diagnosis and management of acute crisis\", section on 'Anesthesia history'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Family members",
"    </span>",
"    &nbsp;&mdash;&nbsp;Family members of a newly diagnosed MH-susceptible patient (ie, positive MH-susceptibility testing [muscle contracture or genetic testing], or history of acute MH crisis) are evaluated since most MH-susceptibility is inherited. The patient's parents are generally evaluated first. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'MH-susceptibility testing'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The benefit in evaluating the parents is the identification of the side of the family (maternal or paternal) carrying the mutation, eliminating the need to screen the unaffected half. If the parents are negative for MH-susceptibility, suggesting a spontaneous mutation, the risk to family members other than the patient's children is low. The patient's children should be screened as transmission is typically autosomal dominant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Conditions associated with MH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals who should undergo MH-susceptibility testing include those with conditions at high risk for MH but for which a specific receptor abnormality is not yet known (eg, Native American myopathy), and some conditions at risk for rhabdomyolysis, particularly exercise- or heat-related rhabdomyolysis. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'MH-susceptibility testing'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H9\">",
"     'Myopathies'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H10\">",
"     'Conditions associated with rhabdomyolysis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Inherited conditions such as central core myopathy, multiminicore disease, and King-Denborough syndrome are known to have genetic abnormalities in receptors controlling muscle calcium regulation. Anesthetic triggering agents are absolutely contraindicated in this group of individuals so MH-susceptibility testing is not required. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Myopathies'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     MH-SUSCEPTIBILITY TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with a clinical event suspicious for MH should undergo MH-susceptibility testing, ideally with a contracture test; however, only a minority of patients and their families are willing or able to travel to the few centers where the test is performed, and some insurance plans may not cover muscle biopsy and contracture testing which costs about $5000.",
"   </p>",
"   <p>",
"    In lieu of contracture testing, some patients with suspected MH-susceptibility will opt for molecular genetic testing (sensitivity 30 to 50 percent), or simply consider themselves (and their family members) MH-susceptible. Although this strategy is practical, it may not provide guidance or specific answers to the patient or their family members who are then labeled as MH-susceptible forever. Future anesthetic options are then limited.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Contracture tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;MH-susceptibility can be confirmed using contracture testing, which is an in vitro muscle bioassay. Contracture testing has a low false negative rate (sensitivity &gt;97 percent), thus negative results generally rule out a diagnosis of MH-susceptibility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36921/abstract/93,94\">",
"     93,94",
"    </a>",
"    ]. Some individuals with known MH mutations have a negative response to this test [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36921/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the face of equivocal test results, the decision to withhold anesthetic triggering agents in the future depends upon the results of genetic tests or the clinical scenario prompting contracture testing. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Genetic tests'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H12\">",
"     'MH clinical grading'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Up to 22 percent of patients with positive contracture tests have a false positive results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36921/abstract/93\">",
"     93",
"    </a>",
"    ]. Methods to enhance the test (eg, 4-chloro-m-cresol test, ryanodine contracture testing) have been reported but are not yet routinely used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36921/abstract/94,95\">",
"     94,95",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The contracture test is performed at specific centers around the world (four in the United States) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36921/abstract/38\">",
"     38",
"    </a>",
"    ]. Following testing, the referring physician receives a report indicating whether testing was positive, negative, or equivocal. Positive or equivocal results should be followed-up with genetic testing. Referral information can be found on the Malignant Hyperthermia Association of the United States (MHAUS) website. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'MH resources'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Indications for contracture testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contracture testing is not usually needed when genetic testing within a family is positive. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Genetic tests'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Contracture testing is indicated for:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with a history suspicious for MH (high MH clinical grade). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'MH clinical grading'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      First degree relatives of a patient with a suspicious history if the clinically affected patient is unwilling or unable to travel to a testing center.",
"     </li>",
"     <li>",
"      Patients with a suspicious history who are contemplating military service since MH-susceptible individuals are not eligible for military service.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other clinical scenarios in which contracture testing may be helpful include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Unexplained rhabdomyolysis following anesthesia",
"     </li>",
"     <li>",
"      Mild to moderate masseter muscle rigidity following",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33510?source=see_link\">",
"       succinylcholine",
"      </a>",
"      administration",
"     </li>",
"     <li>",
"      Severe or recurrent exercise- or heat-induced rhabdomyolysis",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Protocols",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contracture tests evaluate the in vitro response of a fresh sample of the patient's muscle tissue to caffeine and halothane. Two different protocols were developed independently by the North American Malignant Hyperthermia Group (NAMHG) and the European Malignant Hyperthermia Group (EMHG). These protocols differ slightly in the concentrations of halothane and caffeine used in testing, and number of muscle strips used. The sensitivity and specificity of these protocols are different due to the different criteria each has for indicating a positive result [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36921/abstract/39\">",
"     39",
"    </a>",
"    ]. The caffeine-halothane contracture test (CHCT) is available in the United States and Canada while the in-vitro contracture (IVCT) test is performed in Europe.",
"   </p>",
"   <p>",
"    For both protocols, an excisional muscle biopsy is required (3 to 4 inches from the thigh) and is obtained under general anesthesia with non-triggering agents or regional anesthesia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36921/abstract/96\">",
"     96",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Next the fresh muscle specimen is placed into a physiologic solution and taken immediately to the laboratory where it is divided into smaller strips. The muscle is placed in physiologic solution (no drugs), attached to a strain gauge, and first carefully stretched to a standard baseline tension. The muscle is then electrically stimulated (60 Hz) causing it to contract and the generated tension is measured. Separate strips are tested with either halothane or caffeine which is added to the physiologic solution at specific concentrations depending upon the protocol. Contractile responses to these pharmacologic agents are measured relative to baseline tension. Varying the threshold of contractile response considered for a positive result (ie, 0.2 to 0.7 g relative to baseline) alters the level of sensitivity and specificity.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Caffeine-halothane contracture test &mdash; The caffeine-halothane contracture test (CHCT) is used in the United States and Canada. A minimum of three separate muscle strips for each pharmacologic agent are used in testing. Following electrical stimulation, muscle strips are exposed to a 3 percent halothane solution or gradually increasing concentrations of caffeine solution beginning at 0.5 mM (",
"      <a class=\"graphic graphic_waveform graphicRef70048 \" href=\"mobipreview.htm?11/50/12079\">",
"       waveform 1",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      A positive response is indicated if the contractile tension is greater than or equal to 0.7 g relative to baseline tension for halothane (tension between 0.5 and 0.69 g are considered equivocal), and 0.3 g for caffeine at 0.5, 1, or 2 mM. The sensitivity and specificity achieved with these thresholds are 97 and 78 percent, respectively.",
"      <br/>",
"      <br/>",
"      If any one of the three strips exposed to halothane",
"      <strong>",
"       or",
"      </strong>",
"      all strips exposed to caffeine exhibit a positive contracture response, the test is positive and indicates MH-susceptibility. Otherwise the test is negative.",
"     </li>",
"     <li>",
"      In vitro contracture test &mdash; A slightly different protocol referred to as the in vitro contracture test (IVCT) is used in Europe [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/3/36921/abstract/39,97,98\">",
"       39,97,98",
"      </a>",
"      ]. The criteria for a positive test are different because the protocol differs from CHCT; two muscle fiber strips, and different concentrations of halothane and caffeine are used. The sensitivity and specificity achieved with the IVCT are 99 and 94 percent, respectively. Information on specific details of this protocol can be found on the European malignant hyperthermia group website [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/3/36921/abstract/99\">",
"       99",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Genetic tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic analysis is performed to confirm the presence of a known causative mutation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36921/abstract/33-37\">",
"     33-37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Molecular genetic testing for known MH-causing mutations, implemented in the United States and Europe, consists of a genetic panel evaluating 17 of the most common RYR1 mutations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36921/abstract/29,32,51,75,98,100\">",
"     29,32,51,75,98,100",
"    </a>",
"    ]. A blood sample can be sent to one of two testing centers in the United States and costs around $800 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36921/abstract/11\">",
"     11",
"    </a>",
"    ]. Because testing evaluates only a relatively small percentage of possible mutations, the overall sensitivity of RYR1 panel testing is low. Individual mutations known to occur within a family can be specifically evaluated and cost $200 dollars per mutation tested [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36921/abstract/100\">",
"     100",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Compared to contracture testing, the advantages of genetic testing are that it is convenient for the patient, minimally invasive, and typically covered by insurance. However, because the panel evaluates primarily RYR1 mutations, it has a high false negative rate for MH-susceptibility (about 30 to 50 percent). Thus, a disadvantage is that a negative test does not rule out MH-susceptibility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36921/abstract/75,98\">",
"     75,98",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Indications for genetic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic testing is indicated for:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with a positive or equivocal contracture test to determine the presence of a specific mutation.",
"     </li>",
"     <li>",
"      Individuals with a positive genetic test for MH in a family member.",
"     </li>",
"     <li>",
"      Patients with a clinical history suspicious for MH (acute MH episode, masseter muscle rigidity, postoperative myoglobinuria, heat or exercise induce rhabdomyolysis) who are unable or unwilling to undergo contracture testing.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     PATIENT AND FAMILY COUNSELING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients and family members of individuals testing positive for susceptibility to MH should be counseled about this disorder.",
"   </p>",
"   <p>",
"    They are advised that agents that can trigger MH should never be given to them, and of the importance of informing future anesthesiologists of their susceptibility. A letter from the anesthesiologist who supervised the initial incident should be obtained and kept in the patient's personal records and electronic medical record for future reference.",
"   </p>",
"   <p>",
"    MH-susceptible patients are also cautioned about the possibility of developing heat stroke in extremely hot and humid environments. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/40/16007?source=see_link\">",
"     \"Severe hyperthermia (heat stroke) in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because susceptibility to MH has an autosomal dominant inheritance, all first-degree family members are considered potentially MH-susceptible and should be counseled and referred for MH consultation. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'MH resources'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The patient and anyone in their family confirmed positive for MH-susceptibility should obtain and wear alert identification indicating his or her susceptibility. Identification bracelets specific for MH can be obtained through the Malignant Hyperthermia Association of the United States (MHAUS). (See",
"    <a class=\"local\" href=\"#H28\">",
"     'MH resources'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The MH-susceptible patient and his or her family are encouraged to learn as much as possible about the nature of the disorder and should be directed to appropriate educational resources. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'MH resources'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     ANESTHESIA IN MH-SUSCEPTIBLE PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;MH-susceptible patients can be safely anesthetized using non-triggering agents. Prophylactic pharmacologic intervention (ie,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/22/22887?source=see_link\">",
"     dantrolene",
"    </a>",
"    ) is not indicated. End-tidal carbon dioxide (ETCO2) levels, minute ventilation, and core body temperature are monitored closely in MH-susceptible patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2126295\">",
"    <span class=\"h2\">",
"     Preventive measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anesthesiologist can \"clean\" the anesthesia machine by flushing it with high-flow oxygen to ensure that the MH-susceptible patient will not be exposed to trace anesthetic gases. Tape is placed over the vaporizer canisters to avoid accidental administration of volatile anesthetic or the canisters can be removed altogether (",
"    <a class=\"graphic graphic_picture graphicRef54970 \" href=\"mobipreview.htm?28/54/29539\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Alternatively, a charcoal filter (",
"    <a class=\"graphic graphic_picture graphicRef81599 \" href=\"mobipreview.htm?43/9/44179\">",
"     picture 2",
"    </a>",
"    ) can be attached to the inspiratory",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    expiratory breathing circuits to absorb any traces of anesthetic gas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36921/abstract/101\">",
"     101",
"    </a>",
"    ]. The use of charcoal filters eliminates the need for prolonged oxygen flushing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36921/abstract/102\">",
"     102",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Safe anesthetic agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common non-triggering agent used in MH-susceptible patients is",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    via continuous infusion. Regional anesthesia is also appropriate when feasible. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/22/19817?source=see_link\">",
"     \"Overview of anesthesia and anesthetic choices\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/37/5719?source=see_link\">",
"     \"Overview of peripheral nerve blocks\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Agents that can be safely administered to MH-susceptible patients include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All intravenous anesthetic, and sedative agents including",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/25/17816?source=see_link\">",
"       propofol",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10967?source=see_link\">",
"       ketamine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/34/15908?source=see_link\">",
"       etomidate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/53/33622?source=see_link\">",
"       dexmedetomidine",
"      </a>",
"      , and barbiturates.",
"     </li>",
"     <li>",
"      All local anesthetics (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/60/34758?source=see_link\">",
"       bupivacaine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/38/7782?source=see_link\">",
"       ropivacaine",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Nondepolarizing neuromuscular blockers (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/46/15079?source=see_link\">",
"       vecuronium",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Inhalational agents limited to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/29/11732?source=see_link\">",
"       nitrous oxide",
"      </a>",
"      and xenon",
"     </li>",
"     <li>",
"      Pain relievers and anxiolytics including opioids and benzodiazepines",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Ambulatory surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine day surgery discharge criteria are applicable to MH-susceptible patients who have not received anesthetic triggering agents. Upon discharge, the patient is instructed to call their physician or go to the emergency room if elevated temperature or brown urine develop.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     MH RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Malignant Hyperthermia Association of the United States (MHAUS) was formed to educate the medical and lay communities about MH and serve as a resource for affected families. A wide variety of educational information for health professionals and the public is available at the MHAUS Web site (",
"    <a class=\"external\" href=\"file://www.mhaus.org/\">",
"     www.mhaus.org",
"    </a>",
"    ). In 1987, the North American MH Registry (",
"    <a class=\"external\" href=\"file://www.mhaus.org/index.cfm/fuseaction/Content.Display/PagePK/NARegistry.cfm\">",
"     www.mhaus.org/index.cfm/fuseaction/Content.Display/PagePK/NARegistry.cfm",
"    </a>",
"    ) was established to collect and analyze information about clinical episodes of MH and the results of laboratory tests. These organizations merged in 1995.",
"   </p>",
"   <p>",
"    MHAUS maintains a free, 24-hour \"hot line\" for acute cases (1-800-MH HYPER) that is continuously staffed by anesthesiologists who are experts in managing cases of MH, answering questions about prospective management of MH-susceptible patients, and directing callers to appropriate resources. General information is available through the MHAUS office located at 39 East State St., Sherburne, NY 13460, 607-674-7901.",
"   </p>",
"   <p>",
"    MHAUS also sponsors and supports the Neuroleptic Malignant Syndrome Information Service (",
"    <a class=\"external\" href=\"file://www.nmsis.org/\">",
"     www.nmsis.org",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The European malignant hyperthermia group was established in 1983 and information on European protocols can be found on their website (",
"    <a class=\"external\" href=\"file://www.emhg.org/\">",
"     www.emhg.org",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Malignant hyperthermia (MH) is a genetic disorder of skeletal muscle metabolism that can manifest clinically as a hypermetabolic crisis in genetically susceptible individuals exposed to inhalational anesthetics or depolarizing muscle relaxants (ie,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33510?source=see_link\">",
"       succinylcholine",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Susceptibility to MH is inherited in an autosomal dominant fashion and is suspected in individuals with a clinical event strongly suspicious for MH, a family history of proven susceptibility or hypermetabolism with anesthesia, or conditions associated with MH. The mainstay of prevention is the identification of MH-susceptible individuals. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      MH-susceptible individuals have skeletal muscle receptor abnormalities allowing excessive intracellular calcium to accumulate in response to volatile anesthetic agents or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33510?source=see_link\">",
"       succinylcholine",
"      </a>",
"      which can trigger intracellular events leading to skeletal muscle hypermetabolism. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Genes responsible for coding proteins of the sarcolemmal membrane RYR1 and DHP receptors are responsible for approximately 30 to 50 percent of the mutations known to cause MH-susceptibility. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Genetic basis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Preexisting muscle diseases known to be linked to MH-susceptibility due to genetic abnormalities in RYR1 or DHP receptors include central core myopathy, multiminicore myopathy, Native American myopathy, King-Denborough syndrome, and other rare ryanodine-receptor related myopathies. There is some evidence that individuals with a history of exercise- or heat-induced rhabdomyolysis may also be at risk.",
"     </li>",
"     <li>",
"      Some conditions characterized by muscle atrophy are associated with an increased risk for life-threatening rhabdomyolysis or hyperkalemia following inhalational anesthetic administration. This clinical syndrome may resemble acute MH. These include the dystrophinopathies, myoadenylate deaminase deficiency, McArdle's disease, and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/16/21766?source=see_link\">",
"       carnitine",
"      </a>",
"      palmitoyl transferase type 2 (CPT2) deficiency.",
"     </li>",
"     <li>",
"      There are no practical MH-susceptibility screening tests for the general population. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'General population'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Susceptibility testing",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Two tests are available for MH-susceptibility evaluation: contracture testing and molecular genetic testing. These tests are indicated only under specific circumstances. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Indications for contracture testing'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22\">",
"       'Indications for genetic testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Contracture testing has few false negatives; a negative test effectively rules out MH-susceptibility. Contracture testing is the preferred initial test for individuals with an event suspicious for MH, and some pre-existing conditions. However, contracture testing is invasive and offered at only a limited number of centers. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Contracture tests'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Genetic testing is indicated in individuals with a positive or equivocal contracture test, positive family history for a gene mutation, and those who are unable or unwilling to undergo contracture testing. Genetic testing identifies approximately 30 to 50 percent of MH-susceptible individuals. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Genetic tests'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Withholding triggering agents",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Individuals at high risk for acute malignant hyperthermia crisis are not given triggering agents. Included are patients with confirmed susceptibility to malignant hyperthermia through either contracture or genetic testing, and patients with certain genetic disorders (ie, central core myopathy, multiminicore myopathy, King-Denborough syndrome and Native American myopathy). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'MH-susceptibility testing'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Myopathies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest withholding triggering agents from individuals with conditions characterized by muscle atrophy and associated with an increased risk for life-threatening rhabdomyolysis or hyperkalemia (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). These include: heat or exercise induced rhabdomyolysis, dystrophinopathies, myoadenylate deaminase deficiency, McArdle's disease, and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/16/21766?source=see_link\">",
"       carnitine",
"      </a>",
"      palmitoyl transferase type 2 deficiency. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Conditions associated with rhabdomyolysis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with a prior perioperative event strongly suspicious for MH but negative MH-susceptibility testing, or who have been unable to be tested, the decision to withhold triggering agents is individualized and based upon the MH clinical grading score (see",
"      <a class=\"local\" href=\"#H12\">",
"       'MH clinical grading'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/1\">",
"      Denborough M. Malignant hyperthermia. Lancet 1998; 352:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/2\">",
"      Simon HB. Hyperthermia. N Engl J Med 1993; 329:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/3\">",
"      Litman RS, Rosenberg H. Malignant hyperthermia-associated diseases: state of the art uncertainty. Anesth Analg 2009; 109:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/4\">",
"      Larach MG, Brandom BW, Allen GC, et al. Cardiac arrests and deaths associated with malignant hyperthermia in north america from 1987 to 2006: a report from the north american malignant hyperthermia registry of the malignant hyperthermia association of the United States. Anesthesiology 2008; 108:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/5\">",
"      Rosero EB, Adesanya AO, Timaran CH, Joshi GP. Trends and outcomes of malignant hyperthermia in the United States, 2000 to 2005. Anesthesiology 2009; 110:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/6\">",
"      Wappler F. Malignant hyperthermia. Eur J Anaesthesiol 2001; 18:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/7\">",
"      MacLennan DH, Phillips MS. Malignant hyperthermia. Science 1992; 256:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/8\">",
"      Lee-Chiong TL Jr, Stitt JT. Disorders of temperature regulation. Compr Ther 1995; 21:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/9\">",
"      O'Sullivan GH, McIntosh JM, Heffron JJ. Abnormal uptake and release of Ca2+ ions from human malignant hyperthermia-susceptible sarcoplasmic reticulum. Biochem Pharmacol 2001; 61:1479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/10\">",
"      Berchtold MW, Brinkmeier H, M&uuml;ntener M. Calcium ion in skeletal muscle: its crucial role for muscle function, plasticity, and disease. Physiol Rev 2000; 80:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/11\">",
"      Ohnishi ST, Taylor S, Gronert GA. Calcium-induced Ca2+ release from sarcoplasmic reticulum of pigs susceptible to malignant hyperthermia. The effects of halothane and dantrolene. FEBS Lett 1983; 161:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/12\">",
"      Struk A, Lehmann-Horn F, Melzer W. Voltage-dependent calcium release in human malignant hyperthermia muscle fibers. Biophys J 1998; 75:2402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/13\">",
"      Vilven J, Coronado R. Opening of dihydropyridine calcium channels in skeletal muscle membranes by inositol trisphosphate. Nature 1988; 336:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/14\">",
"      Wappler F, Scholz J, K&ouml;chling A, et al. Inositol 1,4,5-trisphosphate in blood and skeletal muscle in human malignant hyperthermia. Br J Anaesth 1997; 78:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/15\">",
"      Stewart SL, Hogan K, Rosenberg H, Fletcher JE. Identification of the Arg1086His mutation in the alpha subunit of the voltage-dependent calcium channel (CACNA1S) in a North American family with malignant hyperthermia. Clin Genet 2001; 59:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/16\">",
"      Quane KA, Healy JM, Keating KE, et al. Mutations in the ryanodine receptor gene in central core disease and malignant hyperthermia. Nat Genet 1993; 5:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/17\">",
"      Censier K, Urwyler A, Zorzato F, Treves S. Intracellular calcium homeostasis in human primary muscle cells from malignant hyperthermia-susceptible and normal individuals. Effect Of overexpression of recombinant wild-type and Arg163Cys mutated ryanodine receptors. J Clin Invest 1998; 101:1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/18\">",
"      Sambuughin N, Holley H, Muldoon S, et al. Screening of the entire ryanodine receptor type 1 coding region for sequence variants associated with malignant hyperthermia susceptibility in the north american population. Anesthesiology 2005; 102:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/19\">",
"      Gronert GA, Theye RA. Halothane-induced porcine malignant hyperthermia: metabolic and hemodynamic changes. Anesthesiology 1976; 44:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/20\">",
"      Mickelson JR, Louis CF. Malignant hyperthermia: excitation-contraction coupling, Ca2+ release channel, and cell Ca2+ regulation defects. Physiol Rev 1996; 76:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/21\">",
"      Louis CF, Zualkernan K, Roghair T, Mickelson JR. The effects of volatile anesthetics on calcium regulation by malignant hyperthermia-susceptible sarcoplasmic reticulum. Anesthesiology 1992; 77:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/22\">",
"      Dirksen RT, Avila G. Distinct effects on Ca2+ handling caused by malignant hyperthermia and central core disease mutations in RyR1. Biophys J 2004; 87:3193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/23\">",
"      Schuster F, M&uuml;ller R, Hartung E, et al. Inhibition of sarcoplasmic Ca2+-ATPase increases caffeine- and halothane-induced contractures in muscle bundles of malignant hyperthermia susceptible and healthy individuals. BMC Anesthesiol 2005; 5:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/24\">",
"      Paul-Pletzer K, Yamamoto T, Bhat MB, et al. Identification of a dantrolene-binding sequence on the skeletal muscle ryanodine receptor. J Biol Chem 2002; 277:34918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/25\">",
"      Harrison GG. Control of the malignant hyperpyrexic syndrome in MHS swine by dantrolene sodium. Br J Anaesth 1975; 47:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/26\">",
"      Kolb ME, Horne ML, Martz R. Dantrolene in human malignant hyperthermia. Anesthesiology 1982; 56:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/27\">",
"      Davis PJ, Brandom BW. The association of malignant hyperthermia and unusual disease: when you're hot you're hot or maybe not. Anesth Analg 2009; 109:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/28\">",
"      Carpenter D, Robinson RL, Quinnell RJ, et al. Genetic variation in RYR1 and malignant hyperthermia phenotypes. Br J Anaesth 2009; 103:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/29\">",
"      Robinson RL, Anetseder MJ, Brancadoro V, et al. Recent advances in the diagnosis of malignant hyperthermia susceptibility: how confident can we be of genetic testing? Eur J Hum Genet 2003; 11:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/30\">",
"      Eltit JM, Bannister RA, Moua O, et al. Malignant hyperthermia susceptibility arising from altered resting coupling between the skeletal muscle L-type Ca2+ channel and the type 1 ryanodine receptor. Proc Natl Acad Sci U S A 2012; 109:7923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/31\">",
"      MacLennan DH, Duff C, Zorzato F, et al. Ryanodine receptor gene is a candidate for predisposition to malignant hyperthermia. Nature 1990; 343:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/32\">",
"      McCarthy TV, Healy JM, Heffron JJ, et al. Localization of the malignant hyperthermia susceptibility locus to human chromosome 19q12-13.2. Nature 1990; 343:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/33\">",
"      Yang T, Ta TA, Pessah IN, Allen PD. Functional defects in six ryanodine receptor isoform-1 (RyR1) mutations associated with malignant hyperthermia and their impact on skeletal excitation-contraction coupling. J Biol Chem 2003; 278:25722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/34\">",
"      Broman M, Gehrig A, Islander G, et al. Mutation screening of the RYR1-cDNA from peripheral B-lymphocytes in 15 Swedish malignant hyperthermia index cases. Br J Anaesth 2009; 102:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/35\">",
"      Brandt A, Schleithoff L, Jurkat-Rott K, et al. Screening of the ryanodine receptor gene in 105 malignant hyperthermia families: novel mutations and concordance with the in vitro contracture test. Hum Mol Genet 1999; 8:2055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/36\">",
"      Girard T, Urwyler A, Censier K, et al. Genotype-phenotype comparison of the Swiss malignant hyperthermia population. Hum Mutat 2001; 18:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/37\">",
"      Monnier N, Procaccio V, Stieglitz P, Lunardi J. Malignant-hyperthermia susceptibility is associated with a mutation of the alpha 1-subunit of the human dihydropyridine-sensitive L-type voltage-dependent calcium-channel receptor in skeletal muscle. Am J Hum Genet 1997; 60:1316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/38\">",
"      Rueffert H, Olthoff D, Deutrich C, et al. Mutation screening in the ryanodine receptor 1 gene (RYR1) in patients susceptible to malignant hyperthermia who show definite IVCT results: identification of three novel mutations. Acta Anaesthesiol Scand 2002; 46:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/39\">",
"      Sei Y, Sambuughin NN, Davis EJ, et al. Malignant hyperthermia in North America: genetic screening of the three hot spots in the type I ryanodine receptor gene. Anesthesiology 2004; 101:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/40\">",
"      Bachand M, Vachon N, Boisvert M, et al. Clinical reassessment of malignant hyperthermia in Abitibi-T&eacute;miscamingue. Can J Anaesth 1997; 44:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/41\">",
"      Monnier N, Krivosic-Horber R, Payen JF, et al. Presence of two different genetic traits in malignant hyperthermia families: implication for genetic analysis, diagnosis, and incidence of malignant hyperthermia susceptibility. Anesthesiology 2002; 97:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/42\">",
"      Sewry CA, M&uuml;ller C, Davis M, et al. The spectrum of pathology in central core disease. Neuromuscul Disord 2002; 12:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/43\">",
"      Bush A, Dubowitz V. Fatal rhabdomyolysis complicating general anaesthesia in a child with Becker muscular dystrophy. Neuromuscul Disord 1991; 1:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/44\">",
"      Tang TT, Oechler HW, Siker D, et al. Anesthesia-induced rhabdomyolysis in infants with unsuspected Duchenne dystrophy. Acta Paediatr 1992; 81:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/45\">",
"      Obata R, Yasumi Y, Suzuki A, et al. Rhabdomyolysis in association with Duchenne's muscular dystrophy. Can J Anaesth 1999; 46:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/46\">",
"      Kerr TP, Duward A, Hodgson SV, et al. Hyperkalaemic cardiac arrest in a manifesting carrier of Duchenne muscular dystrophy following general anaesthesia. Eur J Pediatr 2001; 160:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/47\">",
"      Girshin M, Mukherjee J, Clowney R, et al. The postoperative cardiovascular arrest of a 5-year-old male: an initial presentation of Duchenne's muscular dystrophy. Paediatr Anaesth 2006; 16:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/48\">",
"      Fricker RM, Raffelsberger T, Rauch-Shorny S, et al. Positive malignant hyperthermia susceptibility in vitro test in a patient with mitochondrial myopathy and myoadenylate deaminase deficiency. Anesthesiology 2002; 97:1635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/49\">",
"      Isaacs H, Badenhorst ME, Du Sautoy C. Myophosphorylase B deficiency and malignant hyperthermia. Muscle Nerve 1989; 12:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/50\">",
"      Lobato EB, Janelle GM, Urdaneta F, Malias MA. Noncardiogenic pulmonary edema and rhabdomyolsis after protamine administration in a patient with unrecognized McArdle's disease. Anesthesiology 1999; 91:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/51\">",
"      Mitchell LW, Leighton BL. Warmed diluent speeds dantrolene reconstitution. Can J Anaesth 2003; 50:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/52\">",
"      Klingler W, Rueffert H, Lehmann-Horn F, et al. Core myopathies and risk of malignant hyperthermia. Anesth Analg 2009; 109:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/53\">",
"      Zhang Y, Chen HS, Khanna VK, et al. A mutation in the human ryanodine receptor gene associated with central core disease. Nat Genet 1993; 5:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/54\">",
"      Guis S, Figarella-Branger D, Monnier N, et al. Multiminicore disease in a family susceptible to malignant hyperthermia: histology, in vitro contracture tests, and genetic characterization. Arch Neurol 2004; 61:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/55\">",
"      D'Arcy CE, Bjorksten A, Yiu EM, et al. King-denborough syndrome caused by a novel mutation in the ryanodine receptor gene. Neurology 2008; 71:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/56\">",
"      Stamm DS, Aylsworth AS, Stajich JM, et al. Native American myopathy: congenital myopathy with cleft palate, skeletal anomalies, and susceptibility to malignant hyperthermia. Am J Med Genet A 2008; 146A:1832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/57\">",
"      K&ouml;chling A, Wappler F, Winkler G, Schulte am Esch JS. Rhabdomyolysis following severe physical exercise in a patient with predisposition to malignant hyperthermia. Anaesth Intensive Care 1998; 26:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/58\">",
"      Tobin JR, Jason DR, Challa VR, et al. Malignant hyperthermia and apparent heat stroke. JAMA 2001; 286:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/59\">",
"      Denborough M, Hopkinson KC, O'Brien RO, Foster PS. Overheating alone can trigger malignant hyperthermia in piglets. Anaesth Intensive Care 1996; 24:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/60\">",
"      Chelu MG, Goonasekera SA, Durham WJ, et al. Heat- and anesthesia-induced malignant hyperthermia in an RyR1 knock-in mouse. FASEB J 2006; 20:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/61\">",
"      Wappler F, Fiege M, Steinfath M, et al. Evidence for susceptibility to malignant hyperthermia in patients with exercise-induced rhabdomyolysis. Anesthesiology 2001; 94:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/62\">",
"      Kleopa KA, Rosenberg H, Heiman-Patterson T. Malignant hyperthermia-like episode in Becker muscular dystrophy. Anesthesiology 2000; 93:1535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/63\">",
"      Hoffman EP, Brown RH Jr, Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 1987; 51:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/64\">",
"      Gronert GA. Cardiac arrest after succinylcholine: mortality greater with rhabdomyolysis than receptor upregulation. Anesthesiology 2001; 94:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/65\">",
"      Larach MG, Rosenberg H, Gronert GA, Allen GC. Hyperkalemic cardiac arrest during anesthesia in infants and children with occult myopathies. Clin Pediatr (Phila) 1997; 36:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/66\">",
"      Goresky GV, Cox RG. Inhalation anesthetics and Duchenne's muscular dystrophy. Can J Anaesth 1999; 46:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/67\">",
"      Rubiano R, Chang JL, Carroll J, et al. Acute rhabdomyolysis following halothane anesthesia without succinylcholine. Anesthesiology 1987; 67:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/68\">",
"      Boba A. Fatal postanesthetic complications in two muscular dystrophic patients. J Pediatr Surg 1970; 5:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/69\">",
"      Marchildon MB. Malignant hyperthermia. Current concepts. Arch Surg 1982; 117:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/70\">",
"      McKishnie JD, Muir JM, Girvan DP. Anaesthesia induced rhabdomyolysis--a case report. Can Anaesth Soc J 1983; 30:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/71\">",
"      Kelfer HM, Singer WD, Reynolds RN. Malignant hyperthermia in a child with Duchenne muscular dystrophy. Pediatrics 1983; 71:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/72\">",
"      Bollig G, Mohr S, Raeder J. McArdle's disease and anaesthesia: case reports. Review of potential problems and association with malignant hyperthermia. Acta Anaesthesiol Scand 2005; 49:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/73\">",
"      Katsuya H, Misumi M, Ohtani Y, Miike T. Postanesthetic acute renal failure due to carnitine palmityl transferase deficiency. Anesthesiology 1988; 68:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/74\">",
"      Schaer H, Steinmann B, Jerusalem S, Maier C. Rhabdomyolysis induced by anaesthesia with intraoperative cardiac arrest. Br J Anaesth 1977; 49:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/75\">",
"      Ellis FR, Harriman DG, Keaney NP, et al. Halothane-induced muscle contracture as a cause of hyperpyrexia. Br J Anaesth 1971; 43:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/76\">",
"      Capacchione JF, Muldoon SM. The relationship between exertional heat illness, exertional rhabdomyolysis, and malignant hyperthermia. Anesth Analg 2009; 109:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/77\">",
"      Gurnaney H, Brown A, Litman RS. Malignant hyperthermia and muscular dystrophies. Anesth Analg 2009; 109:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/78\">",
"      Benca J, Hogan K. Malignant hyperthermia, coexisting disorders, and enzymopathies: risks and management options. Anesth Analg 2009; 109:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/79\">",
"      Hogan KJ, Vladutiu GD. Malignant hyperthermia-like syndrome and carnitine palmitoyltransferase II deficiency with heterozygous R503C mutation. Anesth Analg 2009; 109:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/80\">",
"      Ryan CA, Al-Ghamdi AS, Gayle M, Finer NN. Osteogenesis imperfecta and hyperthermia. Anesth Analg 1989; 68:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/81\">",
"      Kill C, Leonhardt A, Wulf H. Lacticacidosis after short-term infusion of propofol for anaesthesia in a child with osteogenesis imperfecta. Paediatr Anaesth 2003; 13:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/82\">",
"      Rampton AJ, Kelly DA, Shanahan EC, Ingram GS. Occurrence of malignant hyperpyrexia in a patient with osteogenesis imperfecta. Br J Anaesth 1984; 56:1443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/83\">",
"      Porsborg P, Astrup G, Bendixen D, et al. Osteogenesis imperfecta and malignant hyperthermia. Is there a relationship? Anaesthesia 1996; 51:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/84\">",
"      Martin S, Tobias JD. Perioperative care of the child with arthrogryposis. Paediatr Anaesth 2006; 16:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/85\">",
"      Baines DB, Douglas ID, Overton JH. Anaesthesia for patients with arthrogryposis multiplex congenita: what is the risk of malignant hyperthermia? Anaesth Intensive Care 1986; 14:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/86\">",
"      Hopkins PM, Ellis FR, Halsall PJ. Hypermetabolism in arthrogryposis multiplex congenita. Anaesthesia 1991; 46:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/87\">",
"      Smego RA Jr, Durack DT. The neuroleptic malignant syndrome. Arch Intern Med 1982; 142:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/88\">",
"      Caroff SN, Rosenberg H, Fletcher JE, et al. Malignant hyperthermia susceptibility in neuroleptic malignant syndrome. Anesthesiology 1987; 67:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/89\">",
"      Ward A, Chaffman MO, Sorkin EM. Dantrolene. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in malignant hyperthermia, the neuroleptic malignant syndrome and an update of its use in muscle spasticity. Drugs 1986; 32:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/90\">",
"      Bello N, Adnet P, Saulnier F, et al. [Lack of sensitivity to per-anesthetic malignant hyperthermia in 32 patients who developed neuroleptic malignant syndrome]. Ann Fr Anesth Reanim 1994; 13:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/91\">",
"      Parness J, Bandschapp O, Girard T. The myotonias and susceptibility to malignant hyperthermia. Anesth Analg 2009; 109:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/92\">",
"      Larach MG, Localio AR, Allen GC, et al. A clinical grading scale to predict malignant hyperthermia susceptibility. Anesthesiology 1994; 80:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/93\">",
"      Rosenberg H, Antognini JF, Muldoon S. Testing for malignant hyperthermia. Anesthesiology 2002; 96:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/94\">",
"      Hopkins PM, Hartung E, Wappler F. Multicentre evaluation of ryanodine contracture testing in malignant hyperthermia. The European Malignant Hyperthermia Group. Br J Anaesth 1998; 80:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/95\">",
"      Ording H, Glahn K, Gardi T, et al. 4-Chloro-m-cresol test--a possible supplementary test for diagnosis of malignant hyperthermia susceptibility. Acta Anaesthesiol Scand 1997; 41:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/96\">",
"      Serfas KD, Bose D, Patel L, et al. Comparison of the segregation of the RYR1 C1840T mutation with segregation of the caffeine/halothane contracture test results for malignant hyperthermia susceptibility in a large Manitoba Mennonite family. Anesthesiology 1996; 84:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/97\">",
"      Deufel T, Sudbrak R, Feist Y, et al. Discordance, in a malignant hyperthermia pedigree, between in vitro contracture-test phenotypes and haplotypes for the MHS1 region on chromosome 19q12-13.2, comprising the C1840T transition in the RYR1 gene. Am J Hum Genet 1995; 56:1334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/98\">",
"      A protocol for the investigation of malignant hyperpyrexia (MH) susceptibility. The European Malignant Hyperpyrexia Group. Br J Anaesth 1984; 56:1267.",
"     </a>",
"    </li>",
"    <li>",
"     www.emhg.org/en/emhg/mh-diagnosis/.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/100\">",
"      Fortunato G, Carsana A, Tinto N, et al. A case of discordance between genotype and phenotype in a malignant hyperthermia family. Eur J Hum Genet 1999; 7:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/101\">",
"      Birgenheier N, Stoker R, Westenskow D, Orr J. Activated charcoal effectively removes inhaled anesthetics from modern anesthesia machines. Anesth Analg 2011; 112:1363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36921/abstract/102\">",
"      Gunter JB, Ball J, Than-Win S. Preparation of the Dr&auml;ger Fabius anesthesia machine for the malignant-hyperthermia susceptible patient. Anesth Analg 2008; 107:1936.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 403 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-486B9E35E6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_3_36921=[""].join("\n");
var outline_f36_3_36921=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Normal muscle physiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Malignant hyperthermia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      GENETIC BASIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Classification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PREVALENCE OF SUSCEPTIBILITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CONDITIONS ASSOCIATED WITH MH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Myopathies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Conditions associated with rhabdomyolysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Other conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      MH CLINICAL GRADING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SCREENING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      General population",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Family members",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Conditions associated with MH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      MH-SUSCEPTIBILITY TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Contracture tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Indications for contracture testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Protocols",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Genetic tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Indications for genetic testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      PATIENT AND FAMILY COUNSELING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      ANESTHESIA IN MH-SUSCEPTIBLE PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2126295\">",
"      Preventive measures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Safe anesthetic agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Ambulatory surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      MH RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/403\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/403|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?23/34/24106\" title=\"figure 1\">",
"      Pathophysiology of acute malignant hyperthermia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/403|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?28/54/29539\" title=\"picture 1\">",
"      Anesthesia machine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?43/9/44179\" title=\"picture 2\">",
"      Anesthesia machine charcoal filter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/403|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?37/49/38687\" title=\"table 1\">",
"      Conditions associated with malignant hyperthermia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?32/15/33020\" title=\"table 2\">",
"      Clinical indicators of acute malignant hyperthermia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/403|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?11/50/12079\" title=\"waveform 1\">",
"      Caffeine-halothane contracture test waveforms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?14/19/14642?source=related_link\" title=\"calculator 1\">",
"      Calculator: Clinical indicators for malignant hyperthermia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/55/32632?source=related_link\">",
"      Clinical manifestations and diagnosis of rhabdomyolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/13/32984?source=related_link\">",
"      Malignant hyperthermia: Clinical diagnosis and management of acute crisis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31288?source=related_link\">",
"      Neuromuscular blocking agents (NMBA) for rapid sequence intubation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/22/19817?source=related_link\">",
"      Overview of anesthesia and anesthetic choices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/37/5719?source=related_link\">",
"      Overview of peripheral nerve blocks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/40/16007?source=related_link\">",
"      Severe hyperthermia (heat stroke) in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_3_36922="Prognosis and treatment of primary myelofibrosis";
var content_f36_3_36922=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prognosis and treatment of primary myelofibrosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/3/36922/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/3/36922/contributors\">",
"     Ayalew Tefferi, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/3/36922/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/3/36922/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/3/36922/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/3/36922/contributors\">",
"     Stephen A Landaw, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/3/36922/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1167105\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary myelofibrosis (PMF), known in the past as agnogenic myeloid metaplasia or chronic idiopathic myelofibrosis, is one of the myeloproliferative neoplasms (",
"    <a class=\"graphic graphic_figure graphicRef56283 \" href=\"mobipreview.htm?24/16/24835\">",
"     figure 1",
"    </a>",
"    ). In addition to PMF, the group includes essential thrombocythemia (ET), and polycythemia vera (PV), both of which may undergo delayed disease transformation into a fibrotic state called post-ET myelofibrosis (post-ET MF) or post-PV MF, respectively. The conversion rates after 10 to 20 years of disease are less than 5 percent for ET and approximately 10 to 20 percent for PV. PMF, post-ET MF, and post-PV MF are all referred to as myelofibrosis (MF).",
"   </p>",
"   <p>",
"    The prognosis and treatment of PMF will be reviewed here [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. An overview of the myeloproliferative neoplasms, as well as discussions of pathogenetic mechanisms, clinical manifestations, and diagnosis of PMF, are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/52/21322?source=see_link\">",
"     \"Overview of the myeloproliferative neoplasms\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/63/1018?source=see_link\">",
"     \"Clinical manifestations and diagnosis of primary myelofibrosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/30/25064?source=see_link\">",
"     \"Pathogenetic mechanisms in primary myelofibrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with PMF present with anemia, marked splenomegaly, early satiety, and hypercatabolic symptoms including severe fatigue, low grade fever, night sweats, and weight loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/5\">",
"     5",
"    </a>",
"    ]. During their clinical course, most patients experience massive hepatosplenomegaly along with progressive anemia requiring frequent red blood cell transfusions. Portal hypertension might accompany marked splenomegaly and could contribute to variceal bleeding or ascites. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/63/1018?source=see_link\">",
"     \"Clinical manifestations and diagnosis of primary myelofibrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hepatosplenomegaly in PMF results from extramedullary hematopoiesis (EMH), which might also involve other organ sites, including around the spinal column, causing cord compression, or in the pleural and peritoneal cavity, causing pleural effusion or ascites, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In an epidemiologic study of patients within Olmsted county, the three-year survival rate was 52 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/6\">",
"     6",
"    </a>",
"    ]. Longer survival times have been reported in several non-population-based studies, including the series used for constructing the International Prognostic Scoring System (IPSS) for PMF, in which the median survival was reported to be 69 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of prognostic models are available for assessing prognosis in PMF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/7-15\">",
"     7-15",
"    </a>",
"    ]. The most recent and internationally-recognized is the IPSS for PMF, described below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     International Working Group Scoring System",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of prognostic scoring systems have been developed for PMF.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7384931\">",
"    <span class=\"h3\">",
"     IPSS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The International Working Group for Myelofibrosis Research and Treatment has devised a prognostic scoring system (IPSS) from an evaluation of presenting signs and symptoms in 1054 consecutively-studied patients diagnosed with PMF at seven different centers. The following five adverse prognostic features were noted on multivariate analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Presence of constitutional symptoms (ie, weight loss &gt;10 percent, night sweats, or fever)",
"     </li>",
"     <li>",
"      Age &gt;65 years",
"     </li>",
"     <li>",
"      Hemoglobin &lt;10",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"     </li>",
"     <li>",
"      Leukocyte count",
"      <span class=\"nowrap\">",
"       &gt;25,000/microL",
"      </span>",
"     </li>",
"     <li>",
"      Circulating blast cells &ge;1 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Subjects with zero (low risk), one (intermediate risk-1), two (intermediate risk-2), or &ge;3 (high risk) of these variables at presentation had non-overlapping median survivals of 135, 95, 48, and 27 months, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7384938\">",
"    <span class=\"h3\">",
"     Dynamic IPSS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The IPSS has been modified to take into account the adverse effect of the acquisition of these risk factors over time, as well as age (ie, the Dynamic IPSS (DIPSS) and the age-adjusted IPSS) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/16\">",
"     16",
"    </a>",
"    ]. The DIPSS is calculated as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age &gt;65 years: 1 point",
"     </li>",
"     <li>",
"      Leukocyte count",
"      <span class=\"nowrap\">",
"       &gt;25,000/microL:",
"      </span>",
"      1 point",
"     </li>",
"     <li>",
"      Hemoglobin &lt;10",
"      <span class=\"nowrap\">",
"       g/dL:",
"      </span>",
"      2 points",
"     </li>",
"     <li>",
"      Circulating blast cells &ge;1 percent: 1 point",
"     </li>",
"     <li>",
"      Presence of constitutional symptoms: 1 point",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Subjects with zero, one to two, three to four, or 5 to 6 points were considered low, intermediate-1, intermediate-2, or high risk, respectively.",
"   </p>",
"   <p>",
"    In a separate analysis, the DIPSS predicted the progression of subjects with PMF to acute myeloid leukemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/17\">",
"     17",
"    </a>",
"    ]. The incidence of blast phase development was 0.3, 0.7, 2.6, and 8.6 per 100 patient-years for those in the low-risk, intermediate-1, intermediate-2, and high risk categories, respectively. Worsening of the DIPSS during follow-up also appeared to predict for a significantly higher risk for blast phase development.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7384945\">",
"    <span class=\"h3\">",
"     DIPSS Plus",
"    </span>",
"    &nbsp;&mdash;&nbsp;IPSS-independent prognostic factors for survival in PMF have been identified, such as unfavorable karyotype (complex karyotype or sole or two abnormalities that include +8,",
"    <span class=\"nowrap\">",
"     -7/7q-,",
"    </span>",
"    i(17q),",
"    <span class=\"nowrap\">",
"     -5/5q-,",
"    </span>",
"    12p-, inv(3), or 11q23 rearrangements) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/18-22\">",
"     18-22",
"    </a>",
"    ], red cell transfusion need [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/23\">",
"     23",
"    </a>",
"    ], and thrombocytopenia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/24\">",
"     24",
"    </a>",
"    ]. These three additional risk factors were added to the DIPSS score to develop DIPSS-Plus, with scoring as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/25\">",
"     25",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      DIPSS Low risk score: 0 points",
"     </li>",
"     <li>",
"      DIPSS Intermediate risk-1 score: 1 point",
"     </li>",
"     <li>",
"      DIPSS Intermediate risk-2 score: 2 points",
"     </li>",
"     <li>",
"      DIPSS High risk score: 3 points",
"     </li>",
"     <li>",
"      Unfavorable karyotype: 1 point",
"     </li>",
"     <li>",
"      Platelet count",
"      <span class=\"nowrap\">",
"       &lt;100,000/microL:",
"      </span>",
"      1 point",
"     </li>",
"     <li>",
"      Transfusion need: 1 point",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When the DIPSS Plus scoring system was applied to a group of 793 consecutive patients with PMF seen at the Mayo Clinic, those with zero points (low risk), one point (intermediate risk-1), two to three points (intermediate risk-2), or four to six points (high risk), had median survivals of 15.4, 6.5, 2.9, and 1.3 years, respectively. When this scoring system was applied to 299 young (ie, age &lt;60 years) patients with PMF seen at Mayo Clinic, median survivals (from the time of referral) were 20, 14.3, 5.3, and 1.7 years, respectively, confirming the better prognosis of younger patients with PMF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A &ldquo;very high&rdquo; risk category, with a median survival of nine months and a two-year mortality rate of 83 percent was obtained from a study of 884 patients with PMF seen at the Mayo Clinic between 1977 and 2011. This group had either monosomal karyotype or",
"    <span class=\"nowrap\">",
"     inv(3)/i(17q)",
"    </span>",
"    abnormalities, or any two of the following: circulating blasts &gt;9 percent, leukocyte count",
"    <span class=\"nowrap\">",
"     &ge;40,000/microL,",
"    </span>",
"    or other unfavorable karyotype (ie, complex karyotype or any sole or two abnormalities including +8,",
"    <span class=\"nowrap\">",
"     -7/7q-,",
"    </span>",
"    <span class=\"nowrap\">",
"     -5/5q-,",
"    </span>",
"    inv(3), i(17q), 12p-, 11q23 rearrangement). The difference in survival between the &ldquo;very high&rdquo; and &ldquo;high&rdquo; risk groups was explained, in part, by a difference in the risk of leukemic transformation (two-year incidences of 31 and 7 percent, respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19313047\">",
"    <span class=\"h4\">",
"     Predicting leukemic transformation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two of the three additional risk factors (ie, unfavorable karyotype, platelet count",
"    <span class=\"nowrap\">",
"     &lt;100,000/microL)",
"    </span>",
"    were used to construct a prognostic model to predict for leukemic transformation. Those with none of these two risk factors or those with one or more of these risk factors had 10-year risks of leukemic transformation of 12 and 31 percent, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12714880\">",
"    <span class=\"h3\">",
"     Elevated cytokine levels",
"    </span>",
"    &nbsp;&mdash;&nbsp;Significantly increased levels of a number of cytokines were found in a comprehensive study of 127 patients with PMF. A risk model based on levels of two of these cytokines (IL-8 and IL-2R) delineated prognostically different groups within the DIPSS plus intermediate risk-1 and intermediate risk-2 categories [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     JAK2 mutational burden",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two studies have shown that a low burden of the JAK2V617F allele in PMF might indicate the presence of an overriding V617F-negative clone that confers a more aggressive disease phenotype with shortened overall survival, although the biologic mechanisms underlying this correlation remain to be established [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Response criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;The International Working Group for Myelofibrosis Research and Treatment (IWG-MRT), the group that was responsible for the above-mentioned IPSS for PMF, has also devised treatment response criteria based on spleen size, hemoglobin level, leukocyte count, platelet count, peripheral blood smear, and bone marrow histology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Candidates for hematopoietic cell transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognostic variables in the above studies were determined in all patients, most of whom were over the age of 55 and not candidates for allogeneic hematopoietic cell transplantation (allo-HCT). This issue was addressed in a report of 123 patients with PMF under the age of 55, who might be candidates for allo-HCT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/9\">",
"     9",
"    </a>",
"    ]. This subgroup, representing approximately 25 percent of all patients with PMF, had a median survival of 11 years, three years longer than the low-risk group noted above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/8\">",
"     8",
"    </a>",
"    ]. Three factors predicted poor survival in these younger patients:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hemoglobin &lt;10",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"     </li>",
"     <li>",
"      Constitutional symptoms present (eg, fever, sweats, weight loss)",
"     </li>",
"     <li>",
"      Circulating blasts &gt;1 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Median survival was 15 versus 3 years for those with no or one adverse factor versus two or more adverse factors, respectively.",
"   </p>",
"   <p>",
"    The prognostic usefulness of the DIPSS was evaluated in 170 patients (median age 51.5 years, range: 12 to 78) with PMF who received HCT between 1990 and 2009. The following observations were made [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/32\">",
"     32",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Five-year incidences of relapse, relapse-free survival, overall survival, and nonrelapse mortality for the entire group were 10, 57, 57, and 34 percent, respectively.",
"     </li>",
"     <li>",
"      Compared with the 12 percent who had low-risk disease, the hazard ratio for post-HCT mortality in the 30 percent who had high-risk disease was 4.11 (95% CI 1.44-11.8).",
"     </li>",
"     <li>",
"      After a median follow-up of 5.9 years, median survivals had not been reached for the low and intermediate-1 groups, and were 7 and 2.5 years for the intermediate-2 and high risk groups, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is scant information concerning the management and prognosis of pregnant women with PMF. Fetal mortality is high, although some pregnancies have been brought to term [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/33-35\">",
"     33-35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SPECIFIC TREATMENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;At present, allogeneic hematopoietic cell transplantation (allo-HCT) constitutes the only treatment modality with a curative potential in PMF. Other treatment modalities are, at best, palliative and are discussed below [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. The potential for improvement in both medical and transplant therapy suggests that the decision concerning if and when to employ HCT will continue to be a complex issue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Allogeneic HCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allo-HCT has traditionally been limited to patients less than 60 years of age and to those who have an HLA-identical sibling donor, although there has been increasing use of both matched unrelated and mismatched related donors. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/38/26218?source=see_link\">",
"     \"Donor selection for hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to limited availability of donors, other problems associated with allo-HCT include a high transplant-related mortality due to complications such as acute and chronic graft-versus-host disease (GVHD). On the other hand, responses to donor lymphocyte infusions in patients relapsing after allo-HCT suggest the presence of a graft-versus-myelofibrosis effect in this disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/37,39-41\">",
"     37,39-41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/22/25960?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/25/23962?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and grading of chronic graft-versus-host disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most reports of allo-HCT in PMF have included relatively small numbers of patients with a median age of approximately 40 to 50 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/42-49\">",
"     42-49",
"    </a>",
"    ]. This represents a small subset of patients, since only 17 percent of those with PMF present before the age of 50 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/50\">",
"     50",
"    </a>",
"    ]. The largest study to date was a retrospective report using registry data on HCT results in 147 patients with myelofibrosis (median age 53 years, range: 20 to 68); 59 percent were transplanted from a matched sibling donor and conditioning was myeloablative in 31 percent. Results included the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/51\">",
"     51",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fifty-four percent of the subjects receiving reduced intensity conditioning were of intermediate-2 or high risk according to the IPSS score, and 24 percent had previously transformed into acute myeloid leukemia. Of those receiving myeloablative conditioning, the corresponding percentages were 39 and 15 percent, respectively. There was no significant difference in either overall survival or non-relapse mortality between the two conditioning regimens.",
"     </li>",
"     <li>",
"      Ninety percent of the subjects engrafted. Factors favorably affecting engraftment included splenectomy prior to HCT, HLA-matched sibling donor, peripheral stem cell use for HCT, and absence of pre-transplant thrombocytopenia.",
"     </li>",
"     <li>",
"      Four-year overall survival, progression-free survival, and non-relapse mortality were 39, 32, and 39 percent, respectively. On multivariate analysis, HLA-identical sibling donor, chronic phase disease, and splenectomy in men had a favorable impact on overall survival.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another study included 55 patients with PMF (median age 42 years) who underwent allo-HCT, 90 percent of whom engrafted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/48\">",
"     48",
"    </a>",
"    ]. Overall survival at five years was 47 percent; 22 patients (40 percent) achieved a complete histohematologic remission (ie, complete hematologic remission plus disappearance of marrow fibrosis). Five-year survivals of 83, 43, and 31 percent were seen in the low, intermediate, and high risk groups, as defined above (see",
"    <a class=\"local\" href=\"#H3\">",
"     'Prognosis'",
"    </a>",
"    above) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/8\">",
"     8",
"    </a>",
"    ]. Predictors of survival at five years were hemoglobin &gt;10",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    and the absence of osteomyelosclerosis; predictors of failure were abnormal pretransplant karyotype, absence of grade II to IV acute GVHD, and age &gt;45 at transplant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although one of the above studies noted an estimated five-year overall survival post-transplant of 14 percent for patients &ge;45 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/48,52\">",
"     48,52",
"    </a>",
"    ], a preliminary report from Seattle indicated three- and five-year disease-free survival rates of 63 and 50 percent, respectively, for patients in that age range [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It has been concluded that young patients with two or more adverse features (ie, hemoglobin &lt;10",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    constitutional symptoms, isolated cytogenetic abnormality, or blasts &gt;1 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/9,48\">",
"     9,48",
"    </a>",
"    ] should be considered for HCT shortly after diagnosis. For low-risk patients, who might live 10 to 15 years with supportive treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/9\">",
"     9",
"    </a>",
"    ], but might have a transplant-related mortality of at least 8 percent, the answer is not yet clear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/54\">",
"     54",
"    </a>",
"    ]. Until further information is available, a suggested strategy is to offer transplantation to the latter group when an adverse risk factor appears, at a time when their median survival time is expected to be less than 5 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/2,37,55\">",
"     2,37,55",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Prognosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Initial studies raised a concern that engraftment would be delayed in the severely fibrotic marrow. However, the above observations suggest that engraftment is not a problem in most patients with MF. This is in keeping with a study that compared the outcome after HCT in 33 patients with severe myelofibrosis to 33 matched controls without myelofibrosis; there was no significant difference between the two groups in engraftment parameters [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/56\">",
"     56",
"    </a>",
"    ]. While preliminary information from two different centers has indicated no significant advantage or disadvantage of splenectomy on posttransplantation outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/57,58\">",
"     57,58",
"    </a>",
"    ], the study noted above indicated that prior splenectomy in men had a favorable impact on overall survival (adjusted HR 0.29; 95% CI 0.17-0.48) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Nonmyeloablative allogeneic HCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of studies have reported on the successful use of allogeneic HCT following reduced-intensity conditioning in patients with PMF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/37,39,51,59-67\">",
"     37,39,51,59-67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In two series (median age 55 to years; range: 32 to 73), treatment-related mortality was 16 to 22 percent at one year, with estimated five-year event-free and overall survivals of 46 to 51 and 62 to 67 percent, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/63,65\">",
"       63,65",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Carefully selected (criteria not specified) older patients with primary or secondary myelofibrosis have also done relatively well following HCT. This was shown in a retrospective analysis of 30 patients with a median age of 65 years (range: 60 to 78), most of whom received low intensity conditioning [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/68\">",
"       68",
"      </a>",
"      ]. Day 100 mortality for this group was 13 percent, with estimated three-year overall and progression-free survivals of 45 and 40 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a study of 46 patients with PMF and a median age of 51 years, adverse factors for survival included: &gt;20 red cell transfusions, a spleen size &gt;22 cm, and use of an alternative donor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/64\">",
"     64",
"    </a>",
"    ]. Subjects with zero or one (low-risk) or two or more (high-risk) adverse factors had five-year survivals of 77 and 8 percent, respectively. Other adverse prognostic features for those undergoing reduced intensity conditioning have included JAK2 wild-type status, age &ge;57 years, and the presence of constitutional symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nonmyeloablative HCT has led to full donor chimerism, along with loss of the JAK2 mutation when present, attesting to achievement of complete molecular remission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. This was most convincingly shown in a study of allogeneic HCT following reduced-intensity conditioning in a total of 162 patients, in which the JAK2 V617F mutation status was known in 139. Results included [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/65\">",
"     65",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      On multivariate analysis, five-year overall survival was significantly longer in patients harboring a JAK2 mutation compared with those having wild-type JAK2 (70 versus 44 percent). No significant influence on outcome was noted for mutated JAK2 allele burden.",
"     </li>",
"     <li>",
"      Achievement of JAK2 V617F negativity in the peripheral blood at six months following HCT was significantly associated with a decreased incidence of relapse (5 versus 35 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Guidance for patients who fail nonmyeloablative HCT is limited. In one study, 26 patients with myelofibrosis who either relapsed or had graft rejection after dose-reduced allogeneic HCT were treated with a median of three donor lymphocyte infusions (DLI); 10 achieved complete remission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/41\">",
"     41",
"    </a>",
"    ]. Thirteen of the 16 nonresponders to DLI and four who had not received DLI underwent a second transplant, with overall responses in 12. After a median follow-up of 27 months, two-year overall and progression-free survivals for all 30 patients were 70 and 67 percent, respectively, suggesting that this two-step strategy is an effective and well-tolerated salvage approach for such patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Androgens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who are not candidates for allo-HCT are treated palliatively. The combination of an androgen preparation (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/34/41508?source=see_link\">",
"     fluoxymesterone",
"    </a>",
"    , Halotestin, 10 mg PO twice per day) and a corticosteroid (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    30",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    PO) improves anemia in some patients. After one month of therapy, treatment with fluoxymesterone is continued in responders and the corticosteroid is tapered.",
"   </p>",
"   <p>",
"    All patients treated with androgens should have periodic monitoring of liver function tests and men should be screened for prostate cancer (digital rectal examination and measurement of serum prostate specific antigen) before initiating therapy. The virilizing side effects of this treatment program should be emphasized in advance to female patients.",
"   </p>",
"   <p>",
"    In our experience, approximately one-third of the patients respond to androgens, although rates varying from 29 to 57 percent have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/71,72\">",
"     71,72",
"    </a>",
"    ]. In one series of 23 patients, the response rate was 92 percent in those with normal chromosomes compared with 22 percent in those with chromosomal abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/72\">",
"     72",
"    </a>",
"    ]. Nonresponders were more likely to have severely compromised hematopoiesis, as evidenced by the presence of thrombocytopenia, erythroid suppression on ferrokinetic studies, and lack of activity on bone marrow scans.",
"   </p>",
"   <p>",
"    In a controlled study of 24 patients with myeloproliferative neoplasms (more than one-half of whom had myelofibrosis), a good response to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/34/41508?source=see_link\">",
"     fluoxymesterone",
"    </a>",
"    , 30",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    was seen in 4 of 14 (29 percent) compared with no good responses in the control arm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/71\">",
"     71",
"    </a>",
"    ]. As in the above-noted study, non-responders were more likely than responders to have reduced effective erythropoiesis.",
"   </p>",
"   <p>",
"    Other modalities have been tried with variable success:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Erythropoietin or darbepoetin have generally not been successful in alleviating the anemia associated with PMF [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/73-75\">",
"       73-75",
"      </a>",
"      ], although others have reported responses, most often in patients not requiring transfusional support",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      those with inappropriately low serum erythropoietin levels [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/76-78\">",
"       76-78",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Some patients respond to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/0/26629?source=see_link\">",
"       danazol",
"      </a>",
"      (200 to 800",
"      <span class=\"nowrap\">",
"       mg/day),",
"      </span>",
"      both in our experience and that of others [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/79,80\">",
"       79,80",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Approximately 25 to 50 percent of anemic patients experience a reduction in transfusion requirement after splenectomy (see",
"      <a class=\"local\" href=\"#H15\">",
"       'Splenectomy'",
"      </a>",
"      below) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/81-83\">",
"       81-83",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemotherapy in PMF is used to diminish the degree of hepatosplenomegaly with attendant improvement in ascites, pain",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cytopenias, to relieve constitutional symptoms such as fever and weight loss, or reduce symptomatic thrombocytosis. In the Mayo Clinic series of patients with PMF receiving chemotherapy, a significant reduction in splenic size with relief of pressure symptoms occurred in 70 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/84\">",
"     84",
"    </a>",
"    ]. Responses lasted a median of 4.5 months and only 16 percent of patients obtained sustained symptomatic relief. Toxicity was common and often necessitated cessation of treatment.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/10/10408?source=see_link\">",
"     Busulfan",
"    </a>",
"    (Busulfex, Myleran; starting dose 2 to 4",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    PO) and other alkylating agents have been used in the past [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/84\">",
"     84",
"    </a>",
"    ]. However, patients with PMF are unusually sensitive to these agents, which may result in prolonged and severe cytopenias even after therapy has been discontinued.",
"   </p>",
"   <p>",
"    An Italian study employed the alkylating agent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    (Alkeran) in reduced doses (initial dose 2.5 mg PO three",
"    <span class=\"nowrap\">",
"     times/week",
"    </span>",
"    increasing to a maximum dose of 2.5",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    in 104 patients with PMF and splenomegaly, transfusion-dependent anemia, leucocytosis,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    thrombocytosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/85\">",
"     85",
"    </a>",
"    ]. All eligible patients were pretreated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/0/26629?source=see_link\">",
"     danazol",
"    </a>",
"    (200",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (0.25",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) for at least two months. Responses were noted in 66 of 99 evaluable patients at a median time of 6.7 months. Splenic size, leukocytosis, and thrombocytosis were normalized in 23, 86, and 93 percent, respectively. Anemia improved in 12 of 20 severely anemic patients not requiring transfusion; of the 16 patients requiring transfusion, 6 became transfusion independent. Hematologic toxicity was common, but was reversible in all patients by discontinuing or reducing the treatment. However, the potential leukemogenicity of this agent has tempered our enthusiasm for its use in this disorder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Hydroxyurea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of its demonstrated utility in the other chronic myeloproliferative disorders (eg, chronic myeloid leukemia, PV, and ET),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    has become the agent of choice for the treatment of PMF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/86\">",
"     86",
"    </a>",
"    ]. Hydroxyurea may result in a reduction in spleen size, control of thrombocytosis and leukocytosis,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    control of constitutional symptoms (eg, bone pain, fever, pruritus) in some patients with PMF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/86-90\">",
"     86-90",
"    </a>",
"    ]. In one series of 59 patients with a chronic myeloproliferative disease (10 with PMF) and thrombocytosis, chronic therapy with hydroxyurea reduced the platelet count to less than",
"    <span class=\"nowrap\">",
"     500,000/microL",
"    </span>",
"    in 6 of the 10 with PMF (and over 80 percent of those with PV or ET) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/86\">",
"     86",
"    </a>",
"    ]. In another report by the same authors, hydroxyurea also reduced the degree of bone marrow fibrosis in these patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the suggested starting dose for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    in PV and ET is 15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day PO (average adult daily dose of 500 mg twice per day PO), the initial dose in advanced PMF should be much lower, given the presence of cytopenias in many patients. A starting oral dose of 500 to 1000 mg every other day, with dose modifications depending upon results of frequent blood counts and the patient's clinical status, would seem to be the most prudent approach under these circumstances.",
"   </p>",
"   <p>",
"    The effectiveness of HU appears to be related to presence of the JAK2 V617F mutation. In our series of 69 patients with PMF, response to treatment with HU was 48 versus 8 percent in those with or without this mutation, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Splenectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Splenomegaly, often massive and occupying a large portion of the abdomen, is present in virtually all patients with PMF. Surgical removal of such spleens is considered for patients who have symptomatic splenomegaly as manifested by mechanical discomfort, recurrent episodes of splenic infarction, transfusion-dependent anemia, refractory thrombocytopenia, hypercatabolic symptoms, or portal hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/2,81-83,92\">",
"     2,81-83,92",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/63/1018?source=see_link&amp;anchor=H5#H5\">",
"     \"Clinical manifestations and diagnosis of primary myelofibrosis\", section on 'Splenomegaly'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Preoperative laboratory evidence of low-grade disseminated intravascular coagulation (positive soluble fibrin monomer and plasma D-dimer &gt;500",
"    <span class=\"nowrap\">",
"     mcg/L)",
"    </span>",
"    may increase the risk of perioperative bleeding, and it is recommended that the operation be postponed until these abnormalities are corrected. At experienced centers, the mortality rate from the procedure should be less than 10 percent, provided that the operation is conducted by an experienced senior surgeon, who pays meticulous attention to achieving hemostasis.",
"   </p>",
"   <p>",
"    Given the complications that may be associated with removing a massively enlarged spleen (see below), an initial report described success with subtotal splenectomy in three patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/93\">",
"     93",
"    </a>",
"    ]. More experience is required before this approach can be recommended.",
"   </p>",
"   <p>",
"    Two large reported series analyzed the indications for and efficacy of splenectomy in PMF in 321 published cases and 314 patients at a single institution, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/81,82\">",
"     81,82",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The main indications for the procedure were transfusion-dependent anemia (25 percent) and symptomatic splenomegaly (49 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/82\">",
"       82",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The frequency of improvement in one series was 97 percent for painful splenomegaly, 83 percent for portal hypertension, 70 percent for anemia, and 56 percent for thrombocytopenia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/81\">",
"       81",
"      </a>",
"      ]. However, long-term improvements were less common in the second series, with respective values of 49, 40, 50, and 30 percent, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/82\">",
"       82",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The operative mortality after splenectomy was 7.5 to 9 percent, rising to 26 percent after three months; operative morbidity was 31 to 46 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/81\">",
"       81",
"      </a>",
"      ]. Patients at greatest risk for perioperative death were those with spleen weight exceeding 2000 g or a platelet count less than",
"      <span class=\"nowrap\">",
"       70,000/microL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/81\">",
"       81",
"      </a>",
"      ]. In the second series, operative mortality was in the range of 5.5 to 7.6 percent, with a perioperative morbidity of 25 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/82\">",
"       82",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Postsplenectomy thrombocytosis of &gt;450,000 and",
"      <span class=\"nowrap\">",
"       &gt;1,000,000/microL",
"      </span>",
"      occurred in 29 and 5 percent of patients, respectively, and was significantly associated with postoperative thrombosis and decreased survival [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/82\">",
"       82",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There was no evidence for an effect of splenectomy on survival, the median values for which were 13 and 19 months after surgery in the 2 series [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/81,82\">",
"       81,82",
"      </a>",
"      ]. The main causes of death not related to surgery were infection, cardiac or thrombotic events, bleeding, and leukemic transformation (which occurred in 11 to 16 percent of patients).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Splenectomy is not a trivial procedure in PMF and is associated with both immediate postoperative and longer term complications. Postsurgical complications include intraabdominal bleeding, subphrenic abscess, sepsis, extreme thrombocytosis that may be associated with thrombosis (eg, stroke, pulmonary embolus, portal vein thrombosis), and accelerated hepatomegaly in 16 to 24 percent due to worsening hepatic myeloid metaplasia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    loss of splenic sequestration of immature myeloid precursors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/82,83\">",
"     82,83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The thrombocytosis and hepatomegaly may be transiently controlled with plateletpheresis,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    (starting dose 500 mg PO three times per day) or the purine analog",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/22/19815?source=see_link\">",
"     cladribine",
"    </a>",
"    (a two-hour intravenous administration of 0.14",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for five days) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/94,95\">",
"     94,95",
"    </a>",
"    ]. Once postoperative hemostasis has been achieved, short-term anticoagulation (eg, one month of therapeutic anticoagulation with low molecular weight",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    ) may be reasonable in order to minimize the risk of splanchnic vein thrombosis.",
"   </p>",
"   <p>",
"    As noted above, splenectomy is often performed in an attempt to reduce extremely high transfusion requirements associated with splenic sequestration. The question has been raised concerning the potential effect of splenectomy in removing an important site of (extramedullary) erythropoiesis, thereby worsening transfusion requirements. The following information may be helpful in making this decision:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Massively enlarged spleens, even with significant degrees of erythropoiesis, also exhibit significant degrees of splenic sequestration and ineffective erythropoiesis.",
"     </li>",
"     <li>",
"      The transfusion requirement for an adult with no effective erythropoiesis (as in severe aplastic anemia or pure red cell aplasia) is usually two to three units of packed red cells every two weeks. Thus, a chronic transfusion requirement in a nonbleeding patient with PMF greater than three units of red cells every two weeks indicates that the spleen is not an \"effective\" source of red cell production.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another concern that has been raised is the potential facilitation of leukemic transformation following splenectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/96\">",
"     96",
"    </a>",
"    ]. The concern of these investigators was based on a retrospective series of splenectomized patients compared to a \"control\" group of patients who had not undergone splenectomy. In our experience, it is impossible to case-match patients who are in need of splenectomy. However, splenic histopathology may help in determining the course of the disease post-splenectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/97\">",
"     97",
"    </a>",
"    ]. Thus, the presence of microscopic splenic infarcts, a pattern of immature granulocyte predominance, or the detection of an abnormal splenic karyotype were found to be significantly associated with decreased survival post-splenectomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Radiation therapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Splenic irradiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Splenic irradiation (SI) usually provides only a transient (three to six months) benefit and can be appropriate for patients who are poor surgical candidates, or those with accelerated phase disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/98\">",
"     98",
"    </a>",
"    ]. In our series of 23 patients with PMF, 8 of whom received multiple courses of SI, 94 percent of courses resulted in an objective reduction in splenic size and symptomatic relief; the median duration of response was six months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/99\">",
"     99",
"    </a>",
"    ]. The median dose of SI per course was 2.8 Gy, administered in a median of 7.5 fractions. Significant cytopenia occurred in 32 percent of courses, and life-threatening pancytopenia after a single course of SI occurred in six patients (26 percent), resulting in fatal sepsis or hemorrhage in three. Nine patients underwent subsequent splenectomy with a perioperative mortality of 11 percent; three of these required re-exploration for postoperative bleeding.",
"   </p>",
"   <p>",
"    We and other centers have also used total SI doses as low as 0.10 Gy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/98\">",
"     98",
"    </a>",
"    ] and as high as 65 Gy, with generally excellent results, especially if SI is started in small fractions of 0.25 to 0.50 Gy given two to four times per week, with modifications as dictated by the clinical situation and frequently obtained blood counts. The range of regimens can be illustrated by the following reports:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective study of 14 patients with PMF treated with SI for symptoms due to splenomegaly, doses ranged from 7 to 24 Gy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/100\">",
"       100",
"      </a>",
"      ]. Relief of symptoms was achieved in all patients, with 30 to 70 percent reduction in splenic size. Side effects were mild and did not require interruption of treatment, although four patients developed severe anemia.",
"     </li>",
"     <li>",
"      In another series, 17 patients with CML or PMF were treated with SI to a total dose of 0.15 to 16 Gy, with fractions given only two to three times per week [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/89\">",
"       89",
"      </a>",
"      ]. Fourteen of 19 courses given for splenic pain produced a significant subjective relief, while 17 of 26 courses given for splenomegaly obtained at least 50 percent reduction in splenic size.",
"     </li>",
"     <li>",
"      In a third report, radiation therapy to the entire spleen was delivered by two parallel opposed fields using 0.5 Gy daily fractions given five days per week for a total dose of 6 to 10 Gy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/101\">",
"       101",
"      </a>",
"      ]. For the 21 patients with MPNs, reduction in splenic size, pain control, improvement of hemoglobin level, and improvement in platelet count were noted in 79, 87, 84, and 68 percent of patients, respectively. The mean duration of response was 19 months (range: 4 to 42 months). Grade III to IV toxicity rates for leukopenia, thrombocytopenia, and anemia were 14, 25, and 10 percent, respectively. None of the toxicity events was fatal, included febrile neutropenia, or required hospitalization.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Of interest, similar degrees of splenic shrinkage have been described following use of JAK-2 inhibitors. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'JAK2 inhibitors'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Other sites of disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation therapy is extremely successful in the management of symptomatic foci of extramedullary hematopoiesis (EMH), including the spinal cord, peritoneal and pleural cavities, focal areas of bone pain due to myeloid sarcoma (also called granulocytic sarcoma or chloroma) or periostitis, and whole-lung treatment for pulmonary hypertension. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/58/20393?source=see_link&amp;anchor=H11#H11\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia\", section on 'Myeloid sarcoma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Specific treatment programs that have been successfully employed include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/102-106\">",
"     102-106",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In five patients with severe extremity bone pain unresponsive to narcotic medication, radiation was given as one fraction of 100 to 600 cGy. Most patients achieved complete response within days to weeks, with response lasting from one month to two years. Retreatment was performed in four and achieved a durable response in three. No acute or late side effects of radiation were experienced.",
"     </li>",
"     <li>",
"      In four patients with paraspinal or intraspinal EMH, the median dose of radiation was 1 Gy (range: 1 to 10 Gy), delivered in one to five fractions.",
"     </li>",
"     <li>",
"      Two patients with pulmonary",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      pleural EMH requiring treatment received 1.0 to 1.5 Gy delivered in one to 10 fractions. A single whole lung dose of 1.0 Gy may be reasonable in patients with symptomatic myelofibrosis-associated pulmonary hypertension [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/102\">",
"       102",
"      </a>",
"      ]. Administration of fractional doses of radiation (0.25",
"      <span class=\"nowrap\">",
"       Gy/day,",
"      </span>",
"      with rotation into all four abdominal quadrants, to a total dose of 5 to 10 Gy) is extremely effective in the treatment of ascites due to peritoneal implants of EMH [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/104\">",
"       104",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Low-dose radiation to the liver (median dose per course: 1.50 Gy; range: 0.50 to 10 Gy) has been given for symptomatic hepatomegaly in 14 patients with advanced PMF [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/105\">",
"       105",
"      </a>",
"      ]. Such treatment has been found to be myelosuppressive, providing only temporary (median three months), and mainly subjective, relief.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Anagrelide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/19/6454?source=see_link\">",
"     Anagrelide",
"    </a>",
"    is an oral agent that has a specific platelet-lowering effect in humans, and is capable of controlling thrombocytosis associated with PV and ET [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/107\">",
"     107",
"    </a>",
"    ]. In one study, 17 patients with PMF (including patients with post-polycythemia and post-thrombocythemia myelofibrosis) were treated with anagrelide (starting and median maintenance doses of 1",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    PO) for a median period of two years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/108\">",
"     108",
"    </a>",
"    ]. Platelet counts were decreased in 13, unchanged in one, and increased in three patients. No clinical benefit was obtained in any patient in terms of anemia, transfusion requirement, or reduction in hepatosplenomegaly. Bone marrow megakaryocyte numbers were increased after six months of treatment; no patient had a significant change in either bone marrow fibrosis or osteosclerosis. Information on the toxicity of this agent in PV and ET can be found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/28/32202?source=see_link&amp;anchor=H13#H13\">",
"     \"Prognosis and treatment of essential thrombocythemia\", section on 'Anagrelide'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Interferon alfa",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interferon alfa (IFNa) induces both hematologic and cytogenetic remissions in chronic-phase CML, and has shown utility in ET and PV. IFNa has multiple effects on reducing proliferation of fibroblasts and bone marrow progenitor cells in vitro, suggesting that it might be useful in patients with PMF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/109-115\">",
"     109-115",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The efficacy of IFNa was evaluated in a series 54 patients with myeloproliferative neoplasms (PV, ET, PMF) who were treated with initial subcutaneous doses of IFNa of five million",
"    <span class=\"nowrap\">",
"     IU/day;",
"    </span>",
"    the following benefits were noted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/109\">",
"     109",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Control of thrombocythemia was seen in 24 of 24 patients with this problem",
"     </li>",
"     <li>",
"      Control of hyperleukocytosis was seen in 14 of 14 patients",
"     </li>",
"     <li>",
"      At least a 10 percent reduction in splenic size was seen in 26 of 39 patients with splenomegaly.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, our own experience with IFNa, as well as that of others, has not been as favorable, with rates of overall response and treatment discontinuation averaging 3 and 51 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/110,111\">",
"     110,111",
"    </a>",
"    ]. In a phase II trial involving 11 patients with previously untreated \"hyperproliferative\" PMF, weekly doses of up to 15 million units of IFNa were given for as long as one year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/112\">",
"     112",
"    </a>",
"    ]. Unacceptable drug toxicity was present in seven of the 11 patients, necessitating discontinuation. No beneficial changes in splenic size, reticulin fibrosis, osteosclerosis, or microvessel density were seen in any patient.",
"   </p>",
"   <p>",
"    Results may be better with pegylated interferon alpha-2a, but experience with this agent is limited [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/113,114\">",
"     113,114",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Thalidomide and lenalidomide",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14572188\">",
"    <span class=\"h3\">",
"     Single agent thalidomide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     Thalidomide",
"    </a>",
"    has been evaluated mainly in previously-treated patients with PMF. Beneficial responses, which have been seen in 20 to 40 percent of patients, have included disappearance of constitutional symptoms, reduction in splenic size, improvements in hemoglobin concentration, white blood cell, and platelet counts, as well as transfusion independence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/116-120\">",
"     116-120",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In these studies, few patients were able to tolerate doses higher than 400",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    because of side effects, which included drowsiness, constipation, fatigue, paresthesias, and neutropenia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/121\">",
"     121",
"    </a>",
"    ]. In one study of 63 patients, the median maximally-tolerated dose was 100",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    and the cumulative drop-out rate due to adverse drug side effects was 51 percent after six months of therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/119\">",
"     119",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In our study, the median duration of treatment was only 16 weeks; preliminary results have suggested that low starting doses (ie, 50",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    with more gradual dose escalation may be as effective and more tolerable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/118,122,123\">",
"     118,122,123",
"    </a>",
"    ]. Adverse hematologic effects were seen in 4 of 15 patients (eg, extreme thrombocytosis and leukocytosis and pericardial extramedullary hematopoiesis with clinical tamponade).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Thalidomide plus prednisone",
"    </span>",
"    &nbsp;&mdash;&nbsp;In order to improve tolerability of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    , we prospectively treated symptomatic PMF patients with low-dose thalidomide (50",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    PO) plus a three-month oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    taper (starting prednisone dose 0.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    PO per day) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/122,124\">",
"     122,124",
"    </a>",
"    ]. Twenty of the 21 patients were able to complete the three-month course, with an objective clinical response in 13. Responses included improvement of anemia in 13 patients, red cell transfusion independence in 4, platelet count increases in 6, and &gt;50 percent decreases in splenic size in 4. This dose of thalidomide was better tolerated than those used in previous studies (see",
"    <a class=\"local\" href=\"#H22\">",
"     'Thalidomide and lenalidomide'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    Leukocytosis and thrombocytosis were observed in 38 and 19 percent of patients, respectively; one episode of deep vein thrombosis was noted, a complication which has been seen with this agent when used in other malignant disorders. Adverse events associated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    were mild and transient. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/57/29594?source=see_link\">",
"     \"Thrombotic complications following treatment of multiple myeloma with thalidomide and its analogues\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    At a median follow-up of 25 months for the 36 patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    in our two series, the overall long-term response rate was 28 percent (10 patients) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/118,122,124\">",
"     118,122,124",
"    </a>",
"    ]. Durable treatment responses were seen for anemia and thrombocytopenia, but not for splenomegaly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Lenalidomide with or without prednisone",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of cooperative phase II studies are evaluating the utility of the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    analog",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    with or without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    in patients with PMF.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one report employing single agent",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"       lenalidomide",
"      </a>",
"      (initial dose 10",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      or 5",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      if baseline platelet count",
"      <span class=\"nowrap\">",
"       &lt;100,000/microL)",
"      </span>",
"      in 68 patients, overall response rates were 22, 33, and 50 percent for anemia, splenomegaly, and thrombocytopenia, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/125\">",
"       125",
"      </a>",
"      ]. Grades 3 or 4 adverse events included neutropenia and thrombocytopenia in 31 and 19 percent of patients, respectively.",
"     </li>",
"     <li>",
"      In a second report,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"       lenalidomide",
"      </a>",
"      (same dosing as above on days 1 through 21 of a 28-day cycle for 6 cycles) plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (30",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      during cycle 1, 15",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      during cycle 2, and 15",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      every other day during cycle 3) were given to 40 patients with PMF [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/126\">",
"       126",
"      </a>",
"      ]. Overall response rates were 30 and 42 percent for anemia and splenomegaly, respectively, with a median time to response of 12 weeks. Reductions in reticulin fibrosis and JAK2 mutant allele burden were also seen. Grades 3 or 4 adverse events included neutropenia, anemia, and thrombocytopenia in 58, 42, and 13 percent of patients, respectively.",
"     </li>",
"     <li>",
"      A multicenter ECOG phase II trial of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"       lenalidomide",
"      </a>",
"      (10",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (initial dose 30",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      in 42 subjects with PMF obtained an overall response rate of 23 percent, with clinical improvement of anemia in 19 percent",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      decreased splenic size in 10 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/127\">",
"       127",
"      </a>",
"      ]. Serial bone marrow analysis showed no resolution of disease-related fibrosis. Myelosuppression was the main toxicity, with 88 percent of the subjects having grade 3 or 4 hematologic toxicity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3270847\">",
"    <span class=\"h4\">",
"     Patients with myelofibrosis and 5q-",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three of our patients with biopsy-proven myelofibrosis (two post-PV and one PMF) and del(5) on cytogenetic analysis were treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    (10",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    resulting in complete hematologic remission in all three [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/128\">",
"     128",
"    </a>",
"    ]. As a result of this success, we encourage screening for del(5)(q) in all patients with PMF or post-PV MF. If found, lenalidomide therapy should be offered and continued indefinitely, if tolerated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/30/31210?source=see_link&amp;anchor=H2443602#H2443602\">",
"     \"Treatment of intermediate, low, or very low risk myelodysplastic syndromes\", section on 'Patients with 5q deletion'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Pomalidomide",
"    </span>",
"    &nbsp;&mdash;&nbsp;The related investigational immunomodulatory agent,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/33/33303?source=see_link\">",
"     pomalidomide",
"    </a>",
"    , with or without an abbreviated course of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , had activity in the treatment of patients with myelofibrosis-associated anemia in a phase II trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/129\">",
"     129",
"    </a>",
"    ], but has limited activity in reducing splenic size [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/130\">",
"     130",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a Mayo Clinic study of 94 patients with myelofibrosis who participated in two consecutive clinical trials of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/33/33303?source=see_link\">",
"     pomalidomide",
"    </a>",
"    (0.5 to 3.5 mg per day), anemia response was 53 percent in those who were JAK2 V617F positive with &lt;10 cm palpable splenomegaly and &lt;5 percent circulating blasts, while it was zero in those who were JAK2 mutation negative with either &ge;10 cm splenomegaly or &ge;5 percent circulating blasts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/131\">",
"     131",
"    </a>",
"    ]. Grade I sensory neuropathy developed in four of 30 patients treated for one year or more.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Etanercept",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    (Enbrel, 25 mg SQ twice weekly), a soluble tumor necrosis factor receptor, resulted in improvement of constitutional symptoms (eg, weight loss, night sweats, fatigue, fever) in 12 of 20 evaluable patients with PMF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/132\">",
"     132",
"    </a>",
"    ]. Objective responses (eg, anemia, thrombocytopenia, spleen size) were noted in four patients. Reversible pancytopenia was noted in one patient, necessitating cessation of this agent. Toxicity was otherwise mild and well tolerated.",
"   </p>",
"   <p>",
"    In a small phase II trial, the combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    alleviated symptoms and was well tolerated, but did not appear to be superior to",
"    <span class=\"nowrap\">",
"     thalidomide/prednisone",
"    </span>",
"    in terms of therapeutic value for anemia, thrombocytopenia, or splenomegaly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/133\">",
"     133",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Imatinib mesylate",
"    </span>",
"    &nbsp;&mdash;&nbsp;We have conducted a phase II trial with the tyrosine kinase inhibitor",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    mesylate in 23 patients with PMF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/134\">",
"     134",
"    </a>",
"    ]. Toxicity was appreciable, with no discernible clinical benefit. In a second study, 13 of 18 patients treated with this agent showed only minor degrees of clinical or hematologic improvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/135\">",
"     135",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     JAK2 inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Significant reductions in splenic size and relief of symptoms (eg, pruritus, fatigue) have been reported for a number of JAK2 inhibitors in patients with myelofibrosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/136-141\">",
"     136-141",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/52/21322?source=see_link&amp;anchor=H13#H13\">",
"     \"Overview of the myeloproliferative neoplasms\", section on 'JAK2 mutations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14969007\">",
"    <span class=\"h3\">",
"     Ruxolitinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most of the clinical information on the use of JAK2 inhibitors in PMF concerns the selective",
"    <span class=\"nowrap\">",
"     JAK1/JAK2",
"    </span>",
"    inhibitor INCB018424 (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/35/29239?source=see_link\">",
"     ruxolitinib",
"    </a>",
"    , Jakafi). While ruxolitinib has shown clinical usefulness in reducing splenomegaly and symptoms in PMF, we believe that it is best reserved for patients with debilitating constitutional symptoms or severely symptomatic splenomegaly, for the reasons to be described below.",
"   </p>",
"   <p>",
"    The major results of a phase",
"    <span class=\"nowrap\">",
"     I/II",
"    </span>",
"    trial in 153 patients with JAK2 V617F-positive or &ndash;negative primary myelofibrosis or post-polycythemia",
"    <span class=\"nowrap\">",
"     vera/essential",
"    </span>",
"    thrombocythemia myelofibrosis included the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/142\">",
"     142",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An oral 15 mg twice daily starting dose, followed by individualized dose titration, appeared to be the most effective and safest dosing regimen.",
"     </li>",
"     <li>",
"      Patients with debilitating symptoms (eg, weight loss, fatigue, night sweats, pruritus) had rapid improvement.",
"     </li>",
"     <li>",
"      Clinical benefits were associated with a marked diminution of levels of circulating inflammatory cytokines (eg, MIP-1beta, TNF-alpha, IL-6).",
"     </li>",
"     <li>",
"      Response to therapy was independent of JAK2 V617F mutational status, and was attributed to suppression of phosphorylated STAT3, a marker of JAK signaling.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Results of two phase III trials (COMFORT-I [",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/35/29239?source=see_link\">",
"     ruxolitinib",
"    </a>",
"    versus placebo] and COMFORT-II [ruxolitinib versus best available therapy]) included a &ge;35 percent reduction in splenic volume in 28 to 42 percent of patients taking ruxolitinib, compared with 1 and 5 percent in those treated with placebo or best available therapy, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/143,144\">",
"     143,144",
"    </a>",
"    ]. Two-thirds of the patients with this degree of splenic volume reduction maintained this response for &ge;48 weeks with continued therapy.",
"   </p>",
"   <p>",
"    A greater than 50 percent reduction in total symptom score was seen in 46 versus 5 percent of those treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/35/29239?source=see_link\">",
"     ruxolitinib",
"    </a>",
"    or placebo, respectively. Anemia and thrombocytopenia were common, with grade 3 to 4 toxicity in 45 and 13 percent, respectively, in those treated with ruxolitinib.",
"   </p>",
"   <p>",
"    Neither of the two COMFORT trials was able to show a short-term improvement in overall survival for patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/35/29239?source=see_link\">",
"     ruxolitinib",
"    </a>",
"    . This was also confirmed by our own retrospective study of 51 ruxolitinib-treated patients, which was adjusted for their DIPSS Plus risk status, cytogenetic risk status, and time of diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/145\">",
"     145",
"    </a>",
"    ]. However, uncontrolled observations have suggested a survival advantage:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Evaluation after four additional months of follow-up (median of 51 weeks) in the COMFORT-I trial revealed a significant survival advantage for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/35/29239?source=see_link\">",
"       ruxolitinib",
"      </a>",
"      over placebo (8.4 versus 15.6 percent deaths; HR 0.50; 95% CI 0.25-0.98).",
"     </li>",
"     <li>",
"      In a phase",
"      <span class=\"nowrap\">",
"       I/II",
"      </span>",
"      trial of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/35/29239?source=see_link\">",
"       ruxolitinib",
"      </a>",
"      in 107 patients with intermediate-2 or high-risk myelofibrosis, survival of treated patients, adjusted for their baseline IPSS risk status but not for cytogenetic risk, was significantly better than that of historical, rather than contemporaneous, controls (HR 0.58; 95% CI 0.39-0.85) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/146\">",
"       146",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based on the two COMFORT trials,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/35/29239?source=see_link\">",
"     ruxolitinib",
"    </a>",
"    was approved for the treatment of intermediate and high risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis. The recommended oral starting dose is 20 mg twice daily for patients with a platelet count",
"    <span class=\"nowrap\">",
"     &gt;200,000/microL",
"    </span>",
"    and 15 mg twice daily for those with a platelet count between 100,000 and",
"    <span class=\"nowrap\">",
"     200,000/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/147\">",
"     147",
"    </a>",
"    ]. Full prescribing information is available from the FDA (",
"    <a class=\"external\" href=\"file://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202192lbl.pdf\">",
"     FDA ruxolitinib prescribing information",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/35/29239?source=see_link\">",
"     Ruxolitinib",
"    </a>",
"    was very effective in alleviating constitutional symptoms (eg, abdominal discomfort, left upper quadrant pain, early satiety, night sweats, pruritus, bone or muscle pain) and in reducing splenic size in a high percentage of patients with myelofibrosis, although it does not reverse bone marrow fibrosis, or result in cytogenetic or molecular remission.",
"   </p>",
"   <p>",
"    Drug discontinuation rates during the various reported treatment trials have ranged from 24 to 51 percent during the first year of treatment and were as high as 46 to 89 percent at three years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/145,146\">",
"     145,146",
"    </a>",
"    ]. A wide variation in starting doses in these trials (10 mg twice daily to 200 mg once daily) may have been responsible, in part, for these discontinuation rates (eg, drug ineffectiveness at the lower doses, excess toxicity at the higher doses).",
"   </p>",
"   <p>",
"    As with all JAK2 inhibitors studied to date, drug discontinuation can be associated with full relapse of disease symptoms, with clinical findings (eg, fever, hypotension, hypoxia) suggestive of the systemic inflammatory response syndrome, and often requiring treatment with pressors, systemic glucocorticoids, and the restarting of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/35/29239?source=see_link\">",
"     ruxolitinib",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/145,148\">",
"     145,148",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We believe that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/35/29239?source=see_link\">",
"     ruxolitinib",
"    </a>",
"    should not be used in PMF patients with low or intermediate-1 risk disease and is best reserved for patients with debilitating constitutional symptoms or severely symptomatic splenomegaly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/149,150\">",
"     149,150",
"    </a>",
"    ]. Patients should be counseled about the ruxolitinib withdrawal syndrome and other side effects (eg, anemia and thrombocytopenia) before being started on therapy. If required, drug discontinuation should follow a tapering dose schedule, as is often used for glucocorticoid therapy, under close clinician supervision.",
"   </p>",
"   <p>",
"    Experience with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/35/29239?source=see_link\">",
"     ruxolitinib",
"    </a>",
"    in the related disorders polycythemia vera and essential thrombocythemia is limited [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/151\">",
"     151",
"    </a>",
"    ]; its therapeutic role in these conditions is unclear and its routine use cannot be recommended at this time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/150\">",
"     150",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14152059\">",
"    <span class=\"h2\">",
"     Everolimus",
"    </span>",
"    &nbsp;&mdash;&nbsp;A phase",
"    <span class=\"nowrap\">",
"     I/II",
"    </span>",
"    study evaluated the safety and efficacy of the mTOR kinase inhibitor",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    in the treatment of 39 patients with high- or intermediate-risk PMF or",
"    <span class=\"nowrap\">",
"     post-PV/post-ET",
"    </span>",
"    myelofibrosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/152\">",
"     152",
"    </a>",
"    ]. Responses in 30 evaluable patients included reduction of splenomegaly by &gt;30 percent in 44 percent, complete resolution of systemic symptoms in 69 percent, and resolution of pruritus in 80 percent. Additional information on the use of this agent in patients with myelofibrosis is awaited.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1557239\">",
"    <span class=\"h2\">",
"     Histone deacetylase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Phase I and II trials have shown modest to moderate clinical activity of several different histone deacetylase inhibitors (panobinostat, givinostat, pracinostat) in patients with myelofibrosis, in terms of reduction in splenomegaly, improvement in anemia, and reduction in bone marrow fibrosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/153-155\">",
"     153-155",
"    </a>",
"    ]. Additional trials of these experimental agents appear warranted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Bortezomib",
"    </span>",
"    &nbsp;&mdash;&nbsp;In one phase I trial and one phase II trial in a total of 21 patients (18 primary myelofibrosis and three post-polycythemia",
"    <span class=\"nowrap\">",
"     vera/essential",
"    </span>",
"    thrombocythemia myelofibrosis), there were no complete, major, or moderate responses to treatment with the proteasome inhibitor",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/3/36922/abstract/156,157\">",
"     156,157",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Prognosis and treatment overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis and need for treatment of agnogenic myeloid metaplasia (PMF) or the fibrotic states following polycythemia vera or essential thrombocythemia (postpolycythemic myeloid metaplasia and post-thrombocythemic myeloid metaplasia, respectively) are strongly dependent upon the presence or absence of signs and symptoms of the disease (eg, anemia, painfully enlarged spleen, systemic symptoms, refractory cytopenias, thrombocytosis, portal hypertension, cord compression secondary to foci of extramedullary hematopoiesis). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/63/1018?source=see_link\">",
"     \"Clinical manifestations and diagnosis of primary myelofibrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the absence of adverse prognostic factors such as anemia and constitutional symptoms, there may be very little need for treatment, with an expected survival in excess of 10 years (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Prognosis'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Survival and quality of life can be severely limited in this disorder, with an expected survival as short as one year for the most symptomatic patients (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Prognosis'",
"      </a>",
"      above). While allogeneic hematopoietic cell transplantation (HCT) is the only curative treatment for this disorder, it is associated with a high treatment-related mortality, and may not be available for older patients with severe comorbidities and those without a suitable donor.",
"     </li>",
"     <li>",
"      Other than HCT, all of the other available treatment modalities are palliative, with variable degrees of efficacy and treatment-related complications. There are few randomized trials comparing these modalities, preventing our ability to give strong recommendations for selecting one treatment over another.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Hematopoietic cell transplantation",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For younger patients (ie, age &lt;45 years) at intermediate-2 or high risk according to the DIPSS Plus scoring system, we suggest that the patient be considered for hematopoietic cell transplantation (HCT) shortly after diagnosis (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). We prefer conventional intensity conditioning for those &lt;45 years of age and reduced-intensity conditioning for those 45 to 65 years of age. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Allogeneic HCT'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For DIPSS Plus low-risk patients, who might live 10 to 15 years with supportive treatment alone, but might have a transplant-related mortality of at least 8 percent, the answer is not yet clear. Until further information is available, we suggest against the use of HCT for this group of patients (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Supportive modalities",
"    </span>",
"   </p>",
"   <p>",
"    In the absence of allogeneic HCT as a therapeutic option, we suggest the use of one or more of the following palliative modalities for the symptomatic patient (",
"    <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"     Grade 2C",
"    </a>",
"    ). For each of the agents listed below, the symptom(s) for which is agent is most effective is noted in parentheses.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Androgens,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/0/26629?source=see_link\">",
"       danazol",
"      </a>",
"      (anemia)",
"     </li>",
"     <li>",
"      Blood transfusions with or without erythropoietin (anemia)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"       Hydroxyurea",
"      </a>",
"      (splenomegaly, thrombocytosis, leukocytosis, bone pain, constitutional symptoms, pruritus)",
"     </li>",
"     <li>",
"      Alkylating agents (splenomegaly, thrombocytosis, leukocytosis)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"       Thalidomide",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (systemic symptoms, anemia, splenomegaly, refractory cytopenias)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"       Lenalidomide",
"      </a>",
"      (symptomatic patient with 5q-)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"       Etanercept",
"      </a>",
"      (systemic symptoms)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/35/29239?source=see_link\">",
"       Ruxolitinib",
"      </a>",
"      (debilitating constitutional symptoms or severely symptomatic splenomegaly)",
"     </li>",
"     <li>",
"      Splenic irradiation (painful splenomegaly)",
"     </li>",
"     <li>",
"      Radiation therapy (symptomatic areas of extramedullary hematopoiesis, cord compression)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Investigational drug therapy is always an option for these patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Splenectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Splenectomy can be considered in selected patients with a painfully enlarged spleen, anemia and other refractory cytopenias,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    severe degrees of portal hypertension. This procedure carries a very high operative mortality and morbidity, and should not be undertaken lightly (see",
"    <a class=\"local\" href=\"#H15\">",
"     'Splenectomy'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h3\">",
"     Acute leukemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transformation to acute leukemia, its prognosis, and treatment are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/63/1018?source=see_link&amp;anchor=H20#H20\">",
"     \"Clinical manifestations and diagnosis of primary myelofibrosis\", section on 'Transformation to acute leukemia'",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/1\">",
"      Tefferi A. How I treat myelofibrosis. Blood 2011; 117:3494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/2\">",
"      Barbui T, Barosi G, Birgegard G, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 2011; 29:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/3\">",
"      Reilly JT, McMullin MF, Beer PA, et al. Guideline for the diagnosis and management of myelofibrosis. Br J Haematol 2012; 158:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/4\">",
"      Tefferi A. Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management. Am J Hematol 2013; 88:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/5\">",
"      Tefferi A, Silverstein MN, No&euml;l P. Agnogenic myeloid metaplasia. Semin Oncol 1995; 22:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/6\">",
"      Mesa RA, Silverstein MN, Jacobsen SJ, et al. Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976-1995. Am J Hematol 1999; 61:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/7\">",
"      Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009; 113:2895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/8\">",
"      Dupriez B, Morel P, Demory JL, et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 1996; 88:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/9\">",
"      Cervantes F, Barosi G, Demory JL, et al. Myelofibrosis with myeloid metaplasia in young individuals: disease characteristics, prognostic factors and identification of risk groups. Br J Haematol 1998; 102:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/10\">",
"      Dingli D, Schwager SM, Mesa RA, et al. Prognosis in transplant-eligible patients with agnogenic myeloid metaplasia: a simple CBC-based scoring system. Cancer 2006; 106:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/11\">",
"      Elliott MA, Verstovsek S, Dingli D, et al. Monocytosis is an adverse prognostic factor for survival in younger patients with primary myelofibrosis. Leuk Res 2007; 31:1503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/12\">",
"      Tefferi A, Huang J, Schwager S, et al. Validation and comparison of contemporary prognostic models in primary myelofibrosis: analysis based on 334 patients from a single institution. Cancer 2007; 109:2083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/13\">",
"      Vener C, Fracchiolla NS, Gianelli U, et al. Prognostic implications of the European consensus for grading of bone marrow fibrosis in chronic idiopathic myelofibrosis. Blood 2008; 111:1862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/14\">",
"      Tam CS, Kantarjian H, Cortes J, et al. Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. J Clin Oncol 2009; 27:5587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/15\">",
"      Morel P, Duhamel A, Hivert B, et al. Identification during the follow-up of time-dependent prognostic factors for the competing risks of death and blast phase in primary myelofibrosis: a study of 172 patients. Blood 2010; 115:4350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/16\">",
"      Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 2010; 115:1703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/17\">",
"      Passamonti F, Cervantes F, Vannucchi AM, et al. Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis. Blood 2010; 116:2857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/18\">",
"      Hussein K, Huang J, Lasho T, et al. Karyotype complements the International Prognostic Scoring System for primary myelofibrosis. Eur J Haematol 2009; 82:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/19\">",
"      Tefferi A, Meyer RG, Wyatt WA, Dewald GW. Comparison of peripheral blood interphase cytogenetics with bone marrow karyotype analysis in myelofibrosis with myeloid metaplasia. Br J Haematol 2001; 115:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/20\">",
"      Tam CS, Abruzzo LV, Lin KI, et al. The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course. Blood 2009; 113:4171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/21\">",
"      Hussein K, Pardanani AD, Van Dyke DL, et al. International Prognostic Scoring System-independent cytogenetic risk categorization in primary myelofibrosis. Blood 2010; 115:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/22\">",
"      Caramazza D, Begna KH, Gangat N, et al. Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients. Leukemia 2011; 25:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/23\">",
"      Tefferi A, Siragusa S, Hussein K, et al. Transfusion-dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis--prognostic relevance is independent of IPSS or karyotype. Am J Hematol 2010; 85:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/24\">",
"      Patnaik MM, Caramazza D, Gangat N, et al. Age and platelet count are IPSS-independent prognostic factors in young patients with primary myelofibrosis and complement IPSS in predicting very long or very short survival. Eur J Haematol 2010; 84:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/25\">",
"      Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 2011; 29:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/26\">",
"      Tefferi A, Lasho TL, Jimma T, et al. One thousand patients with primary myelofibrosis: the mayo clinic experience. Mayo Clin Proc 2012; 87:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/27\">",
"      Tefferi A, Vaidya R, Caramazza D, et al. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol 2011; 29:1356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/28\">",
"      Tefferi A, Lasho TL, Huang J, et al. Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. Leukemia 2008; 22:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/29\">",
"      Guglielmelli P, Barosi G, Specchia G, et al. Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. Blood 2009; 114:1477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/30\">",
"      Barosi G, Bordessoule D, Briere J, et al. Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET). Blood 2005; 106:2849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/31\">",
"      Tefferi A, Barosi G, Mesa RA, et al. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood 2006; 108:1497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/32\">",
"      Scott BL, Gooley TA, Sorror ML, et al. The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation. Blood 2012; 119:2657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/33\">",
"      Taylor UB, Bardeguez AD, Iglesias N, Gascon P. Idiopathic myelofibrosis in pregnancy: a case report and review of the literature. Am J Obstet Gynecol 1992; 167:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/34\">",
"      Goti M, Cvetkovi M, Bozanovi T, Cemeriki V. [Successful treatment of primary myelofibrosis with thrombocytosis during pregnancy with alfa-interferon]. Srp Arh Celok Lek 2001; 129:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/35\">",
"      Tulpule S, Bewley S, Robinson SE, et al. The management and outcome of four pregnancies in women with idiopathic myelofibrosis. Br J Haematol 2008; 142:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/36\">",
"      Cervantes F. Modern management of myelofibrosis. Br J Haematol 2005; 128:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/37\">",
"      Arana-Yi C, Quint&aacute;s-Cardama A, Giles F, et al. Advances in the therapy of chronic idiopathic myelofibrosis. Oncologist 2006; 11:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/38\">",
"      Kr&ouml;ger N, Mesa RA. Choosing between stem cell therapy and drugs in myelofibrosis. Leukemia 2008; 22:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/39\">",
"      Merup M, Lazarevic V, Nahi H, et al. Different outcome of allogeneic transplantation in myelofibrosis using conventional or reduced-intensity conditioning regimens. Br J Haematol 2006; 135:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/40\">",
"      Kr&ouml;ger N, Alchalby H, Klyuchnikov E, et al. JAK2-V617F-triggered preemptive and salvage adoptive immunotherapy with donor-lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell transplantation. Blood 2009; 113:1866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/41\">",
"      Klyuchnikov E, Holler E, Bornh&auml;user M, et al. Donor lymphocyte infusions and second transplantation as salvage treatment for relapsed myelofibrosis after reduced-intensity allografting. Br J Haematol 2012; 159:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/42\">",
"      Guardiola P, Esperou H, Cazals-Hatem D, et al. Allogeneic bone marrow transplantation for agnogenic myeloid metaplasia. French Society of Bone Marrow Transplantation. Br J Haematol 1997; 98:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/43\">",
"      Deeg HJ, Gooley TA, Flowers ME, et al. Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood 2003; 102:3912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/44\">",
"      Przepiorka D, Giralt S, Khouri I, et al. Allogeneic marrow transplantation for myeloproliferative disorders other than chronic myelogenous leukemia: review of forty cases. Am J Hematol 1998; 57:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/45\">",
"      Singhal S, Powles R, Treleaven J, et al. Allogeneic bone marrow transplantation for primary myelofibrosis. Bone Marrow Transplant 1995; 16:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/46\">",
"      Creemers GJ, L&ouml;wenberg B, Hagenbeek A. Allogeneic bone marrow transplantation for primary myelofibrosis. Br J Haematol 1992; 82:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/47\">",
"      Benesch M, Deeg HJ. Hematopoietic cell transplantation for adult patients with myelodysplastic syndromes and myeloproliferative disorders. Mayo Clin Proc 2003; 78:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/48\">",
"      Guardiola P, Anderson JE, Bandini G, et al. Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Soci&eacute;t&eacute; Fran&ccedil;aise de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study. Blood 1999; 93:2831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/49\">",
"      Lissandre S, Bay JO, Cahn JY, et al. Retrospective study of allogeneic haematopoietic stem-cell transplantation for myelofibrosis. Bone Marrow Transplant 2011; 46:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/50\">",
"      Visani G, Finelli C, Castelli U, et al. Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patients. Br J Haematol 1990; 75:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/51\">",
"      Robin M, Tabrizi R, Mohty M, et al. Allogeneic haematopoietic stem cell transplantation for myelofibrosis: a report of the Soci&eacute;t&eacute; Fran&ccedil;aise de Greffe de Moelle et de Th&eacute;rapie Cellulaire (SFGM-TC). Br J Haematol 2011; 152:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/52\">",
"      Guardiola P, Anderson JE, Gluckman E. Myelofibrosis with myeloid metaplasia. N Engl J Med 2000; 343:659; author reply 659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/53\">",
"      Deeg HJ, Appelbaum FR. Stem-cell transplantation for myelofibrosis. N Engl J Med 2001; 344:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/54\">",
"      Gupta V, Hari P, Hoffman R. Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors. Blood 2012; 120:1367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/55\">",
"      Maziarz RT, Mesa RA, Tefferi A. Allogeneic stem cell transplantation for chronic myeloproliferative disorders and myelodysplastic syndromes: the question is \"when?\". Mayo Clin Proc 2003; 78:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/56\">",
"      Soll E, Massumoto C, Clift RA, et al. Relevance of marrow fibrosis in bone marrow transplantation: a retrospective analysis of engraftment. Blood 1995; 86:4667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/57\">",
"      Li Z, Gooley T, Applebaum FR, Deeg HJ. Splenectomy and hemopoietic stem cell transplantation for myelofibrosis. Blood 2001; 97:2180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/58\">",
"      Ciurea SO, Sadegi B, Wilbur A, et al. Effects of extensive splenomegaly in patients with myelofibrosis undergoing a reduced intensity allogeneic stem cell transplantation. Br J Haematol 2008; 141:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/59\">",
"      Devine SM, Hoffman R, Verma A, et al. Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. Blood 2002; 99:2255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/60\">",
"      Hessling J, Kr&ouml;ger N, Werner M, et al. Dose-reduced conditioning regimen followed by allogeneic stem cell transplantation in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 2002; 119:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/61\">",
"      Kr&ouml;ger N, Zabelina T, Schieder H, et al. Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis. Br J Haematol 2005; 128:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/62\">",
"      Rondelli D, Barosi G, Bacigalupo A, et al. Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia. Blood 2005; 105:4115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/63\">",
"      Kr&ouml;ger N, Holler E, Kobbe G, et al. Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood 2009; 114:5264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/64\">",
"      Bacigalupo A, Soraru M, Dominietto A, et al. Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type. Bone Marrow Transplant 2010; 45:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/65\">",
"      Alchalby H, Badbaran A, Zabelina T, et al. Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis. Blood 2010; 116:3572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/66\">",
"      Abelsson J, Merup M, Birgeg&aring;rd G, et al. The outcome of allo-HSCT for 92 patients with myelofibrosis in the Nordic countries. Bone Marrow Transplant 2012; 47:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/67\">",
"      Alchalby H, Yunus DR, Zabelina T, et al. Risk models predicting survival after reduced-intensity transplantation for myelofibrosis. Br J Haematol 2012; 157:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/68\">",
"      Samuelson S, Sandmaier BM, Heslop HE, et al. Allogeneic haematopoietic cell transplantation for myelofibrosis in 30 patients 60-78 years of age. Br J Haematol 2011; 153:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/69\">",
"      Ruiz-Arg&uuml;elles GJ, Garc&eacute;s-Eisele J, Reyes-N&uacute;&ntilde;ez V, et al. Clearance of the Janus kinase 2 (JAK2) V617F mutation after allogeneic stem cell transplantation in a patient with myelofibrosis with myeloid metaplasia. Am J Hematol 2007; 82:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/70\">",
"      Benjamini O, Koren-Michowitz M, Amariglio N, et al. Relapse of postpolycythemia myelofibrosis after allogeneic stem cell transplantation in a polycythemic phase: successful treatment with donor lymphocyte infusion directed by quantitative PCR test for V617F-JAK2 mutation. Leukemia 2008; 22:1961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/71\">",
"      Brubaker LH, Bri&egrave;re J, Laszlo J, et al. Treatment of anemia in myeloproliferative disorders: a randomized study of fluoxymesterone v transfusions only. Arch Intern Med 1982; 142:1533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/72\">",
"      Besa EC, Nowell PC, Geller NL, Gardner FH. Analysis of the androgen response of 23 patients with agnogenic myeloid metaplasia: the value of chromosomal studies in predicting response and survival. Cancer 1982; 49:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/73\">",
"      Tefferi A, Silverstein MN. Recombinant human erythropoietin therapy in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 1994; 86:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/74\">",
"      Rodr&iacute;guez JN, Martino ML, Di&eacute;guez JC, Prados D. rHuEpo for the treatment of anemia in myelofibrosis with myeloid metaplasia. Experience in 6 patients and meta-analytical approach. Haematologica 1998; 83:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/75\">",
"      Mohr B, Herrmann R, Huhn D. Recombinant human erythropoietin in patients with myelodysplastic syndrome and myelofibrosis. Acta Haematol 1993; 90:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/76\">",
"      Aloe Spiriti M, Latagliata R, Avvisati G, et al. Erythropoietin treatment of idiopathic myelofibrosis. Haematologica 1993; 78:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/77\">",
"      Cervantes F, Alvarez-Larr&aacute;n A, Hern&aacute;ndez-Boluda JC, et al. Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature. Br J Haematol 2004; 127:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/78\">",
"      Cervantes F, Alvarez-Larr&aacute;n A, Hern&aacute;ndez-Boluda JC, et al. Darbepoetin-alpha for the anaemia of myelofibrosis with myeloid metaplasia. Br J Haematol 2006; 134:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/79\">",
"      L&eacute;vy V, Bourgarit A, Delmer A, et al. Treatment of agnogenic myeloid metaplasia with danazol: a report of four cases. Am J Hematol 1996; 53:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/80\">",
"      Cervantes F, Alvarez-Larr&aacute;n A, Domingo A, et al. Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: long-term results in 30 patients. Br J Haematol 2005; 129:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/81\">",
"      Benbassat J, Penchas S, Ligumski M. Splenectomy in patients with agnogenic myeloid metaplasia: an analysis of 321 published cases. Br J Haematol 1979; 42:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/82\">",
"      Mesa RA, Nagorney DS, Schwager S, et al. Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic. Cancer 2006; 107:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/83\">",
"      Barosi G, Ambrosetti A, Buratti A, et al. Splenectomy for patients with myelofibrosis with myeloid metaplasia: pretreatment variables and outcome prediction. Leukemia 1993; 7:200.",
"     </a>",
"    </li>",
"    <li>",
"     Silverstein MN. Agnogenic Myeloid Metaplasia. Publishing Sciences Group, Acton, MA 1975.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/85\">",
"      Petti MC, Latagliata R, Spadea T, et al. Melphalan treatment in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 2002; 116:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/86\">",
"      L&ouml;fvenberg E, Wahlin A. Management of polycythaemia vera, essential thrombocythaemia and myelofibrosis with hydroxyurea. Eur J Haematol 1988; 41:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/87\">",
"      L&ouml;fvenberg E, Wahlin A, Roos G, Ost A. Reversal of myelofibrosis by hydroxyurea. Eur J Haematol 1990; 44:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/88\">",
"      Manoharan A. Management of myelofibrosis with intermittent hydroxyurea. Br J Haematol 1991; 77:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/89\">",
"      Wagner H Jr, McKeough PG, Desforges J, Madoc-Jones H. Splenic irradiation in the treatment of patients with chronic myelogenous leukemia or myelofibrosis with myeloid metaplasia. Results of daily and intermittent fractionation with and without concomitant hydroxyurea. Cancer 1986; 58:1204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/90\">",
"      Mart&iacute;nez-Trillos A, Gaya A, Maffioli M, et al. Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients. Ann Hematol 2010; 89:1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/91\">",
"      Sirhan S, Lasho TL, Hanson CA, et al. The presence of JAK2V617F in primary myelofibrosis or its allele burden in polycythemia vera predicts chemosensitivity to hydroxyurea. Am J Hematol 2008; 83:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/92\">",
"      Lafaye F, Rain JD, Clot P, Najean Y. Risks and benefits of splenectomy in myelofibrosis: an analysis of 39 cases. Nouv Rev Fr Hematol 1994; 36:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/93\">",
"      Petroianu A. Subtotal splenectomy for treatment of patients with myelofibrosis and myeloid metaplasia. Int Surg 1996; 81:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/94\">",
"      Tefferi A, Silverstein MN, Li CY. 2-Chlorodeoxyadenosine treatment after splenectomy in patients who have myelofibrosis with myeloid metaplasia. Br J Haematol 1997; 99:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/95\">",
"      Faoro LN, Tefferi A, Mesa RA. Long-term analysis of the palliative benefit of 2-chlorodeoxyadenosine for myelofibrosis with myeloid metaplasia. Eur J Haematol 2005; 74:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/96\">",
"      Barosi G, Ambrosetti A, Centra A, et al. Splenectomy and risk of blast transformation in myelofibrosis with myeloid metaplasia. Italian Cooperative Study Group on Myeloid with Myeloid Metaplasia. Blood 1998; 91:3630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/97\">",
"      Mesa RA, Li CY, Schroeder G, Tefferi A. Clinical correlates of splenic histopathology and splenic karyotype in myelofibrosis with myeloid metaplasia. Blood 2001; 97:3665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/98\">",
"      Pardanani A, Brown P, Neben-Wittich M, et al. Effective management of accelerated phase myelofibrosis with low-dose splenic radiotherapy. Am J Hematol 2010; 85:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/99\">",
"      Elliott MA, Chen MG, Silverstein MN, Tefferi A. Splenic irradiation for symptomatic splenomegaly associated with myelofibrosis with myeloid metaplasia. Br J Haematol 1998; 103:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/100\">",
"      Sciascia R, Mazza P, Tondi L. [Splenic irradiation in the treatment of idiopathic myelofibrosis. Retrospective study of 14 cases]. Radiol Med 1988; 76:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/101\">",
"      Lavrenkov K, Krepel-Volsky S, Levi I, Ariad S. Low dose palliative radiotherapy for splenomegaly in hematologic disorders. Leuk Lymphoma 2012; 53:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/102\">",
"      Steensma DP, Hook CC, Stafford SL, Tefferi A. Low-dose, single-fraction, whole-lung radiotherapy for pulmonary hypertension associated with myelofibrosis with myeloid metaplasia. Br J Haematol 2002; 118:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/103\">",
"      Koch CA, Li CY, Mesa RA, Tefferi A. Nonhepatosplenic extramedullary hematopoiesis: associated diseases, pathology, clinical course, and treatment. Mayo Clin Proc 2003; 78:1223.",
"     </a>",
"    </li>",
"    <li>",
"     Hoffman R. Agnogenic myeloid metaplasia (ch.63). In: Hematology: Basic Principles and Practice, 3rd ed, Hoffman R, Benz EJ Jr, Shattil SJ, et al. (Eds), Churchill Livingstone, New York 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/105\">",
"      Tefferi A, Jim&eacute;nez T, Gray LA, et al. Radiation therapy for symptomatic hepatomegaly in myelofibrosis with myeloid metaplasia. Eur J Haematol 2001; 66:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/106\">",
"      Neben-Wittich MA, Brown PD, Tefferi A. Successful treatment of severe extremity pain in myelofibrosis with low-dose single-fraction radiation therapy. Am J Hematol 2010; 85:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/107\">",
"      Tefferi A, Silverstein MN, Petitt RM, et al. Anagrelide as a new platelet-lowering agent in essential thrombocythemia: mechanism of actin, efficacy, toxicity, current indications. Semin Thromb Hemost 1997; 23:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/108\">",
"      Yoon SY, Li CY, Mesa RA, Tefferi A. Bone marrow effects of anagrelide therapy in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 1999; 106:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/109\">",
"      Gilbert HS. Long term treatment of myeloproliferative disease with interferon-alpha-2b: feasibility and efficacy. Cancer 1998; 83:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/110\">",
"      Radin AI, Kim HT, Grant BW, et al. Phase II study of alpha2 interferon in the treatment of the chronic myeloproliferative disorders (E5487): a trial of the Eastern Cooperative Oncology Group. Cancer 2003; 98:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/111\">",
"      Kiladjian JJ, Chomienne C, Fenaux P. Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms. Leukemia 2008; 22:1990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/112\">",
"      Tefferi A, Elliot MA, Yoon SY, et al. Clinical and bone marrow effects of interferon alfa therapy in myelofibrosis with myeloid metaplasia. Blood 2001; 97:1896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/113\">",
"      Ianotto JC, Kiladjian JJ, Demory JL, et al. PEG-IFN-alpha-2a therapy in patients with myelofibrosis: a study of the French Groupe d'Etudes des Myelofibroses (GEM) and France Intergroupe des syndromes My&eacute;loprolif&eacute;ratifs (FIM). Br J Haematol 2009; 146:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/114\">",
"      Kiladjian JJ, Mesa RA, Hoffman R. The renaissance of interferon therapy for the treatment of myeloid malignancies. Blood 2011; 117:4706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/115\">",
"      Silver RT, Vandris K, Goldman JJ. Recombinant interferon-&alpha; may retard progression of early primary myelofibrosis: a preliminary report. Blood 2011; 117:6669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/116\">",
"      Barosi G, Giovanni B, Elliott M, et al. Thalidomide in myelofibrosis with myeloid metaplasia: a pooled-analysis of individual patient data from five studies. Leuk Lymphoma 2002; 43:2301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/117\">",
"      Canepa L, Ballerini F, Varaldo R, et al. Thalidomide in agnogenic and secondary myelofibrosis. Br J Haematol 2001; 115:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/118\">",
"      Elliott MA, Mesa RA, Li CY, et al. Thalidomide treatment in myelofibrosis with myeloid metaplasia. Br J Haematol 2002; 117:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/119\">",
"      Marchetti M, Barosi G, Balestri F, et al. Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial. J Clin Oncol 2004; 22:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/120\">",
"      Thomas DA, Giles FJ, Albitar M, et al. Thalidomide therapy for myelofibrosis with myeloid metaplasia. Cancer 2006; 106:1974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/121\">",
"      Merup M, Kutti J, Birgerg&aring;rd G, et al. Negligible clinical effects of thalidomide in patients with myelofibrosis with myeloid metaplasia. Med Oncol 2002; 19:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/122\">",
"      Mesa RA, Elliott MA, Schroeder G, Tefferi A. Durable responses to thalidomide-based drug therapy for myelofibrosis with myeloid metaplasia. Mayo Clin Proc 2004; 79:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/123\">",
"      Berrebi A, Feldberg E, Spivak I, Shvidel L. Mini-dose of thalidomide for treatment of primary myelofibrosis. Report of a case with complete reversal of bone marrow fibrosis and splenomegaly. Haematologica 2007; 92:e15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/124\">",
"      Mesa RA, Steensma DP, Pardanani A, et al. A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood 2003; 101:2534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/125\">",
"      Tefferi A, Cortes J, Verstovsek S, et al. Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood 2006; 108:1158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/126\">",
"      Quint&aacute;s-Cardama A, Kantarjian HM, Manshouri T, et al. Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. J Clin Oncol 2009; 27:4760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/127\">",
"      Mesa RA, Yao X, Cripe LD, et al. Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903. Blood 2010; 116:4436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/128\">",
"      Tefferi A, Lasho TL, Mesa RA, et al. Lenalidomide therapy in del(5)(q31)-associated myelofibrosis: cytogenetic and JAK2V617F molecular remissions. Leukemia 2007; 21:1827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/129\">",
"      Tefferi A, Verstovsek S, Barosi G, et al. Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J Clin Oncol 2009; 27:4563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/130\">",
"      Lacy MQ, Tefferi A. Pomalidomide therapy for multiple myeloma and myelofibrosis: an update. Leuk Lymphoma 2011; 52:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/131\">",
"      Begna KH, Pardanani A, Mesa R, et al. Long-term outcome of pomalidomide therapy in myelofibrosis. Am J Hematol 2012; 87:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/132\">",
"      Steensma DP, Mesa RA, Li CY, et al. Etanercept, a soluble tumor necrosis factor receptor, palliates constitutional symptoms in patients with myelofibrosis with myeloid metaplasia: results of a pilot study. Blood 2002; 99:2252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/133\">",
"      Mesa RA, Steensma DP, Li CY, et al. Phase II study of the combination of low-dose thalidomide, prednisone, and etanercept (PET regimen) in the treatment of anemia, splenomegaly, and constitutional symptoms associated with myelofibrosis with myeloid metaplasia (MMM) (abstract). Blood 2005; 106:724a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/134\">",
"      Tefferi A, Mesa RA, Gray LA, et al. Phase 2 trial of imatinib mesylate in myelofibrosis with myeloid metaplasia. Blood 2002; 99:3854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/135\">",
"      Cortes J, Giles F, O'Brien S, et al. Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders. Cancer 2003; 97:2760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/136\">",
"      Verstovsek S. Therapeutic potential of Janus-activated kinase-2 inhibitors for the management of myelofibrosis. Clin Cancer Res 2010; 16:1988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/137\">",
"      Pardanani A, Gotlib JR, Jamieson C, et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol 2011; 29:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/138\">",
"      Verstovsek S. Janus-activated kinase 2 inhibitors: a new era of targeted therapies providing significant clinical benefit for Philadelphia chromosome-negative myeloproliferative neoplasms. J Clin Oncol 2011; 29:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/139\">",
"      Pardanani A, Tefferi A. Targeting myeloproliferative neoplasms with JAK inhibitors. Curr Opin Hematol 2011; 18:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/140\">",
"      Quint&aacute;s-Cardama A, Verstovsek S. Spleen deflation and beyond: the pros and cons of Janus kinase 2 inhibitor therapy for patients with myeloproliferative neoplasms. Cancer 2012; 118:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/141\">",
"      Cervantes F, Mesa R, Harrison C. JAK inhibitors: beyond spleen and symptoms? Haematologica 2013; 98:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/142\">",
"      Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 2010; 363:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/143\">",
"      Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012; 366:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/144\">",
"      Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012; 366:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/145\">",
"      Tefferi A, Litzow MR, Pardanani A. Long-term outcome of treatment with ruxolitinib in myelofibrosis. N Engl J Med 2011; 365:1455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/146\">",
"      Verstovsek S, Kantarjian HM, Estrov Z, et al. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood 2012; 120:1202.",
"     </a>",
"    </li>",
"    <li>",
"     FDA prescribing information for ruxolitinib: file://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202192lbl.pdf (Accessed on November 17, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/148\">",
"      Tefferi A, Pardanani A. Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis. Mayo Clin Proc 2011; 86:1188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/149\">",
"      Tefferi A. Challenges facing JAK inhibitor therapy for myeloproliferative neoplasms. N Engl J Med 2012; 366:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/150\">",
"      Tefferi A. JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths. Blood 2012; 119:2721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/151\">",
"      Verstovsek S, Passamonti F, Rambaldi A, et al. Durable responses with the JAK1/JAK2 inhibitor, INCB018424, in patients with polycythemia vera (PV) and essential thrombocythemia (ET) refractory or intolerant to hydroxyurea (HU) (abstract 313). Blood 2010; 116:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/152\">",
"      Guglielmelli P, Barosi G, Rambaldi A, et al. Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis. Blood 2011; 118:2069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/153\">",
"      Quint&aacute;s-Cardama A, Kantarjian H, Estrov Z, et al. Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis. Leuk Res 2012; 36:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/154\">",
"      Rambaldi A, Dellacasa CM, Finazzi G, et al. A pilot study of the Histone-Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. Br J Haematol 2010; 150:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/155\">",
"      Mascarenhas J, Lu M, Li T, et al. A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera/essential thrombocythaemia myelofibrosis (post-PV/ET MF). Br J Haematol 2013; 161:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/156\">",
"      Barosi G, Gattoni E, Barbui T, et al. A phase I study of the proteasome inhibitor bortezomib in patients with myelofibrosis (abstract). Blood 2007; 110:1036A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/3/36922/abstract/157\">",
"      Mesa RA, Verstovsek S, Rivera C, et al. Bortezomib therapy in myelofibrosis: a phase II clinical trial. Leukemia 2008; 22:1636.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4531 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-124.240.187.80-339106477A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_3_36922=[""].join("\n");
var outline_f36_3_36922=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1167105\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      International Working Group Scoring System",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7384931\">",
"      - IPSS",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7384938\">",
"      - Dynamic IPSS",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7384945\">",
"      - DIPSS Plus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H19313047\">",
"      Predicting leukemic transformation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12714880\">",
"      - Elevated cytokine levels",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - JAK2 mutational burden",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Response criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Candidates for hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SPECIFIC TREATMENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Allogeneic HCT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Nonmyeloablative allogeneic HCT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Androgens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Hydroxyurea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Splenectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Splenic irradiation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Other sites of disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Anagrelide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Interferon alfa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Thalidomide and lenalidomide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14572188\">",
"      - Single agent thalidomide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Thalidomide plus prednisone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Lenalidomide with or without prednisone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3270847\">",
"      Patients with myelofibrosis and 5q-",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Pomalidomide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Etanercept",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Imatinib mesylate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      JAK2 inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14969007\">",
"      - Ruxolitinib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14152059\">",
"      Everolimus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1557239\">",
"      Histone deacetylase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Bortezomib",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Prognosis and treatment overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Supportive modalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Splenectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      - Acute leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4531\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4531|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?24/16/24835\" title=\"figure 1\">",
"      Organiz heme malignancies",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/63/1018?source=related_link\">",
"      Clinical manifestations and diagnosis of primary myelofibrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/22/25960?source=related_link\">",
"      Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/25/23962?source=related_link\">",
"      Clinical manifestations, diagnosis, and grading of chronic graft-versus-host disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/58/20393?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/38/26218?source=related_link\">",
"      Donor selection for hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/52/21322?source=related_link\">",
"      Overview of the myeloproliferative neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/30/25064?source=related_link\">",
"      Pathogenetic mechanisms in primary myelofibrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/28/32202?source=related_link\">",
"      Prognosis and treatment of essential thrombocythemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/57/29594?source=related_link\">",
"      Thrombotic complications following treatment of multiple myeloma with thalidomide and its analogues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/30/31210?source=related_link\">",
"      Treatment of intermediate, low, or very low risk myelodysplastic syndromes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_3_36923="Muscarinic receptors in lung";
var content_f36_3_36923=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F79055&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F79055&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Muscarinic receptors in the lung and the effect of selected anticholinergic medications",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Type",
"      </td>",
"      <td class=\"subtitle1\">",
"       Predominant location",
"      </td>",
"      <td class=\"subtitle1\">",
"       Action",
"      </td>",
"      <td class=\"subtitle1\">",
"       Atropine",
"      </td>",
"      <td class=\"subtitle1\">",
"       Ipratropium Oxitropium Tiquizium",
"      </td>",
"      <td class=\"subtitle1\">",
"       Tiotropium",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       M1",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       Peribronchial ganglion cells",
"      </td>",
"      <td>",
"       Bronchoconstriction",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       Inhibits",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       Inhibits",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       Inhibits",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Increased secretion",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       M2",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       Postganglionic nerves",
"      </td>",
"      <td>",
"       Inhibit Ach release",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       Inhibits",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       Inhibits",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       Does not inhibit",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Bronchodilation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       M3",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       Smooth muscle mucous glands",
"      </td>",
"      <td>",
"       Bronchoconstriction",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       Inhibits",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       Inhibits",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       Inhibits",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Increased secretion",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_3_36923=[""].join("\n");
var outline_f36_3_36923=null;
var title_f36_3_36924="Drugs associated with immune thrombocytopenia";
var content_f36_3_36924=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F73618&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F73618&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Drugs with evidence (clinical plus presence of drug-dependent antibodies) for association with immune thrombocytopenia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Abciximab*",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acetaminophen",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amiodarone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ampicillin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carbamazepine*",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Eptifibatide",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ethambutol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Haloperidol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ibuprofen",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Irinotecan",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Naproxen",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oxaliplatin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Phenytoin",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Piperacillin",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Quinidine*",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Quinine*",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ranitidine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rifampin*",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Simvastatin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sulfisoxazole",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tirofiban",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trimethoprim-sulfamethoxazole*",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Valproate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vancomycin",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    This table lists 24 different drugs with evidence for a causal association with immune thrombocytopenia by both clinical data from published case reports and by identification of drug-dependent, platelet-reactive antibodies.",
"    <div class=\"footnotes\">",
"     * These six drugs had clinical evidence for a causal association with thrombocytopenia in 10 or more case reports.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      These 11 drugs had evidence for a causal association with thrombocytopenia by detection of drug-dependent, platelet reactive antibodies in 10 or more patients.",
"      <br>",
"       &Delta; For acetaminophen and naproxen, drug-dependent antibodies have only been identified for metabolites and do not react with the unmodified drug. For ibuprofen, drug-dependent antibodies that reacted with the unmodified drug have been identified in some patients; in other patients drug-dependent antibodies only reacted with metabolites of ibuprofen.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Research leading to this compilation of drugs was originally published in Blood and has been modified for use in this publication. Reese JA, Li X, Hauben M, et al. Identifying drugs that cause acute thrombocytopenia: an analysis using 3 distinct methods. Blood 2010; 116:2127. Copyright &copy; 2010 American Society of Hematology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_3_36924=[""].join("\n");
var outline_f36_3_36924=null;
var title_f36_3_36925="Buffers in respiratory acidosis";
var content_f36_3_36925=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F65034&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F65034&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Buffering in respiratory acidosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 256px; height: 269px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Mechanisms of buffering of CO2 in respiratory acidosis in the dog. Virtually all buffering occurs within the cells, 37 percent in exchange for sodium, 14 percent in exchange for potassium, and 29 percent via chloride entry into cells. The source of approximately 11 percent of the buffering has not been identified.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Pitts, RF, Physiology of the Kidney and Body Fluids, 3d ed, Year Book, Chicago, and from Giebisch, G, Berger, L, Pitts, RF, J Clin Invest, 34:231, 1955.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_3_36925=[""].join("\n");
var outline_f36_3_36925=null;
var title_f36_3_36926="Bleeding after medical abortion";
var content_f36_3_36926=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F56315&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F56315&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 494px\">",
"   <div class=\"ttl\">",
"    Types of vaginal bleeding as recorded by women from day 1 (administration of mifepristone) to day 15",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 474px; height: 319px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The data are from 1506 women who did not undergo surgical termination of pregnancy and who recorded the types of bleeding they had from study day 1 to day 15 on menstrual diary cards. Bleeding was characterized as spotting, as similar to normal menstrual bleeding (normal), or as heavier than normal menstrual bleeding (heavy).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Spitz, IM, Bardin, CW, Benton, L, Robbins, A. N Engl J Med 1998; 388:1241.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_3_36926=[""].join("\n");
var outline_f36_3_36926=null;
var title_f36_3_36927="Rash of primary varicella";
var content_f36_3_36927=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F55533&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F55533&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Primary varicella lesions",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 382px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Vesicular lesions on an erythematous base are characteristic of chickenpox. The lesions occur in crops and are present in a variety of stages from maculopapular to vesicular or even pustular. Central necrosis and early crusting is also visible.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Lee T Nesbitt, Jr. The Skin and Infection: A Color Atlas and Text, Sanders CV, Nesbitt LT Jr (Eds), Williams &amp; Wilkins, Baltimore 1995.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_3_36927=[""].join("\n");
var outline_f36_3_36927=null;
